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NFTs Neurofibrillary tangles 
PBS Phosphate-buffered saline 
PC Phosphatidylcholine 
PE Phosphatidylethanolamine 
PEMT Phosphatidylethanolamine N-methyl transferase 
PS Phosphatidylserine 
PSD Phosphatidylserine decarboxylase 
PSS1/2 Phosphatidylserine serine synthase 1/2 
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PUFA Polyunsaturated fatty acid 
PVDF Polyvinylidene fluoride 
ROS Reactive oxygen species 
sER Smooth endoplasmic reticulum 
TBST Tris-buffered saline with Tween®-20 
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ABSTRACT 
The world’s population is rapidly ageing, and with that has come a corresponding 
increase in the number of people suffering age-related diseases. Dementia is a group of 
age-related neurocognitive disorders, with the most common of these being Alzheimer’s 
disease (AD). The number one risk factor for developing AD is advanced age, with the 
incidence rising from 1 in 10,000 at age 60 to 1 in 3 by age 85. AD is characterised by 
the deposition of extracellular amyloid-β aggregates (Aβ) and intracellular 
neurofibrillary tangles (NFTs) formed by hyperphosphorylated tau. Both Aβ and NFTs 
spread throughout the brain by separate but predictable pathways during the progression 
of the disease. Many studies have shown an involvement of membrane lipids, including 
phospholipids, in the pathogenesis of AD. Less is known about the changes occurring in 
membrane lipids such as phospholipids within the brain over the normal adult lifespan. 
Lipids are major components of the brain comprising 40-55% of the dry matter present, 
with phospholipids making up half of total brain lipid. The human brain undergoes a 
number of structural changes during the course of ageing that could theoretically lead to 
alterations in brain phospholipids. Changes to phospholipids with age within the human 
brain could be driven by two current theories of ageing: i) the mitochondrial free radical 
oxidative stress theory of ageing, which proposes that ageing is driven by damage to 
macromolecules such as lipids by reactive oxygen species produced by the 
mitochondria; or ii) the “inflammageing” theory, which suggests that ageing is driven 
by chronic, low-grade inflammation over the lifetime of an organism. Several studies 
conducted over twenty years ago attempted to characterise any changes occurring to 
brain phospholipids with age, but newer methods utilising mass spectrometry to identify 
and quantify lipids have become available since then. Understanding the changes 
occurring to phospholipids during normal ageing may lead to a better interpretation of 
the changes occurring during AD while also clarifying what fundamental mechanism 
underpins ageing within the human brain. 
Therefore, the aim of this thesis was to characterize any age-related changes occurring 
to the three dominant phospholipid classes present in the human brain: 
phosphatidylcholine (PC), phosphatidylethanolamine (PE) and phosphatidylserine (PS). 
To accomplish this, post-mortem tissue (n = 36, age range 18-104 years) from five 
different regions of the brain was obtained from neurologically normal donors via the 
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New South Wales Tissue Resource Centre at the University of Sydney. These five areas 
of the brain were chosen based on the spread of Aβ and NFTs during the progression of 
AD. The dorsolateral prefrontal cortex, entorhinal cortex and hippocampus all develop 
Aβ and NFTs during the progression of AD while the motor cortex and cerebellum 
remain relatively unaffected. Tissue from each region was homogenised, fractionated 
into a mitochondrial and microsomal component, and lipids were extracted. Molecular 
phospholipids were identified by complementary positive and negative ion scans using 
tandem mass spectrometry, and linear regression was performed to determine any age-
related changes. The fractionation of the tissue into mitochondrial and microsomal 
membranes allowed the characterisation of any observed age-related changes to 
phospholipids to a particular theory of ageing. 
A variety of phospholipids underwent changes with age, with no specific trend 
identified for one membrane fraction over another. No changes with age in total 
quantified phospholipid levels were seen in either membrane fraction across the five 
regions. Only the entorhinal cortex experienced age-related changes in a phospholipid 
class, with increases in mitochondrial PC with age found alongside decreases in 
mitochondrial PE. Several key age-related changes were seen in phospholipids across 
the five brain regions. The phospholipid with the largest increase with age was PS 
18:0_22:6 within the mitochondrial membranes of the hippocampus and both the 
mitochondrial and microsomal membranes of the prefrontal cortex and cerebellum. PE 
18:0_22:6 also underwent sizeable increases in both membrane fractions of the 
cerebellum. The largest decrease with age was seen in PS 18:0_18:1 in both membrane 
fractions of the cerebellum. This was followed by PE 18:0_20:4 in the mitochondria of 
the prefrontal cortex, the microsomes of the entorhinal cortex, and in both membrane 
fractions within the cerebellum. The cerebellum showed the largest number of changes 
to its phospholipids with age in both the mitochondrial and microsomal membranes 
while the entorhinal and motor cortices experienced the fewest. The only phospholipid 
to show consistent age-related changes across all five regions was an increase in 
mitochondrial PC 16:0_18:2. A trend was identified across the five brain regions for 
increases in phospholipids containing a 22:6 fatty acid (docosahexaenoic acid, DHA) 
with age, while those containing 20:4 (arachidonic acid, AA) or 22:4 (adrenic acid) 
tended to decrease. All three fatty acids are polyunsaturated fatty acids that can be 
classified into omega-3 (DHA) and omega-6 (AA and adrenic acid). Further regressions 
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with age were conducted to confirm these findings across all five regions of the brain. 
Total DHA levels increased significantly with age within the mitochondrial and 
microsomal membranes of the prefrontal cortex and cerebellum. These increases with 
age were driven by rises in PS-DHA in both of these regions, and by PE-DHA in the 
cerebellum. Likewise, decreases were seen with age for AA and adrenic acid across 
both membrane fractions in nearly all regions of the brain examined. This finding 
suggests that there is a loss of long-chain omega-6 fatty acids within the brain over the 
adult lifespan, while the omega-3 fatty acids increase. 
Compared to the previous literature, the novel finding of this thesis is that the level of 
DHA increases within specific regions of the brain in neurologically normal subjects 
over the course of the adult lifespan. This differs drastically from what is seen in the 
brain during the progression of AD, in which levels of DHA within the affected brain 
regions are severely reduced. Due to this increase in DHA within both membrane 
fractions of the brain with age, it was determined that the findings of this thesis aligned 
more closely with the “inflammageing” theory of ageing than the mitochondrial free 
radical oxidative theory. Several key pathways involved in the production of 
phospholipids primarily containing DHA were identified as being useful targets for 
future research. Future research should also focus on eicosanoid production pathways in 
order to confirm the involvement of phospholipids in low-grade, chronic inflammation, 
and the role that this may play in healthy ageing in the human brain. 
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SECTION 1 
INTRODUCTION
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Chapter 1 Thesis Overview 
1.1 Introduction 
An increase in lifespan has led to a dramatic shift in the age demographic of the 
population worldwide, with the number of people over the age of 65 years projected to 
triple to 1.5 billion by 2050 [1]. Within Australia, our total population has increased 
fivefold over the 20th century, but the number of people aged 65 years and over 
increased more than fifteen-fold in the same period [2]. This aged population is also 
expected to continue to rise from 13% in 2007 to 23-25% of the population by 2056 [3]. 
Alongside this increasingly aged population is a corresponding increase in the number 
of people suffering from age-related disease. Dementia is a group of neurocognitive 
disorders resulting in the disturbance of higher cortical functions, including memory, 
thinking, comprehension, language and learning ability. An estimated 35.6 million 
people were living with dementia worldwide in 2011, with that number predicted to 
double every 20 years [4]. The economic burden of dementia is staggering, with the 
global societal costs of the disease estimated at around US$604 billion in 2010 [4]. In 
Australia alone there were an estimated 298,000 people suffering from dementia 
nationally in 2011, which resulted in direct and indirect costs of around $4.9 billion [5]. 
With an increasingly older population and a rising rate of dementia incidence 
worldwide, research into effective prevention and treatment strategies for such age-
related diseases are becoming more and more important. 
Alzheimer’s disease (AD), the most common form of dementia, is a neurodegenerative 
disease typified by synaptic loss and increased neuron apoptosis that leads to the 
extreme atrophy of several brain regions, particularly those involved in memory, speech 
and behaviour. AD is characterised by the presence of intracellular protein aggregates 
formed from amyloid-β (Aβ) peptides and extracellular neurofibrillary tangles (NFTs) 
of hyperphosphorylated Tau. The deposition of Aβ plaques and NFTs follow a different 
progression to each other during the pathogenesis of AD, but both pathways follow 
predictable patterns of spread within the brain with little variation between individuals 
[6,7]. Aβ accumulation can be divided into three stages (Figure 1-1) [7]. Aβ plaques are  
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Figure 1-1: The progression of deposition of amyloid-β plaques (upper, stages A 
through C) and neurofibrillary tangles formed from hyperphosphorylated tau (lower, 
stages I-VI) in the human brain during the pathogenesis of Alzheimer’s disease. From 
Braak and Braak [7]. 
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initially found within the isocortex (particularly in the basal regions of the frontal, 
temporal and occipital lobes), and during the progression of the disease spread to almost 
all of the isocortical association areas. Only the primary sensory and motor cortices 
remain free of Aβ in the late stages of AD. Aβ accumulation occurs in the hippocampus 
and entorhinal cortex from the middle stages onwards. Levels of Aβ do not necessarily 
correlate with cognitive performance, with Aβ plaques commonly seen in the brain of 
non-demented elderly on autopsy [8] and by imaging techniques in vivo [9]. 
Conversely, NFTs are first present in the region bordering the entorhinal cortex and 
temporal cortex. In the middle stages, NFTs are found in the limbic system, particularly 
the hippocampus, which produces mild cognitive impairment and personality changes 
[6]. In the final stages, large numbers of NFTs are displayed throughout virtually all 
subdivisions of the neocortex, alongside severe destruction of neocortical association 
areas. The highest risk factor for developing AD is advanced age with incidence rising 
sharply from 1 in 10,000 at age to 60 to 1 in 3 by age 85 [10]. Most cases of AD are 
sporadic in nature with the genetic causes being largely unknown; however, the few 
genetic associations that are known point towards an involvement of lipid metabolism 
in the pathogenesis of AD. The strongest known genetic risk factor for AD is 
homozygosity of the APOE-ε4 allele [11,12]. The APOE gene encodes for 
apolipoprotein E, which is involved in the trafficking of lipids in the brain. Recent 
genome-wide association studies have also unearthed several other genetic markers of 
late-onset AD, several loci of which have roles directly or indirectly in lipid metabolism 
within the brain [13–15]. Alongside these genetic risk factors, there is increasing 
evidence for a cell membrane defect in AD, with alterations in phospholipids and other 
membrane lipids being observed in the disease (reviewed in Chapter 2).  
Given that the principal risk factor for AD is advanced age, there is surprisingly little 
information available on the changes occurring in membrane lipids such as 
phospholipids during normal ageing. The few studies that have been conducted on 
normal ageing in the brain were performed over twenty years ago (reviewed in Chapter 
2). The human brain undergoes a number of structural changes during ageing, including 
decreases in cortical thickness [16–21], volume [16,19,22–26], density [27], surface 
area [16,18], and white matter volume [21,23,26]. Declines in brain metabolic 
parameters such as oxygen consumption and blood flow [28] with age are also seen. All 
of these recorded age-related changes could feasibly lead to alterations in brain 
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phospholipid composition. Since the publication of these past studies on age-related 
changes in human brain phospholipids, newer methods that use mass spectrometry to 
examine phospholipids at a molecular level have been developed [29]. Filling this gap 
in the literature would lead to a better understanding of the changes occurring in 
phospholipids as a result of neurodegenerative diseases such as AD, and potentially a 
better understanding of the cellular mechanisms of ageing.  
1.2 Statement of the problem 
The overall aim of this thesis is to address the current deficit in knowledge regarding the 
changes occurring in the phospholipid composition of the human brain during normal 
ageing. A secondary aim is to compare and contrast these age-related changes in the 
phospholipids of the human brain to those previously reported in the literature for AD. 
AD was chosen specifically due to the established involvement of phospholipids and 
other membrane lipids in the pathogenesis of the disease compared to other types of 
dementia (reviewed in Chapter 2). To achieve the aims of this thesis, the phospholipids 
of five regions of the brain were systematically analysed using state-of-the-art mass 
spectrometry techniques. To aid in pinpointing the specific subcellular location where 
age-related changes occur, the brain tissue from each region was fractionated to give a 
mitochondrial-enriched and microsomal (mixed cellular membrane) fraction. This 
fractionation method required substantial method development (Chapter 3). The five 
brain regions examined in this thesis are shown in Figure 1-2. Three of these five 
regions were chosen based on their involvement in the pathogenesis of AD (Figure 1-1). 
They consisted of the dorsolateral prefrontal cortex (Chapter 4), hippocampus (Chapter 
5), and entorhinal cortex (Chapter 6) (Figure 1-2). The remaining two brain regions, the 
cerebellum (Chapter 7), and the motor cortex (Chapter 8) undergo few changes during 
AD. Due to this they are often used as control brain regions when studying the disease 
(Figure 1-2). Comparison of the five regions was also conducted to establish any 
region-specific changes in phospholipid during normal ageing, as well as 
recommendations for future research (Chapter 9).  
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Figure 1-2: Model of the human brain highlighting the five regions analysed within this 
thesis : dorsolateral prefrontal cortex (purple), hippocampus (green), entorhinal cortex 
(yellow), cerebellum (red) and motor cortex (blue). The dorsolateral prefrontal cortex, 
hippocampus, and entorhinal cortex all undergo substantial changes during the 
pathogenesis of AD, while the cerebellum and motor cortex remain relatively spared (as 
shown in Figure 1-1). 
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Chapter 2 Literature review 
2.1 The importance of phospholipids in the brain 
2.1.1 Phospholipids 
The bilayer present in cellular membranes is formed by a range of lipid molecules, with 
the primary type of lipid present being phospholipids. Glycerophospholipids, more 
commonly known as phospholipids, are amphipathic molecules consisting of a polar 
head group and two fatty acids attached to a glycerol backbone (Figure 2-1). Different 
combinations of head group and fatty acids in a phospholipid can produce up to 10 000 
different molecular species [30]. Such variation in their structure can in turn affect 
membrane properties including membrane fluidity and the modulation of membrane-
bound protein activity [31–33]. 
 
Figure 2-1: Glycerophospholipids. The structural diagrams show possible head group (X) 
and fatty acid placement (R; see Figure 2-2).   
 Glycerophospholipids 
Phospholipids                  
 
R = fatty acids 
 
Saturated 
(no double bonds) 
Monounsaturated 
(1  double bond) 
Polyunsaturated 
(>1 double bond) 
X = head group: 
 
Phosphatidyl 
Choline 
 Phosphatidic 
acid 
 
Phosphatidyl 
Ethanolamine 
 
Phosphatidyl 
Serine 
 
 
Phosphatidyl 
Glycerol 
 
Phosphatidyl 
inositol 
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Figure 2-2: Examples of different fatty acids from the 18-carbon series. 
The three most common phospholipid classes found in mammals are 
phosphatidylcholine (PC), phosphatidylethanolamine (PE) and phosphatidylserine (PS). 
The head groups are linked to the glycerol backbone by phosphate in the sn-3 position 
(Figure 2-1). Other less common phospholipid classes include phosphatidic acid, 
phosphatidylglyercol and phosphatidylinositol. The fatty acids of phospholipids are 
esterified to the sn-1 and sn-2 positions of glycerol, and can be classified by their chain 
length (number of carbons). Fatty acids can also be classified by the number of double 
bonds present: saturated (no double bonds), monounsaturated (one double bond) and 
polyunsaturated (more than one double bond) (Figure 2-2). Polyunsaturated fatty acids 
(PUFA) can be further classified by the position of the first double bond from their 
methyl end into omega-3 (n-3) and omega-6 (n-6) fatty acids. Phospholipids can also 
contain ether-linked fatty acids, which are joined to the glycerol backbone by either an 
alkyl or alkenyl ether bond. In this literature review, the focus will be mainly on the 
three predominant phospholipids present in mammalian cellular membranes, PC, PE 
and PS. 
 
 
Saturated fatty acid (no double bonds) Stearic Acid (18:0) 
 
Monounsaturated fatty acid (one double bond) Oleic Acid (18:1n-9) 
 
Omega-6 Polyunsaturated Fatty Acid Linoleic Acid (18:2n-6) 
(two or more double bonds; first double bond at the 6th carbon from the methyl end) 
 
Omega-3 Polyunsaturated Fatty Acid α-Linolenic Acid (18:3n-3) 
(two or more double bonds; first double bond at the 3rd carbon from the methyl end) 
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2.1.2 Phospholipids in the human brain 
Lipids are found in high amounts in the human brain, making up around 40-55% of the 
dry matter present, but this can be considerably higher in myelinated neurons, rising to 
around 80% of total dry matter [34]. Phospholipids are the dominant lipid found in 
cellular membranes and comprise around half of the lipids present in the dry matter of 
the human brain [34]. The overall phospholipid composition of the top three 
phospholipids found in the adult brain is approximately 35-40% PC, 35-40% PE and 
20% PS [35]. Compared with other tissues, the brain is highly enriched in phospholipids 
containing PUFA, particularly docosahexaenoic acid (DHA, 22:6n-3), which is found 
mostly in the PE and PS classes of phospholipids. Within the grey matter of the human 
cerebral cortex, both PE and PS phospholipids consist of approximately 20-25% DHA 
[35]. Other PUFA, such as arachidonic acid (AA, 20:4n-6), are also present in high 
levels in the human brain, particularly in PC and PE, making up approximately 15% of 
the fatty acid present in each class [35]. PUFA have many important biological roles 
within cell membranes, including the modulation of membrane fluidity, influencing the 
activity of membrane-bound proteins, and acting as secondary messengers in 
inflammatory pathways [31,36–38]. Described below are the ways in which 
phospholipids and their fatty acids are synthesised within mammalian tissues. 
2.1.3 Synthesis of phospholipids  
Phospholipids present in cellular membranes can be obtained directly from the diet, 
synthesised de novo or produced via deacylation and reacylation pathways which 
remodel the fatty acids present in membranes. Only a few phospholipid molecular 
species can be synthesised de novo, with the vast array of structural diversity seen in 
phospholipids being the result of the remodelling pathways [39]. Little is known about 
specific pathways of phospholipid synthesis in the human brain, and as such this section 
will focus on general phospholipid biosynthesis pathways in mammalian tissues. 
Both PC and PE follow a parallel pathway during de novo synthesis (Figure 2-3) [40]. 
The first step in PC synthesis is the phosphorylation of choline by choline kinase. 
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Figure 2-3: Synthesis of the three most abundant phospholipids present in mammalian 
cellular membranes . CK choline kinase; CPT CDP-choline:1,2-diacylglycerol 
cholinephosphotransferase; CT CTP:phosphocholine cytidylyltransferase; DAG 
diacylglycerol; EK ethanolamine kinase; EPT CDP-ethanolamine:1,2-diacylglycerol 
ethanolaminephosphotransferase; ET CTP:phosphoethanolamine cytidylyltransferase; 
PC phosphatidylcholine; PE phosphatidylethanolamine; PEMT 
phosphatidylethanolamine N-methyl transferase; PS phosphatidylserine; PSD 
phosphatidylserine decarboxylase; PSS1 phosphatidylserine synthase 1; PSS2 
phosphatidylserine synthase 2. 
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Next, CDP is added to phosphocholine by CTP:phosphocholine cytidylyltransferase. 
Finally, CDP-choline is transferred to diacylglycerol by CDP-choline:1,2-diacylglycerol 
cholinephosphotransferase (CPT) to form phosphatidylcholine. Phosphatidyl-
ethanolamines are synthesised de novo following the same steps as phosphatidylcholine, 
but by ethanolamine-specific enzymes (Figure 2-3). The synthesis of PC and PE 
phospholipids takes place in the smooth endoplasmic reticulum (sER), but both CPT 
and CDP-ethanolamine:1,2-diacylglycerol ethanolaminephosphotransferase (EPT) can 
also be localised to a specific portion of the sER known as the mitochondria-associated 
membranes (MAM) [41]. CPT is also present in the outer mitochondrial membrane, 
allowing the mitochondria to synthesise PC phospholipids de novo, but EPT is only 
present on the sER. There are four primary PC and PE molecular phospholipids that are 
known to be synthesised de novo via these pathways: 16:0/18:2n-6, 16:0/18:1, 
16:0/22:6n-3 and 18:1/18:2n-6 [42]. The vast bulk of structural diversity seen within 
phospholipids is not the result of de novo synthesis, but arises from deacylation and 
reacylation pathways that remodel the fatty acids present in phospholipids. 
Phospholipase A1 and A2 cleave fatty acids from the sn-1 and sn-2 positions of 
phospholipids respectively to form lysophospholipids. Acyl-CoA:lysophospholipid 
acyltransferases specific to both phospholipid head group and sn position esterify fatty 
acids onto lysophospholipids to reform diacyl phospholipids. The net result of these 
processes are phospholipids predominately with a saturated fatty acid present in the sn-1 
position and an unsaturated fatty acid in the sn-2 position (reviewed by Yamashita et al. 
[43]).  
In contrast to PC and PE, there are no de novo synthesis pathways for the synthesis of 
PS in mammalian membranes. Rather, PS is synthesised through a calcium-dependent 
serine base-exchange reaction from PC by phosphatidylserine synthase 1 (PSS1) and 
from PE by phosphatidylserine synthase 2 (PSS2, Figure 2-3). Both PSS1 and PSS2 are 
located in the sER, primarily within the MAM [44], with the close proximity of the two 
membranes allowing the transfer of PS into the mitochondrial membranes after 
synthesis [40]. PSS2, in particular, is highly expressed in the brain of mammals, yet 
mice with PSS2-deficiency have normal membrane phospholipid content [45]. PSS2 
displays a preference for PE phospholipids containing DHA in the sn-2 position over 
those containing other fatty acids such as AA or oleic acid (18:1) [46]. This preference 
leads to the high level of polyunsaturation seen in PS phospholipids in the brain. 
CHAPTER 2 
 
12 | P a g e  
 
Increases in PS synthesis via serine-base exchanges have been reported in aged rats in 
the cerebellum and cerebral cortex, both with and without the addition of exogenous 
calcium [47]. 
PC and PE phospholipid can also be synthesised via remodelling pathways. Within the 
inner mitochondrial membrane, the synthesis of PE phospholipids occur by 
decarboxylation of PS by phosphatidylserine decarboxylase (PSD, Figure 2-3). This 
pathway displays a preference for generating phospholipids containing PUFA in the sn-
2 position [48] but is thought to only account for 7% of total PE production within the 
brain [49]. Deletion of PSD in mice causes embryonic death at day 9.5, with 
morphologically aberrant, fragmented mitochondria present [50,51]. No changes in the 
activity of PSD have been observed in the cerebral cortex or cerebellum of aged rats 
[47]. PC phospholipids can also be generated by the methylation of PE via 
phosphatidylethanolamine N-methyl transferase (PEMT, Figure 2-3). PEMT activity is 
present in the sER, and immunoreactive PEMT has also been identified in the MAM 
[52]. Although a seemingly redundant pathway, mice with homozygous deletion of 
PEMT show liver failure within three days when choline is eliminated from the diet, 
with no overt changes in the phospholipid composition of any other tissue [53]. PEMT 
activity has been found to increase with age in the cerebral cortex of rats [47]. 
Alterations to PEMT structure and activity may also be involved in AD, with a single 
nucleotide polymorphism in PEMT associated with sporadic AD in a Han Chinese 
population [54]. Decreased levels of PEMT activity have also been seen in the cerebral 
cortex of people with AD [55]. 
2.1.4 Synthesis of polyunsaturated fatty acids 
Unlike saturated and monounsaturated fatty acids, n-3 and n-6 PUFA are considered to 
be essential in the diet because they cannot be synthesised de novo by mammals. 
However, long-chain PUFA of 20 carbons or longer can be synthesised through 
elongation and desaturation of shorter-chain precursors via a pathway common to both 
n-3 and n-6 fatty acids (Figure 2-4). This pathway begins with either linoleic (LA, 
18:2n-6) or α-linolenic (ALA, 18:3n-3) acid in the endoplasmic reticulum. Both of these 
fatty acids undergo a series of alternating double bond insertions (desaturation) by Δ6 
and Δ5 desaturases, followed by the addition of two carbons (elongation) via elongases.  
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Figure 2-4: Biosynthesis of long-chain polyunsaturated fatty acids (PUFA) in humans 
from precursor omega-3 (n-3) and omega-6 (n-6) PUFA, which occurs via a common 
desaturase/elongase system. In the endoplasmic reticulum Δ6- and Δ5-desaturases 
introduce double bonds at the sixth and fifth carbons from the carboxyl end 
respectively, while several elongase isoforms increase the fatty acid chain length by two 
carbons at the carboxyl end. Long chain PUFAs containing 22 carbons are synthesised 
via additional β-oxidation steps in the peroxisomes Adapted from [56]. 
Initially, it was assumed that the 22 carbon series PUFA such as docosapentaenoic acid 
(22:5n-6) and DHA were converted from AA and eicosapentaenoic acid (EPA, 20:5n-3) 
respectively in humans and mammals by elongation and subsequent desaturation by a 
Δ4 desaturase within the endoplasmic reticulum. However, experiments by Voss et al. 
[57] in rat microsomes using either 14C labelled docosapentaenoic acid (22:5n-3) or 
tetracosapentaenoic acid (24:5n-3) and tetracosahexaenoic acid (24:6n-3) resulted in the 
production of radiolabelled DHA. This finding indicated that at least one round of β-
oxidation of 24-carbon series PUFA was required for DHA synthesis. Unknown at this 
time was whether this β-oxidation step was occurring in the mitochondria or the 
peroxisomes. Martinez and colleagues [58,59] had noted that people suffering from the 
peroxisomal disorder Zellweger syndrome were massively deficient in long chain 
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PUFA such as docosapentaenoic acid (both n-3 and n-6) and DHA, particularly in the 
brain, hinting that the peroxisomes are required for the synthesis of long chain PUFA. 
This deficiency in DHA is so severe that children with Zellweger syndrome suffer acute 
neurological impairment and rarely survive past their first year of life. To test this, 
Christensen et al. [60] incubated 14C radiolabelled adrenic acid (22:4n-6) and 
docosapentaenoic acid (22:5n-3) in both normal and Zellweger fibroblasts. They found 
that the Zellweger fibroblasts were unable to retroconvert these fatty acids to AA and 
EPA respectively, demonstrating that the peroxisomes were required for the β-oxidation 
step needed to synthesise long-chain PUFA. This finding was confirmed by Moore et 
al., [61] who found an inability of Zellweger fibroblasts to produce DHA from 14C 
radiolabelled ALA, docosapentaenoic, tetracosapentaenoic or tetracosahexaenoic acid. 
There are three possible ways to meet the brain’s high requirement for DHA: local 
synthesis from short chain precursors within the brain, synthesis by other organs such as 
the liver, or incorporation from the diet. Whether the human brain itself can synthesise 
adequate levels of DHA from ALA has not been well studied. Cho et al. [62] described 
abundant amounts of Δ6 desaturase mRNA within male adult human brain from post-
mortem tissue. However, experiments in rats have shown that the use of DHA by the 
brain vastly outweighs its ability to synthesise it from ALA, with a 10-fold increase in 
the rate of liver DHA synthesis compensating for this deficiency [63]. Experiments in 
vitro have found a low capacity for cultured neurons to make their own DHA from ALA 
or EPA [64], but marked increases in the synthesis of DHA and AA from ALA or LA 
respectively have been reported in cocultures of astrocytes with brain endothelial cells 
[65,66]. Regardless, the production of DHA from either ALA or EPA is known to be 
quite inefficient overall in adult humans [67,68]. Both n-3 and n-6 PUFA use the same 
enzymatic pathway for synthesis and compete for use of this pathway (Figure 2-4). 
Under normal conditions desaturases have a preference for n-3 over n-6 PUFA, but LA 
is so highly abundant in the average Western diet that levels of long-chain n-6 PUFA 
such as AA never fall below optimum levels (except in cases of severe dietary fatty acid 
deprivation) [69]. By comparison, the levels of ALA in the diet are much lower and 
combined with an overall inefficient conversion to long chain PUFA in humans this 
results in a lower available pool of EPA and DHA. Indeed, most of the DHA present 
within the brain accumulates very early on in development [70], either prior to or in the 
first few months after birth [71–73]. However, newer research suggests some capacity 
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for transport of long-chain n-3 PUFA in the brain of adults [74,75], which likely serves 
to maintain levels of PUFA accrued during infant brain development [76]. Due to the 
brain's lifelong need for long-chain n-3 PUFA, this has led to the belief that both EPA 
and DHA should be considered essential dietary fatty acids [69,77]. 
2.1.5 Ether-linked phospholipids  
The human brain is also highly enriched in phospholipids that contain ether-linked fatty 
acids; mainly the vinyl-ether phospholipids known as plasmalogens. Two types of 
ether-linked phospholipids exist: 1-O-alkyl-2-acyl phospholipids, which contain an 
alkyl ether- linked fatty acid in the sn-1 position and an esterified fatty acid in the 
second; and 1-O-alkenyl-2-acyl phospholipids, which have an alkenyl (or vinyl) ether 
bond linking the fatty acid at the sn-1 position (Figure 2-5). 1-O-alkenyl-2-acyl 
phospholipids are better known by their common name, plasmalogens, and are 
particularly abundant within the PE class of phospholipids in the human brain, 
comprising one-half to two-thirds of this phospholipid class [78]. These PE 
plasmalogens contain PUFA such as DHA and AA in the sn-2 position mostly. Ether-
linked phospholipids are synthesised de novo in the peroxisomes and endoplasmic 
reticulum (reviewed by [79,80], Figure 2-6). Biosynthesis of alkyl-ether phospholipids 
and plasmalogens begins in the peroxisomes, where 1-alkyl-dihydroxyacetone 
phosphate is formed from dihydroxyacetone phosphate via a series of steps. 1-alkyl-
dihydroxyacetone phosphate can then be reduced to 1-alkyl-2-hydroxy-sn-
glycerophosphate by an acyl/alkyl reductase located on the outside of both peroxisomal 
and endoplasmic reticulum membranes. Within the endoplasmic reticulum, the 
phosphate group is removed by phosphatidic acid phosphatase and an acyl group is 
placed in the sn-2 position to form 1-alkyl-2-acyl-sn-glycerol. From here it is converted 
to either a PC or PE either by the same CPT and EPT that add CDP-choline and CDP-
ethanolamine on diacylglycerol to produce diacyl PC or PE (discussed in section 2.1.3), 
forming an alkyl-ether containing PC and PE phospholipids. The vinyl-ether bond seen 
in plasmalogens is introduced by Δ-1’-desaturase, with 1-alkyl-2-acyl-PE being the 
preferred substrate. Choline plasmalogens are primarily formed from hydrolysis of 
ethanolamine plasmalogens followed by the addition of choline via choline-transferase 
[81]. The final fatty acid composition of both alkyl-ether phospholipids and 
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Figure 2-5: Three subclasses of phospholipids bearing either 1,2-acyl (top), 1-O-alky-2-
acyl (middle) or 1-O-alkenyl-2-acyl (bottom) fatty acids. 1-O-alkenyl-2-acyl 
phospholipids are more commonly known as plasmalogens. Shorthand notation for each 
type of phospholipid is indicated on the right. The different sn-1 linkages are 
highlighted in red. 
  
 
1-octadecanoyl-2-docosahexaenoyl-phosphatidylethanolamine PE 18:0/22:6 
 
1-O-octadecyl-2-docosahexaenoyl-phosphatidylethanolamine PE O-18:0/22:6 
 
1-O-octadecenyl-2-docosahexaenoyl-phosphatidylethanolamine PE P-18:0/22:6 
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Figure 2-6: Synthesis of ether-linked phospholipids within mammalian cells. Δ-1’ Δ-1’ 
desaturase; AADHAP-R alkyl/acyl DHAP reductase; AAGP-AT acyl/alkyl 
glycerophosphate acyltransferase; AGPS alkylglycerone phosphate synthase; CPT CDP-
choline:1,2-diacylglycerol cholinephosphotransferase; DHAP dihydroxyacetone 
phosphate; EPT CDP-ethanolamine:1,2-diacylglycerol ethanolamine-
phosphotransferase; GPA glycerophosphate; GNPAT glyceronephosphate-O-
acyltransferase; PAP phosphatidic acid phosphatase; PC phosphatidylcholine; PE 
phosphatidylethanolamine. Adapted from [79,80].  
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plasmalogens is mostly attained via the fatty acid remodelling process described above 
in section 2.1.3. 
Plasmalogens and alkyl-ether lipids have several distinct biological roles. Firstly, their 
presence can alter membrane properties by decreasing fluidity, increasing order, and 
promoting the formation of non-bilayer phases at lower temperatures, a process needed 
for membrane fission and fusion events [79]. Plasmalogens are highly enriched in lipid 
raft domains of the plasma membrane [82,83]. The vinyl ether bond present on 
plasmalogens is also thought to be preferentially oxidised by free radicals and singlet 
oxygen, protecting nearby unsaturated fatty acids [79,80,84]. A deficiency of 
plasmalogens within cell membranes has been observed in several diseases, including 
AD [85–87]. The changes that occur to plasmalogens in AD will be discussed in more 
detail below (section 2.3). 
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2.2 Changes to phospholipids in the brain during normal ageing 
It is known that throughout infancy and childhood development DHA accumulates in 
the brain within PE and PC phospholipids [70]. Surprisingly little is known about the 
changes occurring in the composition of phospholipids in the human brain over the 
adult lifespan. The current knowledge regarding age-related changes in phospholipids of 
the human brain and animal models (predominately rat) is reviewed below.  
2.2.1 Human studies 
2.2.1.1 Total phospholipids 
The level of total phospholipid within the different regions of the human brain either 
decreases or remains unchanged with advanced age (Table 2-1). Decreases with age in 
total phospholipids have been noted in whole cerebral cortex [88] frontal cortex 
(including grey matter) [89–91], temporal cortex (including grey matter) [89,91], and 
hippocampus [90]. No changes in total phospholipids with age have been reported in the 
cerebellum [88,90] or temporal white matter [91].  
2.2.1.2 Phospholipid classes 
Only three studies have examined the changes occurring in individual phospholipids 
classes during normal ageing (Table 2-2). The combined weight of evidence suggests 
that there are no changes with age to total PC, PE or PS within the frontal cortex or 
cerebellum [90,92]. However, there is some disagreement within the literature as to 
whether total PC and PE change with age within the hippocampus, with an equal  
 
Table 2-1: Summary of the available literature on changes in total brain phospholipids 
within different regions of the human brain during normal ageing. 
Total phospholipids Change with age 
Whole cerebral cortex  Decreased[88] 
Frontal Cortex  Decreased[89] 
- Grey  Decreased[90,91,93] 
- White No change[91] Decreased[90,93] 
Temporal Cortex  Decreased[89] 
- Grey  Decreased[91] 
- White No change[91]  
Hippocampus  Decreased[90,93] 
Cerebellum No change[88,90]  
Phospholipids determined by phosphorous assay in all studies.  
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Table 2-2: Summary of the available literature on changes in phospholipid classes 
within different regions of the human brain during normal ageing. 
Phospholipid 
class 
Change  
with age 
Frontal 
Cortex 
Cerebellum Hippocampus 
PC No change [90,92] [90] [90] 
 Decrease [93]  [93] 
PE No change [90,92,93] [90] [90] 
 Decrease   [93] 
PS No change [90,92] [90] [90] 
Phospholipid classes separated by thin-layer chromatography and determined by 
phosphorous assay[90,93] or densitometry [92].  
number of studies finding either no change [90] or decreases with age [93] in both PC 
and PE. 
2.2.1.3 Total phospholipid-fatty acids 
Five studies have previously examined the human brain for any age-related changes in 
the total phospholipid fatty acids (Table 2-3). The frontal cortex is the most highly 
studied brain region for changes to phospholipid-fatty acids with age, with all four 
studies finding few changes to the fatty acids of total phospholipids with age. Increases 
have been reported with age in myristic acid (14:0) within the frontal cortex [94,95], as 
well as in the level of arachidic acid (20:0) [94]. Many of the results within this region 
were conflicting though, with an equal number of studies reporting either no change 
[94,96] or a decrease [92,95] in 22:5n-6 with age, as well as age-related increases [94] 
or no change [96] in 22:5n-3. Carver et al. [94] observed several decreases with age 
within the frontal cortex in long-chain n-6 PUFA, including dihomo-γ-linolenic acid 
(20:3n-6) and adrenic acid, but neither finding was replicated by other studies of this 
brain region [95,96]. The other regions examined,were the temporal and parietal 
cortices, as well as the hippocampus, showed no changes to any phospholipid-fatty 
acids with age [93,96], but these regions have each only been examined in a single 
study and more work is needed to confirm these findings.  
2.2.1.4 Phospholipid fatty acids by class 
Only a single study has looked for any age-related changes in fatty acids within separate 
phospholipid classes in the human brain. No changes were found in either PC or PE 
fatty acids during normal ageing in either the frontal cortex, pons or hippocampus [93].   
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Table 2-3: Summary of the available literature showing changes in total phospholipid 
fatty acids within different regions of the human brain during normal ageing 
Fatty acid Change with age 
Frontal 
Cortex 
Temporal 
Cortex 
Parietal 
Cortex Hippocampus 
14:0 Increased [94,95]    No change [96] [96] [96]  
15:0 No change [92]    
16:0 
Increased [94]    
No change [92,93,96] [96] [96] [93] 
Decreased [95]    
16:1 Increased [95]    No change [92,96] [96] [96]  
18:0 No change [92–94,96] [96] [96] [93] Decreased [95]    
18:1 No change [93]   [93] 
 18:1(n-7) Increased [95]    No change [92,96] [96] [96]  
 18:1(n-9) Increased [95]    No change [92,94,96] [96] [96]  
18:2(n-6) Increased [94]    No change [92,95,96] [96] [96]  
20:0 Increased [94]    
20:1 Increased [95]    No change [92–94,96] [96] [96] [93] 
20:2(n-6) No change [94]    
20:3(n-6) No change [95,96] [96] [96]  Decreased [94]    
20:4(n-6) No change [92–94,96] [96] [96] [93] Decreased [95]    
22:0 No change [94]    
22:2 No change [92]    
22:4(n-6) No change [93,95,96] [96] [96] [93] Decreased [94]    
22:5      
 22:5(n-3) Increased [94]    No change [96] [96] [96]  
 22:5(n-6) No change [94,96] [96] [96]  Decreased [92,95]    
22:6(n-3) No change [92–94,96] [96] [96] [93] Decreased [95]    
24:0 No change [94]    
24:1 No changes [94]    
Total phospholipid fatty acids were determined by the following methods: 
phospholipids transmethylated [92–94] or saponified [95,96], and fatty acid methyl 
esters quantified by gas chromatography. 
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2.2.2 Animal models 
Changes in the phospholipid composition of the brain during normal ageing have also 
been studied using animal models, most notably in the rat. One of the most common 
findings across studies of the rat brain during normal ageing is a reduction in the 
amount of PUFA present in phospholipids, particularly in DHA [97–103]. These age-
related losses of DHA have been reported in PC [100], PE [97,99], and PS [100], as 
well as in total phospholipids fatty acids [98,99,101,103]. DHA is also reported to 
decrease with age in the mouse brain [104]. Other losses of PUFA with age in the rat 
brain included AA in PC [100], PS [102] and in total phospholipids [101,103]; LA in PS 
and PC [102] and in total phospholipids [101,103]; and in adrenic acid in PS [100]. 
Increases with age have been seen consistently in the rat brain monounsaturated fatty 
acids, principally in PE [98,100] and total phospholipids [103]. Changes in total amount 
of phospholipid within the classes have also been reported with age in rat and mouse 
brain, with decreases seen in PC [105,106] , PE [98,105,106], PS [106] and total 
phospholipids [99] with age. Conversely, Modi, Katyare and Patel [105] reported 
increases in PS phospholipids with age in the rat brain, while Fabelo et al. [107] found 
increases in both PE and total phospholipids with age.  
2.3 Changes to phospholipids in the brain during dementia 
Compared to normal ageing, the changes occurring to phospholipids in the human brain 
as a result of dementia have been better studied. AD, the most common form of 
dementia, has been particularly well studied for such changes. A summary of what is 
currently known about the changes occurring within the human brain during different 
dementias is detailed below. 
2.3.1 Alzheimer’s disease 
AD is not only the most common type of dementia, but also the best-studied dementia 
in terms of phospholipid changes to the human brain. As stated in Chapter 1 (section 
1.1), there is strong evidence for an involvement of membrane lipids in the pathogenesis 
of AD. The strongest known genetic risk factor for AD is homozygosity of the APOE-
ε4 allele, with apolipoprotein E being involved in lipid trafficking and metabolism 
within the brain [11,12]. Several genome-wide association studies have also unearthed 
other genetic markers of AD, with many loci being either indirectly or directly involved 
in lipid metabolism [13–15]. Over twenty studies to date have looked for any 
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relationship between brain phospholipids and Alzheimer’s disease, and typically 
included subjects aged between 60 and 100 years of age. However, two studies also 
included subjects less than 60 years old in both control and Alzheimer’s disease groups 
[96,108]. 
Decreased amounts of total phospholipid have been reported in the hippocampus in AD 
[86,109,110], with possible increases seen in the temporal cortex [109,111]. No changes 
to total phospholipid amount have been seen in AD in the frontal cortex [87,108], 
occipital cortex or cerebellum [111]. Within the individual phospholipid classes, the 
combined available evidence suggests no changes have been reported in AD in the total 
amount of PC in the frontal [87,92,108,111–116], entorhinal [116], occipital [111–113], 
temporal [111–115,117] or parietal cortices [111–114], or in the cerebellum 
[111,112,115,116]. Similarly, no changes have been observed in total PE in AD within 
the frontal [87,92,108,111–114], parietal [111–114], entorhinal [116] or occipital 
cortices [111–113], or in the cerebellum [85,111,112,116]. However, decreases in total 
PE in AD have been observed in the hippocampus [86,111,113], while an equal number 
of studies have reported either no change [111,114,117] or decreases [85,112,113] in 
total PE within the temporal cortex. Interestingly, there were two studies that reported 
decreases in total PE in AD within the frontal cortex that used mass spectrometry 
techniques [85,116]. Within the PE class, there is conflicting information available on 
what occurs to the levels of plasmalogens in AD. Decreases in PE plasmalogen have 
been observed in the hippocampus in AD [86]. No changes have been observed in PE-
plasmalogen levels in the occipital [112] or entorhinal cortices [116], as well as in the 
cerebellum [85,112,116] in AD. In the frontal cortex, one study reported increases in 
PE-plasmalogens in AD [112] while others reported no change [87,116] or decreases in 
PE-plasmalogens in AD [85,86]. Similarly, either increases [112] or decreases [85] in 
PE-plasmalogens have been reported in AD in the temporal cortex, as well as either no 
change [112] or decreases [85] in the parietal cortex. Levels of total PS have also been 
found to not change in AD within the frontal [86,87,92,108,111–114,116,117], temporal 
[111,112,114,117], parietal [111,113,114,117], occipital [111,113], or entorhinal 
cortices [116], or in the cerebellum [111,112] and hippocampus [86,111]. 
In terms of fatty acids present in phospholipids, several literature reviews have stated 
that there is a distinct loss of PUFA in AD [38,118–120]. However, examination of the 
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available literature suggests that this conclusion is far from clear. In the frontal cortex, 
the brain region best studied for changes to phospholipids in AD, a number of n-6 and 
n-3 phospholipid-fatty acids have shown no changes in total amount in AD, including: 
LA [87,92,96], dihomo-γ-linolenic acid [87,96], AA [87,92,96,121], EPA [87], adrenic 
acid [87,96], docosapentaenoic acid (both 22:5n-3 [87,96] and 22:5 n-6 [87,92,96]), and 
DHA [87,96,121]. Only a single study has looked at the total phospholipid fatty acids in 
either the temporal cortex [96] or parahippocampus [121], with both cited studies also 
examining the parietal cortex. Correspondingly, these two studies also reported a lack of 
change to many PUFA in AD, with only decreases in adrenic acid observed in the 
temporal cortex [96]. When the fatty acids of the three phospholipid classes PC, PE and 
PS are analysed separately, changes to PUFA in AD have been noted. For most PC-fatty 
acids in the frontal cortex, it appears that there are no changes in their amount in AD in 
the frontal cortex [86,93,108]; however, an equal number of studies found either no 
changes [86,108] or decreases [93,122] in the level of PC-AA. Similar results were seen 
for PC-DHA in the frontal cortex, with both no changes [86,108] or decreases [87,93] 
reported in AD. No changes in AD have been observed in PC fatty acids within the 
parahippocampus/hippocampus [93,122,123]. Only a single study has looked at PC-
fatty acid changes in AD in the pons [93], as well as the temporal and parietal cortices 
and cerebellum [123], finding decreases in cerebellar DHA only. Similarly, few changes 
have been reported for PE-fatty acids within the brain in AD. Of note are possible 
increases in PE-myristic acid [93] and decreases in PE-EPA [87] in the frontal cortex, 
decreases in PE-AA [93,122,123], PE-adrenic acid [93,122] and PE-DHA [93,123] in 
the parahippocampus/hippocampus, decreases in PE-stearic acid (18:0), PE-oleic acid 
and PE-AA in the parietal cortex [123]. In the pons increases in PE-myristic acid, PE-
palmitic acid (16:0) and PE-stearic acid have been reported in AD while decreases have 
been seen in PE-AA, PE-adrenic acid and PE-DHA [93]. PS is the least well-studied 
phospholipid class for changes to its fatty acids in AD, but similar to the other two 
phospholipids few changes have been reported in AD when all the current literature is 
compared. Decreases in PS-EPA [87], PS-docosapentaenoic acid (n-3 [87] and n-6 
[87,108]) have been reported in the frontal cortex, with no change to PS-DHA in AD 
[87,108]. Within the parahippocampus/hippocampus, decreases in AD have been 
observed in PS-adrenic acid only [122], as well as in PS-DHA in both the temporal and 
parietal cortices [114].  
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There are several problems that are driving the ambiguity surrounding many of the 
changes observed in phospholipids in AD. The largest problem is that there are several 
different methods that have been used to analyse phospholipids extracted from tissue. 
Historically, phospholipid classes have been separated and quantified by thin-layer 
chromatography, either by densitometry or by scraping off the various separated classes 
and quantifying by the phosphorous assay. Phospholipid fatty acids have been typically 
analysed by gas chromatography after transmethylation or saponification of the 
phospholipids, sometimes in conjunction with thin-layer chromatography for class 
separation. Newer techniques have been developed for the accurate identification and 
quantification of phospholipids from tissue extracts; however, such instruments are 
costly to purchase and maintain. This idea will be further explored in Chapter 3. Only a 
few studies so far have applied mass spectrometry to the study of phospholipids changes 
in the human brain during AD [85,115]. It is expected that as more studies are 
conducted using such techniques that the changes occurring to phospholipids in the 
human brain as a result of AD will become clearer. 
2.3.2 Other dementias 
2.3.2.1 Parkinson’s disease 
Only a single study has examined changes in phospholipid composition in Parkinson’s 
disease (age range of controls: 79-102 years, Parkinson’s: 66-91 years) [124]. This 
study used liquid chromatography mass spectrometry (LC-MS) to identify a number of 
changes to phospholipids of the visual cortex, amygdala and anterior cingulate cortex. A 
number of phospholipid bruto species (phospholipid class and total fatty acids carbon-
chain length and unsaturation) decreased in the brains of those with Parkinson’s disease, 
particularly in the PE-class within the visual cortex. No losses of any particular type of 
unsaturated fatty acid were reported; however, it is unclear if the authors performed 
such an analysis. 
2.3.2.2 Vascular/multi-infarct dementia 
Vascular dementia (also known as multi-infarct dementia) is caused by problems in 
blood supply to the brain, typically by a minor stroke. Occasionally vascular dementia 
can overlap with the presence of lesions typical of AD, leading to the classification of 
mixed dementia. 
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Only a single study has examined the changes occurring to phospholipids in vascular 
and mixed dementia, which used LC-MS to identify and quantify phospholipids of the 
temporal lobe (average ages of controls 79.9±2 years, vascular dementia 85.3±3 years, 
and mixed dementia 83.4±3 years) [125]. Total PC and PS were observed to increase in 
the white matter in vascular dementia, with no change in grey matter for PC, PE or PS. 
Conversely, levels of both total PC and PE decreased in the grey matter of those 
afflicted with mixed dementia. Bruto phospholipids were also analysed in the grey and 
white matter of the temporal cortex in both vascular and mixed dementia. Increased 
amounts of PC and PS phospholipids were seen in the white matter in vascular dementia 
while decreases in PC phospholipid were mostly observed in the grey matter of mixed 
dementia patients. Given the different aetiologies of vascular dementia and AD, it is not 
surprising that such opposing differences were found between vascular and mixed 
dementia. Further research is needed to understand why these differences occur, and if 
the same pattern is repeated in other parts of the brain affected in vascular and mixed 
dementia. 
2.3.2.3 Huntington’s disease 
The only study of changes in phospholipids in Huntington’s disease to date found no 
differences in the ratio of PE-plasmalogen to diacyl PE within the caudate nucleus in 
Huntington’s disease (average age of controls 77±4 years, Huntington’s 55±5 years) 
[126].  
2.3.2.4 Creutzfeld-Jakob disease 
Two studies have been performed to ascertain any changes in phospholipid content in 
Creutzfeld-Jakob disease (CJD) [127,128]. In a case-control study (n=1 per group) 
Federicco, Annunziata and Malentacchi [128] observed decreases in total phospholipids 
in CJD, with increases found in PE in the white matter and PS in grey matter. 
Corresponding reductions in PS and PC were observed in the white matter in CJD, 
alongside decreases in PC and PE in the grey matter (age of control and CJD subject 
both 67 years). Conversely, Tamai et al. [127] found no changes to any phospholipid 
class in CJD, nor within the fatty acids of PC and PS phospholipids (age of subjects not 
stated). However, they did observe marked increases in PE-oleic acid and decreases in 
PE-adrenic acid and PE-DHA in the brain tissue of humans with CJD. Although CJD 
can be transmitted to humans and from animals to humans via ingestion of or exposure 
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to infected tissues (variant CJD), CJD can also be sporadic or familial in nature. Further 
research is needed to ascertain whether there is a membrane lipid involvement in the 
pathogenesis of CJD, particularly in familial cases. 
2.3.2.5 Frontotemporal dementia 
No studies currently exist that have examined changes in phospholipid composition in 
frontotemporal dementia. 
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2.4 The involvement of phospholipids in the current theories of ageing 
2.4.1 Why do we age? 
There are many proposed theories that attempt to explain the mechanism behind the 
ageing process. Many such theories fall into two broad categories: programmed or error 
theories [129]. According to the programmed theory of ageing, ageing depends upon the 
regulation of the body’s internal “biological clock” through the different stages of 
growth, development, maturity and old age via the switching on and off of certain genes 
[129]. Alternatively, the error theory of ageing proposes that ageing is a result of 
continual environmental stress at the molecular, cellular and whole-organism level, 
resulting in cumulative damage and dysfunction over the lifespan and, eventually, 
death. There are two main error theories of ageing that could apply to changes in 
phospholipids during normal ageing within the human brain, and these theories will be 
explored in the final part of this literature review: the mitochondrial free radical 
oxidative theory of ageing and the “inflammageing” theory.  
2.4.2 Mitochondrial free radical oxidative theory of ageing  
Over the lifetime of an organism, many mutations occur within mitochondrial DNA 
(mtDNA) leading to the progressive loss of mitochondrial function with age. This age-
dependent accumulation of mtDNA mutations can be a result of i) the inherent error rate 
of the mtDNA polymerase γ [130]; or ii) due to the accumulation of reactive oxygen 
species (ROS) generated as byproducts of oxidative phosphorylation over time which 
overwhelm the few existing mtDNA repair mechanisms [131]. mtDNA is thought to be 
especially vulnerable to damage by ROS due to its proximity to the electron transport 
chain, a lack of repair mechanisms and an absence of protective histones [132,133]. 
ROS produced by the mitochondria have the capability to damage macromolecules such 
as DNA, proteins and lipids. Over time, these macromolecules become progressively 
more damaged, leading to the production of more ROS, which leads to a vicious cycle 
of ROS production and macromolecule damage; the net result of which is thought to be 
ageing [134]. The principle ROS generated by oxidative phosphorylation is superoxide, 
but other ROS of significance include hydroxyl radicals, hydrogen peroxide and singlet 
oxygen [135]. 
Harman first proposed the free radical theory of ageing in the 1950s [136], and this 
theory was further strengthened by the discovery of superoxide dismutase in the late 
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1960s [137]. Superoxide dismutase is an essential antioxidant defence enzyme that 
catalyses the ROS superoxide into hydrogen peroxide and oxygen. Hydrogen peroxide 
can then be transformed into water by catalase or glutathione peroxidase. Nonenzymatic 
ROS scavengers (also known as antioxidants) also exist within cells, including 
ascorbate, flavonoids, carotenoids and glutathione. In regards to phospholipids, it is the 
fatty acids that are susceptible to oxidative damage by ROS such as superoxide. The 
susceptibility of fatty acids to oxidative damage by ROS is known to be dependent upon 
the degree of unsaturation (i.e. number of double bonds present). Bisallylic methylene 
groups are particularly susceptible to oxidation as the presence of the double bonds 
weakens the bond energy of this group, allowing the extraction of a proton by ROS to 
form a lipid peroxyl radical (Figure 2-7). Due to this, PUFAs with a large number of 
methylene-interrupted double bonds such as DHA are particularly susceptible to 
oxidative damage [138]. A number of oxidative molecules can be derived from lipid 
peroxyl radicals, including lipid peroxides, aldehydes such as malondialdehyde and 
 
 
Figure 2-7: Lipid peroxidation initiation and propagation : 1. a hydrogen is removed 
from a bisallylic group on a PUFA, forming a carbon radical. 2. molecular 
rearrangement occurs to form a more stable conjugated diene. 3. the carbon radical 
reacts with molecular oxygen (O2) to form a lipid peroxyl radical. 4. A second hydrogen 
is then abstracted from a neighbouring PUFA, forming a lipid hydroperoxide and 
propagating the peroxidation cycle. Both lipid hydroperoxides and peroxyl radicals then 
undergo further reactions to form an array of biologically active carbonyls. HHE 4-
hydroxy-2-hexanal,, HNE 4-hydroxy-2-nonenal,  MDA malondialdehyde, PUFA 
polyunsaturated fatty acid, ROS reactive oxygen species.  
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4-hydroxy-2-nonenal (4-HNE), and isoprostanes such as F2-isoprostanes and F4-
neuroprostanes. Elevated levels of malondialdehyde have been observed in the brain 
tissue of aged rats [139–143] and humans [144]. Increases in 4-HNE have also been 
reported in the brains of aged mice [145], senescence-accelerated mice [146], rats [147], 
and dogs [148]. Changes with isoprostanes during normal ageing have been better 
studied in humans using cerebrospinal fluid, with increases reported in F2-isoprostanes 
with age [149,150]. However, in the brain tissue of rats there has been no reported 
changes in F2-isoprostanes or F4-neuroprostanes with age [151]. Elevated amounts of 
lipid oxidation products have also been reported in age-related neurodegenerative 
diseases such as AD [152]. 
If the mitochondrial free radical oxidative theory of ageing is one of the main driving 
forces behind ageing, then from a phospholipid perspective it is likely that decreases in 
phospholipids containing PUFA within the human brain would occur with age. 
Theoretically, long chain PUFA, particularly DHA, would be most susceptible to 
damage by ROS due to the high number of methylene-interrupted double bonds present 
in this fatty acid. The n-6 fatty acids AA and adrenic acid are also expected to be 
significantly reduced with age according to the free radical oxidative theory of ageing. 
Due to the high proportion of PUFA present in the PE and PS phospholipids of the 
human brain we would also expect to see a corresponding reduction in these 
phospholipid classes with age or a corresponding increase in saturated or 
monounsaturated fatty acids. On a subcellular level, as superoxide is unable to cross 
cellular membranes [153,154] and is primarily generated within the mitochondria, we 
would expect to see a greater loss of phospholipids containing PUFA in the 
mitochondrial membranes with age over other cellular membranes.  
2.4.3 “Inflammageing” theory of ageing 
The term “inflammageing” was first coined by Franceshci and colleagues in 2000 [155] 
and represents the idea that ageing is driven by the presence of low-grade, chronic 
inflammation throughout the lifespan. Franceshci and colleagues have pointed to 
increases in inflammatory markers such as interleukins and tumour necrosis factors with 
age [155–157]; however, it is theoretically possible that phospholipids may be involved 
in this process too. AA is the precursor for a number of pro-inflammatory molecules 
 
CHAPTER 2 
 
31 | P a g e  
 
 
Figure 2-8: Synthesis of inflammatory eicosanoids from arachidonic acid after cleavage 
from phospholipids by phospholipase A2. Image adapted from [158] 
including prostaglandins, leukotrienes and thromboxanes (Figure 2-8). AA is liberated 
from phospholipids within cellular membranes by phospholipase A2 [159], and this free 
AA can then be converted to leukotrienes via the lipoxygenase pathway, or 
prostaglandins and thromboxanes via the cyclooxygenase (COX) pathway. The 
cytosolic phospholipid A2 isoforms primarily present within the brain [160] have a high 
specificity for AA in the sn-2 position [161]. Within mammalian tissues, there are two 
COX present: COX-1 and COX-2. COX-1 is expressed ubiquitously in many tissues 
and cell types, and has a role in maintaining general cell physiology and homeostasis 
while COX-2 shows greater restriction and is known for its role as a respondent to stress 
and insult [162–164]. COX-2 is also known to be expressed throughout the 
hippocampus and cortex [165]. Both COX enzymes convert AA into prostaglandin H2, 
which can then be selectively converted into a number of prostanoids by specific 
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synthases. COX-2 expression within the brain is normally very low but is markedly 
increased in age-related neurodegenerative diseases such as AD [166,167]. There is also 
some evidence implicating changes during ageing to prostaglandin levels and to COX-2 
expression and activity levels in animal models [168]. Both COX-1 and COX-2 can also 
utilise other PUFA such as EPA to produce a range of anti-inflammatory eicosanoids 
including resolvin E1 in non-neural cells [169]. Such metabolites of EPA are yet to be 
detected within brain tissue, possibly due to the low level of PL-EPA present within 
neural membranes. COX-2 can also utilise DHA as a substrate to produce various 
docosanoids [170–172], but a rate approximately 7-fold lower than AA [171]. 
If the “inflammageing” theory of ageing is one of the main driving forces behind normal 
ageing in the human brain, then we would expect to see substantial decreases in n-6 
fatty acids such as AA and adrenic acid over the adult lifespan. Inflammatory 
eicosanoids are known to be produced from adrenic acid in kidney [175], but it is also 
likely that adrenic will undergo β-oxidation in the peroxisomes to replenish the pool of 
available AA (section 2.1.4, Figure 2-4). Assuming no change to PUFA synthesis rates 
in humans with age, if the pool of available AA decreases within the membrane then we 
would expect to see a corresponding age-related decrease in adrenic acid in order to 
maintain membrane homeostasis. Levels of long chain n-3 fatty acids such as DHA 
within the cellular membranes would theoretically be minimally impacted in advanced 
age under this theory due to the preference for AA exhibited by inflammatory enzymes 
[159,161,170–172]. Unlike the mitochondrial free radical theory of ageing, where the 
loss of n-6 PUFA with age would theoretically be confined to the mitochondria, in the 
inflammageing theory of ageing it is hypothesised that all of the membranes making up 
the various organelles of the cell would be affected. 
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2.5 Summary and conclusion 
In this review the importance of phospholipids in the human brain was established, 
particularly those that contain long-chain PUFA such as DHA and AA. The known 
changes to phospholipids within the human brain during normal ageing were detailed, 
with very few studies having been performed in this area. To make up for this deficit in 
the literature, normal ageing in the brains of animal models were also discussed. 
Between animals and human, there appears to be some loss of total PC and PE 
phospholipids with age while animal studies alone showed significant decreases in 
PUFA within the brain over the lifespan. The changes in phospholipid composition in 
the brain as a result of AD have not only been better studied than normal ageing, but 
also more thoroughly than other types of dementia. However, the abundance of 
literature available on the topic (particularly within the frontal cortex), compounded 
with the range of different methods used have produced conflicting results. The sum of 
the available literature suggests that there are perturbations in the total amounts of each 
phospholipid class in several regions of the brain in AD, with possible changes in the 
fatty acid composition. Finally, the current theories of ageing in which phospholipids 
could be involved were explored. In particular, the mitochondrial free radical theory of 
ageing was discussed, as well as the inflammation theory of ageing. 
In order to understand how any changes to the phospholipids of the human brain fit into 
either theory of ageing, there is a requirement to isolate particular organelles by 
subcellular fractionation in order to examine their membranes separately. The next 
chapter will detail the method development of such a technique, as well as refinements 
to the shotgun lipidomic method used to profile membrane composition. 
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Chapter 3 Method development 
3.1 Introduction 
There are many methods described for the fractionation of subcellular components from 
cell culture and fresh tissues. These methods often rely on differences in sedimentation 
rates and buoyant density between different subcellular organelles and components. 
Subcellular fractionation of frozen tissue, however, requires more consideration. The 
use of frozen tissue samples are necessary for the study of the human brain, as fresh 
tissue collection is unfeasible, and human tissue banks store their archived samples 
snap-frozen at -80°C. Frozen tissue that has undergone multiple freeze/thaw cycles 
becomes unsuitable for subcellular fractionation, as freezing and thawing can lead to 
large ice crystal formation which causes lysis of organelles [176,177]. Therefore, the 
first step was to develop a suitable method for the fractionation of frozen human brain 
tissue.  
The method developed for the subcellular fractionation of frozen tissue also had to be 
suitable for the extraction and analysis of both membrane lipids and proteins. While the 
focus of this thesis was age-related changes in membrane lipids in the human brain, this 
work formed part of a larger study also examining age-related changes to membrane 
proteins. The most commonly used method for membrane lipid extraction is a biphasic 
organic solvent system that requires very little starting sample, but this method is 
incompatible with samples containing a large amount of salt or water. Conversely, the 
conventional methods used for protein extraction and analysis require large amounts of 
starting material, plus buffered salt and detergent solutions that would interfere with 
lipid extraction and analysis. Thus, several potential methods were investigated in order 
to achieve a compatible method for both membrane lipid and protein analysis from the 
same tissue specimens. 
In this chapter, method development will be presented and discussed, including the final 
method used for subcellular fractionation and analysis of membrane lipids from frozen 
post-mortem human brain tissue.   
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3.2 Results/Discussion 
3.2.1 Subcellular fractionation of frozen tissue 
The first step in method development was to find a subcellular fractionation method for 
use with frozen tissue. Method development was conducted using lamb brain sourced 
from a local butcher. This tissue was purchased for use directly after delivery from the 
abattoir, which ensured that the tissue had not been previously frozen. Approximately 
10 mm sections of frontal lobe (anterior to ansate sulcus) from both hemispheres were 
dissected from the lamb brain and snap frozen in liquid nitrogen. The samples were then 
stored at -80°C until required.  
3.2.1.1 Subcellular fractionation: method one 
The first fractionation method assessed followed the procedure outlined by Bourova et 
al. [178]. Frozen lamb brain tissue (250 mg, n = 6) was homogenised using a glass 
dounce homogeniser in an ice-cold buffer consisting of: 250 mM sucrose, 20 mM Tris-
HCl (pH 7.4), 3 mM MgCl2, 1 mM ethylenediaminetetraacetic acid (EDTA), and 
complete protease inhibitor cocktail. After centrifugation to remove large cellular debris 
(1000 x g, 10 min), the homogenate was filtered (80 µm pore) and applied to the top of 
a 30% Percoll solution. Ultracentrifugation (65 000 x g, 30 min) was then used to 
separate mitochondria from the other cellular membranes. Two visible layers were 
expected after the 30 min centrifugation; however, this did not occur. Accordingly, the 
filtered homogenate was subjected to a second centrifugation (65 000 x g, 30 min). 
After the second centrifugation two layers were present: a thick, viscous upper layer 
identified by Bourova et al. [178] as the “plasma membrane layer”, and a second 
mitochondrial layer under a compacted layer of Percoll sediment. The upper plasma 
membrane layer was collected; however the mitochondrial layer was small and unable 
to be separated from the compacted Percoll. The collected plasma membrane layer was 
resuspended in the same buffer, and any remaining Percoll was removed by 
ultracentrifugation (175 000 x g 90 min). Following this, the plasma membrane fraction 
(n = 3) was suspended in a second buffer containing: 150 mM NaCl, 20 mM Tris-HCl 
pH (7.4), 3 mM MgCl2, and 1 mM EDTA, and applied to a density gradient consisting 
of 1.5 mL layers of 15%, 20%, 25%, 30%, 35% sucrose. This gradient was 
ultracentrifuged (187 000 x g 24 hours) to separate the plasma membrane into two  
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Figure 3-1: Sucrose density gradient profile of total protein as a plasma membrane 
marker. Total protein was measured from n=3 samples, and results reported as mean ± 
S.E.M 
layers. These layers were identified by Bourova et al. [178] as being “low density 
(myelin)” and “bulk plasma membrane”. As neither of these fractions were clearly 
visible, the gradient was collected from the top to the bottom in 1 mL aliquots and 
subjected to a protein assay for determination of membrane location (Figure 3-1).  
According to the results of Bourova et al. [178], the bulk plasma membrane fraction 
should have been easily located in fractions 7-8 by the highest levels of total protein. 
However, our results showed that fraction 12 contained the largest amount of total 
protein (Figure 3-1). Examination of the literature revealed that the subcellular 
fractionation of frozen tissue is difficult to perform successfully as freeze-thaw cycles 
tend to lyse the cells and their subcellular compartments [176,177]. Since our 
experiment used frozen tissue this would explain the abundance of protein present in the 
lowest fraction: the lamb brain tissue may have been exposed to multiple freeze-thaw 
cycles, damaging membrane integrity and resulting in fragmentation which prevented 
the cellular membranes from fractionating completely. Bourova et al. [178] used fresh 
rat brain tissue in their study, which meant that they would not suffer the same 
problems. Therefore, an alternative method was needed for use in this study. 
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3.2.1.2 Subcellular fractionation: method two 
With that in mind, a simpler method using differential centrifugation was trialled. The 
advantage of subcellular fractionation by differential centrifugation without a gradient 
such as sucrose or Percoll is that it requires fewer purification steps, which can increase 
the yield of the available substrate [179]. This method also had the advantage of having 
been successfully applied to frozen human brain tissue with a sufficient degree of 
specificity for the isolation of the intended subcellular compartment [177]. To explore 
the suitability of this method, approximately 100 mg of frozen lamb brain was 
homogenised using a bead homogeniser (FastPrep®-24 Instrument, MP Biomedicals, 
NSW, Australia) with 1.4 mm zirconium oxide beads at a speed of 6.0 m/s, in 1 mL of 
an ice-cold 20 mM Tris buffer (pH 7.4) containing: 250 mM sucrose, 2 mM of EDTA, 2 
mM of dithiothreitol (DTT) and complete protease inhibitor. The homogenate was 
centrifuged (1000 x g, 10 min) to give a pellet containing nuclei and large cellular 
debris, which was discarded. The supernatant was collected and centrifuged (35 min, 10 
000 x g) to produce a pellet enriched in mitochondria. The supernatant was centrifuged 
again (40 min, 100 000 x g) to produce a microsomal pellet (endomembranous system 
comprised of Golgi, endoplasmic reticulum and plasma membrane) and cytosolic 
supernatant. Both the mitochondrial and microsomal pellets were resuspended in milliQ 
H2O (4°C) prior to being prepared for lipid and protein analysis. 
3.2.1.3 Western blotting 
To test whether this subcellular fractionation method isolated the correct fraction, a 
series of Western blots were performed looking for specific subcellular markers. Both 
the microsomal and mitochondrial fractions were obtained from lamb brain using the 
second fractionation method (section 3.2.1.2). Whole mitochondrial and microsomal 
pellets were solubilised in 500 µL and 100 µL respectively of a solution consisting of 7 
M Urea, 10 mM Tris buffer (pH 8.0) and 5 µL of 1 mM DTT. Both 1x and 2x dilutions 
were made for both membrane fractions, and these were incubated with cracking buffer 
(100°C, 10 min). The dilutions of both fractions were separated by electrophoresis on a 
12.5% sodium dodecyl sulphate-polyacrylamide gel electrophoresis gel and transferred 
to a polyvinylidene fluoride (PVDF) membrane. The PVDF membrane was probed for 2 
hours at 4°C with a primary antibody corresponding to a marker of a particular 
subcellular organelle. Sodium-potassium-ATPase were used as a plasma membrane 
marker (1:5000, Sapphire Biosciences, Australia), cytochrome c for mitochondria 
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(1:1000, Sigma-Aldrich, Australia) and β-actin as a control (1:4000, Sigma-Aldrich, 
Australia). An additional marker for endoplasmic reticulum was also trialed (ERP29, 
Sigma-Aldrich, Australia), but this antibody was found to be unsuitable for use with 
lamb brain. After incubation with the primary antibodies the membrane was washed in 
TBST (3 times, 5 mins each), and incubated with horseradish peroxidase-conjugated 
IgGs (anti-rabbit or anti-mouse depending on primary antibodies, 1:2000, Sapphire 
Biosciences, Australia) at room temperature for 1 hour. Following this the membrane 
was washed again in TBST (3 times, 5 mins each) and developed colourmetrically using 
0.05% 3,3’-diaminobenzidine  and 30% hydrogen peroxide. After 2-5 mins of 
incubation with 0.05% 3,3’-diaminobenzidine, the membrane was washed in milliQ 
H2O and stored in PBS. The bands typically developed their maximum colour overnight 
while stored in PBS, after which they were recorded using a densitometer (GS-800™, 
BioRad, USA). The results of the Western blotting for the subcellular markers can be 
seen in Figure 3-2. 
Immunoblotting of the mitochondrial and microsomal subcellular fractions showed that 
the sodium-potassium-ATPase was primarily located in the microsomal fraction. Lower 
amounts sodium-potassium-ATPase were also seen in the mitochondrial  
 
 
Figure 3-2: Western blot of mitochondrial (Mito) and microsomal (Micro) subcellular 
fractions obtained from frozen lamb brain.  Fractions were run either undiluted (1x) or 
at 1:1 dilution (2x) in buffer containing 7M urea and 10mM Tris (pH 8.0). Primary 
antibodies used included sodium-potassium-ATPase (Na-K-ATPase) as a plasma 
membrane marker, and cytochrome c as the mitochondrial marker, with β-actin run as a 
control. The labelled bands were visualised colourmetrically by developing with 3,3'-
diaminobenzidine and hydrogen peroxide after application of secondary antibodies. 
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fraction as well, but this was expected with this crude method of fractionation. 
Cytochrome c appeared in the mitochondrial fraction as a tetramer at around 50-60 kDa, 
but most importantly it was not present in the microsomes, indicating that there was no 
mitochondria present in the microsomal fraction. These results show that while crude, 
this fractionation method was suitable for use with frozen brain tissue in this study.  
3.2.2 Membrane lipid extraction and analysis 
Recent advances in mass spectrometry techniques such as electrospray ionisation have 
enabled increased sensitivity in the detection and accurate characterization, 
identification, and quantitation of membrane lipid species from biological samples. A 
shotgun lipidomic approach involves direct infusion of extracted lipid mixtures from 
biological samples into the mass spectrometer without any prior chromatographic 
separation. The most commonly reported method for extraction of membrane lipids 
from biological samples is the Folch method [180]. The Folch method is a biphasic 
solvent system consisting of a 2:1 v/v mixture of chloroform:methanol which separates 
into an organic phase and an aqueous phase upon the addition of water and salt, 
allowing the partitioning of polar and non-polar lipids from the tissue homogenate. This 
method also results in the precipitation of any proteins in the extract, which appear as a 
layer at the interface between the organic and aqueous phases. In the present study, 2 
mL of the chloroform:methanol solvent mixture was added directly to the mitochondrial 
and microsomal pellets obtained from lamb brain tissue, along with butylated 
hydroxytoluene (BHT; 0.01% w/v) to prevent oxidation of the lipids during extraction.  
3.2.2.1 Membrane lipid extraction: method one 
An internal standard solution was employed during initial experiments for use in lipid 
quantification and consisted of the following lipids stored in chloroform:methanol (2:1, 
v/v): 250 µM PC 19:0/19:0, 188 µM PE 17:0/17:0, 188 µM PS 17:0/17:0, 25 µM 
phosphatidylglycerol 17:0/17:0, 25 µM phosphatidic acid 17:0/17:0, 25 µM cardiolipin 
14:0/14:0/14:0/14:0, 250 µM dihydrosphingomyelin 12:0, 25 µM lyso-PC 17:0, 25 µM 
lyso-PE 14:0 and 13 µM ceramide 17:0. Internal standards were added to the whole 
fractionated mitochondrial and microsomal pellets at a volume of 20 µL and 10 µL 
respectively. After the addition of the internal standards, all samples were allowed to 
rotate overnight at 4°C. Lipid extraction then followed a modified Folch extraction 
method reported by Deeley et al. [181]. Firstly, 500µL of 0.15 M ammonium acetate 
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was added to each sample. Samples were vortexed vigorously and centrifuged (1000 x 
g, 10 min) in order to separate the aqueous (upper) and organic (lower) phases. The 
organic (lipid-containing) phase was then removed and a second 2 mL volume of 
chloroform:methanol (2:1 v/v with 0.01% BHT) was added. Following a second round 
of vortexing and centrifugation the lower phase was again removed and combined with 
the first organic phase. A second 500 µL of 0.15 M ammonium acetate was added to the 
combined organic phases, and the samples were vortexed and centrifuged a final time. 
The upper aqueous phase was removed, and the lower phase dried at 37°C under 
nitrogen. The dried lipids were then reconstituted in 1 – 1.5 mL of chloroform:methanol 
(1:2 v/v with 0.01% BHT) and stored at -20°C until mass spectrometry was performed. 
3.2.2.2 Membrane lipid analysis by mass spectrometry 
Nano-electrospray ionization (nano-ESI) mass spectrometry of lipid extracts was 
performed using a hybrid triple quadrupole linear ion trap mass spectrometer (QTRAP® 
5500 AB Sciex, USA) equipped with an automated chip-based nano-ESI source 
(TriVersa Nanomate™, Advion Biosciences, USA). Samples were diluted to 
approximately 10 µM for total phospholipids, spiked with 5 mM of ammonium acetate, 
and loaded onto a 96-well plate. The plate was centrifuged (2200 x g, 10 min) prior to 
direct infusion. Spray parameters were set at a gas pressure of 0.4 psi and a voltage of 
1.2 and 1.1 kV for positive and negative ion mode respectively for all acquisitions. 
Phospholipid data was acquired by targeted ion scans using multi-channel acquisition 
(Table 3-1). A faster scan rate (1000 Da/s) was used for negative ion fatty acid scans to 
ensure spectra could be obtained within one hour (average maximum stability of 
nanospray for 10 µL of sample). 
Lipidview™ software (version 1.2, AB Sciex, USA) was used to quantify phospholipids 
from internal standards present in positive ion head group scans. Processing settings in 
LipidView™ were set with a mass tolerance of 0.5 Da, with a minimum intensity of 
0.1% and a minimum signal/noise of 10. Isotopic correction was also used. Any 
phospholipids comprising less than 0.5% of each class across the cohort were removed 
from the final analysis. 
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Table 3-1: nanoESI-MS settings for targeted ion scans used to acquire phospholipid 
data in human brain mitochondria and microsomes 
Lipid Ion Mode Scan CE Mass range (Da) 
Head group scans 
PC +ve PI 184.1 47 640-1000 
PE +ve NL 141.0 30 685-950 
PS +ve NL 185.0 30 755-965 
Lyso-PC +ve PI 184.1 47 450-600 
Lyso-PE +ve NL 141.0 30 400-600 
Fatty acyl chain scans 
14:0 -ve PI 227.2 -55 580-900 
16:1 -ve PI 253.2 -55 600-900 
16:0 -ve PI 255.2 -55 600-900 
17:0 -ve PI 269.3 -55 560-900 
18:2 -ve PI 279.2 -40 600-900 
18:1 -ve PI 281.3 -55 600-900 
18:0 -ve PI 283.3 -55 600-900 
19:0 -ve PI 297.3 -55 600-900 
20:5 -ve PI 301.2 -40 500-1000 
20:4 -ve PI 303.2 -40 600-1000 
20:3 -ve PI 305.2 -40 600-1000 
20:2 -ve PI 307.2 -40 600-1000 
20:1 -ve PI 309.2 -55 600-1000 
20:0 -ve PI 311.2 -55 600-1000 
22:6 -ve PI 327.2 -40 700-1000 
22:5 -ve PI 329.2 -40 700-1000 
22:4 -ve PI 331.2 -40 700-1000 
22:3 -ve PI 333.3 -40 600-1000 
Scan rate for positive ion mode was 200 Da/s, for negative ion mode 1000 Da/s. Mass 
shifting was prevented in negative ion mode by increasing the number of summed 
scans. PI Precursor ion, NL neutral loss, CE collision energy. 
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Figure 3-3: Phosphatidylcholines (PC) obtained from microsomal and mitochondrial 
fractions of lamb brain (n = 4, error bars show S.E.M.).  PC was detected from both 
fractions by tandem mass spectrometry from a precursor ion scan of 184.1 m/z. PCs are 
shown as: A) amount of each phospholipid detected (nmol/sample), and B) as a 
percentage of total PC detected.   
CHAPTER 3 
 
44 | P a g e  
 
3.2.2.3 Analysis of results for membrane lipids 
Due to the inability to obtain an accurate weight for the mitochondrial and microsomal 
fractions, the internal standards were initially added to the fractions in a specific amount 
(20 µL and 10 µL respectively). However, this became problematic during 
quantification as the differences seen in the amount of each molecular phospholipid 
between the two fractions was based on the quantity of total lipid present in the pellet of 
each membrane fraction without considering individual pellet yield of each fraction 
(Figure 3-3A). The mitochondrial fraction produced a much larger pellet during 
fractionation than the microsomes, and when both fractions were plotted against each 
other all phospholipids detected in the mitochondria were higher in abundance than 
those in the microsomes. Plotting the phospholipids as a proportion of total PC (Figure 
3-3B) shows the profile of the two species to be almost equal, however. Therefore it 
was determined that addition of the internal standards should be on the basis of a 
common factor between the two fractions, such as total protein amount, to better show 
any differences in each phospholipid independent of pellet mass per membrane fraction. 
3.2.2.4 Membrane lipid extraction: method two 
To that end, the internal standards were adjusted to 20 µM each of: PC 19:0/19:0, PE 
17:0/17:0, PS 17:0/17:0, phosphatidylglycerol 17:0/17:0, phosphatidic acid 17:0/17:0, 
cardiolipin 14:0/14:0/14:0/14:0 and dihydrosphingomyelin 12:0; along with 10 µM of 
lyso-PC 17:0, lyso-PE 14:0 and ceramide (17:0). Aliquots (75 µg of total protein) from 
the mitochondrial and microsomal fractions were added to chloroform:methanol (2 mL, 
2:1 v/v with 0.01% BHT) with 50 µL of the adjusted internal standard mixture. Lipid 
extraction then followed the method previously outlined above in section 3.2.2.1.  
Results from the analysis of PC from both the microsomal and mitochondrial fractions 
of lamb brain with the new internal standard formulation can be seen in Figure 3-4. In 
Figure 3-4A it can be seen that the quantified values of the microsomal fraction are no 
longer consistently lower than the mitochondrial fraction, and variation in the amount of 
individual phospholipids are seen between the two membrane fractions. The standard 
error of each quantified phospholipid is also significantly reduced. This result 
demonstrates that this second method of quantification using total protein as a 
denominator is superior to the first method trialled, and is more suitable for use in the 
extraction and analysis of lipids from fractionated human brain issue.  
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Figure 3-4: Phosphatidylcholines (PC) obtained from microsomal (n = 6) and 
mitochondrial fractions of lamb brain (n = 5), with error bars showing S.E.M. PC was 
detected from both fractions by tandem mass spectrometry from a precursor ion scan of 
184.1 m/z. PCs are shown as: A amount of each phospholipid detected (pmol/µg total 
protein) and B as a percentage of total PC detected.  
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3.2.2.5 Development of a method for analysing complete phospholipids 
The final hurdle in the development of a method for the extraction, detection, and 
analysis of membrane lipids from the mitochondrial and microsomal fractions of human 
brain tissue was to produce an automated method to characterise all phospholipids 
within a sample complete with fatty acyl chain pairing. The analysis of phospholipids is 
conducted using both positive and negative ion scans by tandem mass spectrometry 
(Table 3-1). These positive precursor ion and neutral loss scans are used to detect the 
head groups for PC, PE and PS, and with the use of Lipidview™ (version 1.2) the bruto 
structure of the phospholipids can be obtained, including the total number of carbons in 
both fatty acids and the presence of any double bonds (i.e PC 34:1). This result does not 
give any specific information on the identity of each of the individual fatty acids present 
on the phospholipid though (i.e. PC 16:0_18:1). The fatty acid data is detected in the 
negative precursor ion scans, but the version of Lipidview™ available at the time of this 
analysis did not allow the concurrent analysis of both positive and negative ion spectra 
to obtain complete molecular phospholipid structure. This procedure has been 
previously performed manually in our laboratory by inspecting the spectra and looking 
for complementary positive and negative ions. An example of how such an analysis can 
be achieved is shown in Figure 3-5. Completing the analysis of the molecular 
phospholipids manually for this study was unfeasible though, due to the high number of 
samples. Therefore, there was a need to develop an automated method for the 
quantification of complete phospholipids with fatty acid pairs. 
The first step in developing this method was to quantify all detected phospholipids from 
the positive ion precursor ion and neutral loss scans using Lipidview™ as described 
previously (section 3.2.2.2). Next, each phospholipid quantified by Lipidview™ was 
assessed for possible isobaric molecular phospholipids (i.e. phospholipid species of the 
same mass but with a different fatty acid combination) using the lipid catalogue tool in 
Lipidview™, and a target list of all possible fatty acid pairs for each phospholipid 
detected in positive ion mode was generated. An example of the target list entry for PC 
34:1 can be seen in Table 3-2. Acetate adducts were used in negative precursor ion 
scans for PC fatty acids, while deprotonated ions were used for the fatty acids of PE and 
PS. Once generated, this target list was then applied to the negative precursor ion scans 
for fatty acids using Lipidview™ with the same settings as described above (section 
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Figure 3-5: Example of how phospholipid composition can be determined using 
negative-ion mass spectra. Neutral loss scan with an offset of -87 Da identifies 
phospholipids with a phosphatidylserine head group. (b) Precursor ion scan for m/z 255 
identifies phospholipids with a palmitate (16:0) acyl chain. (c) Precursor ion scan for 
m/z 281 identifies phospholipids with an oleate (18:1) acyl chain. Observation of m/z 
760 in all three scans identifies the presence of glycerophosphatidyl serine (16:0_18:1) 
in the extract. Figure from Blanskby and Mitchell[29] 
3.2.2.2). After analysis by Lipidview™ the peak areas of each fatty acid detected were 
grouped by molecular phospholipid and exported for further analysis in Microsoft® 
Excel (2010). 
A spreadsheet was developed using Microsoft® Excel (2010) to quantify complete 
molecular species of phospholipids by combining the results of the negative ion fatty 
acid peak areas with the gross phospholipid structure quantified from the positive ions. 
This was achieved for diacyl phospholipids (phospholipids with two esterified fatty 
acids) by several steps. An example of how this spreadsheet quantifies complete 
phospholipid molecular species is shown in Figure 3-6 for six samples of the prefrontal 
cortex using PC 34:1. The target list generated from the negative ion Lipidview™ 
analysis contained fatty acid pairs arranged by mass (see Table 3-2 for example), and 
from this peak areas could be generated and exported directly as a spreadsheet in 
Microsoft® Excel. The next step adds the peak areas for corresponding fatty acids 
together to represent the total peak area for a given molecular phospholipid. Both fatty 
acids within the phospholipid had to have a peak area greater than zero for it to be 
included in the analysis. The following step determines the proportion of a given  
  
 
 
 
 
 
 
Table 3-2: Example of target list entry used for phospholipid molecular species determination of PC 34:1 in negative ion mode. 
PL molecular species Mass (m/z) 
Precursor 
ion scan 
Ion 
Mode Fatty acid PL Class PL species 
Isotope 
 correction factor 
PC 14:0_20:1+AcO 818.6 227.20 Negative 14:0 PC PC 34:1+AcO 1.6420 
PC 14:0_20:1+AcO 818.6 309.20 Negative 20:1 PC PC 34:1+AcO 1.6420 
PC 16:0_18:1+AcO 818.6 281.30 Negative 18:1 PC PC 34:1+AcO 1.6420 
PC 16:0_18:1+AcO 818.6 255.20 Negative 16:0 PC PC 34:1+AcO 1.6420 
PC 16:1_18:0+AcO 818.6 253.20 Negative 16:1 PC PC 34:1+AcO 1.6420 
PC 16:1_18:0+AcO 818.6 283.30 Negative 18:0 PC PC 34:1+AcO 1.6420 
Phospholipid PL Phosphatidylcholine PC Acetate adduct +AcO  
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Figure 3-6: Example of the spreadsheet used for identification and quantification of 
phospholipids with isobaric fatty acids.  Peak areas used in this example come from 6 
microsomal fraction samples taken from the human prefrontal cortex. Peak area PA. 
* Only added if the peak area from both fatty acids is present 
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phospholipid within the total isobaric molecular phospholipids. Using the example of PC 
34:1 from Figure 3-6, the peak area of PC 16:0_18:1 is divided by the sum of the peak 
areas from PC 14:0_20:1, PC 16:0_18:1 and PC 16:1_18:0 to obtain PC 16:0_18:1 as a 
proportion of total PC 34:1. This ratio could then be multiplied by the amount quantified 
for PC 34:1, giving the total quantified amount of PC 16:0_18:1 in the sample. Using a 
worked example from Figure 3-6, in sample 10F Micro PC 16:0_18:1 made up 99% of all 
isobaric phospholipids detected for PC 34:1. Total PC 34:1 was quantified as being134.07 
pmol/µg membrane protein in the same sample from the positive ion spectra. Therefore 
the quantified amount of PC 16:0_18:1 in sample 10F Micro is 99% of 134.07 pmol/µg 
membrane protein, which is equal to 132.08 pmol/µg membrane protein. This same 
process is used for every sample in all regions examined in this study, with the 
spreadsheet designed to handle up to 36 samples. Isobaric phospholipids containing either 
an odd-chain or ether-linked fatty acids in the sn-1 position required a different approach 
to that used for to diacyl phospholipids. The odd-chain fatty acids, being esterified to 
glycerol, can be detected using the negative precursor ion scans. The ether-linked fatty 
acids, however, are not able to be detected as the energy required to break the ether bond 
is not accessible in a triple quadrupole mass spectrometer [182]. The sn-2 esterified fatty 
acid can also be detected, but the peak area measured for this fatty acid will be the total 
peak area for both isobaric species. For example, PE 15:0_22:6 is isobaric with PE O-
16:0_22:6, and in negative ion mode both will have a deprotonated mass of 748.6 m/z. 
We can detect the 15:0 and 22:6 fatty acids for both isobaric species with our precursor 
ion scans, but not O-16:0. We cannot determine the proportion of PE O-16:0_22:6 from 
this data by subtracting the peak area measured for 15:0 from that of 22:6 either due to 
differences in fragmentation efficiency between sn-1 and sn-2 positional fatty acids [183]. 
Therefore we can only say that either isobaric phospholipid may be present at this mass, 
and report it as being either phospholipid (i.e. PE 15:0_22:6/O-16:0_22:6).  
However, there are some limitations to this method of determining complete 
phospholipids, including the previously mentioned inability to separate isobaric species 
with either odd-chain or ether-linked fatty acids. The second limitation is that we cannot 
definitively distinguish between phospholipids containing an alkenyl ether versus 
phospholipids with an alkyl ether-linked fatty acid containing a double bond. Alkenyl 
ethers (also known as plasmalogens) are fatty acids that contain a vinyl ether bond (i.e. a 
double bond on the first carbon from the ether end). With the mass spectrometry 
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technique used in this study, it is impossible to tell the position of that double bond along 
the fatty acid chain. Therefore, we can only say that the double bond is present in an 
ether-linked fatty acid, rather than identifying it specifically as a plasmalogen. Due to the 
presence of the vinyl ether bond in the sn-1 position, plasmalogen PEs do not show 
abundant peaks when detected by the neutral loss of 141 Da compared to diacyl PE 
phospholipids [184,185], and a correction factor is commonly applied to account for this 
[186]. Because we could not definitively distinguish plasmalogens in this study no such 
correction factor was used, and due to this plasmalogen levels will likely be 
underestimated. Likewise we were unable to determine double bond position for PUFA, 
and thus could not distinguish between  n-3 and n-6 fatty acids. Putative classification of 
n-3 and n-6 fatty acids can be made, however, based on their synthesis as this pathway 
produces specific fatty acid isomers. Identification of the fatty acids can also be made 
from previous studies of human brain lipids that used analysis techniques with the ability 
separate n-3/n-6 isomers (such as gas chromatography). The final limitation is that we 
cannot tell which sn position the fatty acids are in on the glycerol backbone using this 
mass spectrometry technique; we can only assume sn position for fatty acids based on the 
previous literature. Hence, the nomenclature employed in this thesis follows that set out 
by Liebisch et al.[187] for fatty acids with unknown positional information, with the two 
fatty acids identified being separated by an underscore.  
3.3 Conclusions 
Described in this chapter are the preliminary stages of this thesis, which investigated 
methods for the subcellular fractionation of frozen post-mortem human brain tissue. Also 
developed were methods for the extraction and analysis of membrane lipids from the 
fractionated tissue.  
The fractionation of frozen human brain tissue into its subcellular components required 
consideration. Only a small amount of tissue could be obtained, and the method needed to 
overcome the problems associated with frozen tissue such as multiple freeze/thaw cycles 
leading to damage of organelles. The methods used were also required to be compatible 
with the downstream analysis of membrane lipids and protein, both of which require very 
different conditions. To that end, a simple but crude fractionation method was developed 
which relied on the differences in sedimentation rates between the various fractions. 
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While crude, this method was specific for the organelles being examined (section 3.2.1.3) 
and gave a sufficient yield of fraction for analysis of lipids. 
After the fractionation method had been developed, procedures for the analysis of 
membrane lipids were examined. Methods for the extraction and analysis of membrane 
lipids had previously been developed in our laboratory, and these methods were tested for 
compatibility with this study. An adjustment to how the internal standards were added to 
the subcellular fractions was required to improve quantification. Additionally, a 
spreadsheet to quantify phospholipids complete with fatty acid data from both the positive 
and negative ion mass spectrometry data was developed for this study. 
The details of the final methods for membrane lipid extraction and analysis as determined 
by these investigations are given in detail in section 3.4 below, as well as the final 
demographics of the cohort from which the brain tissue for all regions studied was 
obtained. These methods for subcellular fractionation and membrane lipid extraction and 
analysis were then applied to the studies described in the following chapters. 
3.4 Method 
3.4.1 Post-mortem human brain tissue 
Neurologically normal frozen post mortem human brain tissue from five different regions 
was obtained from the New South Wales Tissue Resource Centre at the University of 
Sydney. These regions included the dorsolateral prefrontal cortex, hippocampus, 
entorhinal cortex, primary motor cortex, and cerebellum. The complete demographics for 
these samples are listed in Table 3-3. No differences between the two sexes were 
observed in post-mortem interval and brain pH, but females were significantly older than 
males (71.4±7.0 years versus 52.7±3.9 respectively, p < 0.05). The samples were shipped 
on dry ice and stored at -80°C prior to analysis. The brain tissue was pulverised on dry ice 
prior to being accurately weighed for subcellular fractionation. All experiments were 
approved by and conducted in accordance with the Human Research Ethics Committee of 
the University of Wollongong (HE11/267). 
3.4.2 Subcellular Fractionation 
Approximately 100 mg of pulverised brain tissue from each brain region was 
homogenised with a bead homogeniser (FastPrep®-24 instrument, MP Biomedicals, 
NSW, Australia) set at a speed of 6.0 m/s for 40 seconds, using 1.4mm zirconium oxide 
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beads in 1 mL of an ice-cold 20 mM Tris buffer (pH 7.4) containing 250 mM sucrose, 2 
mM EDTA, 2 mM DTT and complete protease inhibitor. The homogenate was then 
centrifuged (1000 x g, 10 min) to give a pellet containing nuclei and large cellular debris. 
The supernatant was collected and centrifuged (10 000 x g, 35 min) to produce a pellet 
enriched in mitochondria. The supernatant was centrifuged again (100 000 x g, 40 min) to 
produce a microsomal pellet and cytosolic supernatant. All centrifugation steps were 
performed at 4°C. Both the mitochondrial and microsomal pellets were resuspended in 
milliQ H2O, and total protein content was determined using the BCA assay 
(ThermoFisher, USA). 
3.4.3 Lipid extraction 
Aliquots (75 µg of total protein) from the mitochondrial and microsomal fractions were 
added to chloroform:methanol (2 mL, 2:1 v/v with 0.01% BHT) with 50 µL of internal 
standard mixture (as described in 3.2.2.4). Lipids were extracted using a modified Folch 
method as previously outlined in this chapter (section 3.2.2.1). Extracted lipids were 
reconstituted in chloroform:methanol (1 mL, 1:2 v/v with 0.01% BHT), and stored at -
20°C until analysed. All solvents used were of HPLC-grade or higher. 
3.4.4 Mass spectrometry and lipid analysis 
NanoESI mass spectrometry of lipid extracts was performed using a hybrid triple 
quadrupole linear ion trap mass spectrometer (QTRAP® 5500 AB Sciex, MA, USA) 
equipped with an automated chip-based nanoESI source (TriVersa Nanomate™, Advion 
Biosciences, NY, USA). Samples were diluted to approximately 10 µM for total 
phospholipids, spiked with 5 mM of ammonium acetate, and loaded onto a 96-well plate. 
The plate was then centrifuged (10 min, 2200 x g) prior to direct infusion. Spray 
parameters were set at a gas pressure of 0.4 psi and a voltage of 1.2 kV and 1.1 kV for 
positive and negative ion mode respectively for all acquisitions. Phospholipid data was 
acquired by targeted ion scans using multi-channel acquisition (Table 3-1).  
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Table 3-3: Demographics and cause of death of donors from which all brain tissue was 
obtained. 
 
  
Age 
(Years) 
Gender PMI 
(hours) 
Brain pH Cause of death 
category 
Cause of death 
clinical 
18 Male 28.5 6.7 Cardiac Primary cardiac arrhythmia 
21 Female 39.5 6.83 Cardiac Primary cardiac arrhythmia 
22 Male 50 6.86 Trauma Blunt trauma 
24 Male 43 6.27 Cardiac Undetermined (but consistent with idiopathic cardiac 
arrhythmia). 
33 Female 24 6.77 Cardiac Cardiac arrhythmia; myocardial fibrosis 
36 Male 34 6.67 Cardiac Acute chronic cardiac failure 
37 Male 14.5 6.46 Cardiac Presumed Cardiac Dysrhythmia due to natural cause 
37 Male 24 6.7  Unascertained. 
40 Male 27 6.79 Vascular 1.a) Pulmonary thromboemboli b) deep venous 
thrombosis 
47 Male 27 6.66 Cardiac Ischaemic heart disease. 
48 Male 17 6.62 Cardiac Ischaemic heart disease. Coronary artery atheroma 
49 Male 38 6.92 Cardiac Coronary Artery Disease 
50 Male 40 6.87 Cardiac Haemopericardium 
50 Male 34 6.77 Cardiac Acute Myocardial infarction 
51 Male 35 7 Cardiac cardiomegaly 
52 Male 36 6.82  Undetermined. 
57 Male 18 6.39 Cardiac Myocardial Infarction 
58 Male 39 6.49 Cardiac Ischaemic heart disease. 
59 Male 15 6.54 Cardiac Hypertensive and atherosclerotic heart disease 
62 Female 35 6.06 Cardiac Hypertensive and atherosclerotic heart disease 
64 Male 17 6.55 Cardiac Haemopericardium 
66 Male 32 6.66 Cardiac cardiomegaly 
67 Male 25 6.7 Cardiac Hypertensive Heart disease 
69 Female 39 6.72 Cardiac Coronary Artery Disease and asthma 
72 Female 25 7 Cardiac Atherosclerotic cardiovascular disease 
73 Female 45 6.86 Cardiac Atherosclerotic cardiovascular disease. 
74 Female 20 6.59 Cancer Cancer of breast, liver and bone metastases 
78 Female 45 6.05 Toxcity Multiple drug toxicity (7-amino nitrazepam, nitrazepam 
and dextropropoxyphene) 
80 Male 12 6.5 Respiratory Emphysema 
81 Male 29 6.57 Cardiac Heart Failure 
83 Male 10 6.67 Respiratory Pulmonary embolus 
86 Female 14.5 6.36 Infection Septicaemia; gangrenous foot; peripheral vascular 
disease 
87 Female 5 6.38 Cancer Metastatic breast cancer 
88 Male 9 6.36 Respiratory Pneumonia; Debility; Chronic obstructive airways 
disease 
98 Female 6 6.7 Respiratory Pneumonia; congestive cardiac failure 
104 Female 27 5.89 Respiratory Bilateral bronchopneumonia 
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Lipidview™ software (version 1.2, AB Sciex, MA, USA) was used to quantify 
phospholipid species against internal standards using positive ion head group scans. 
Processing settings in LipidView™ were set at a mass tolerance of 0.5 Da, with a 
minimum intensity of 0.1% and a minimum signal-to-noise ratio of 10. Any phospholipid 
species comprising less than 0.5% of each phospholipid class across the cohort were 
removed from the analysis. Each phospholipid quantified was then assessed for possible 
isobaric molecular phospholipids using the lipid catalogue tool from Lipidview™, and 
confirmatory ions from the negative ion fatty acid precursor scans were used to identify 
the amount of each molecular phospholipid present in each sample. Isobaric 
phospholipids containing either an odd-chain or ether-linked fatty acid were unable to be 
separated using this method and were reported as being either species. Due to this no 
correction factor was applied to ether-linked PEs (see section 3.2.2.5). Molecular 
phospholipids that appeared in less than 75% of samples were removed prior to statistical 
analysis. Phospholipids are reported using nomenclature outlined by Liebisch et al. [187], 
as normalised values relative to total phospholipid detected in each phospholipid class to 
reduce variation between the samples. Regression parameters for phospholipids showing 
significant age-related changes in quantified amount (pmol of phospholipid/µg total 
membrane protein) have been included for comparison. 
3.4.5 Statistical analysis 
All statistical analysis in the following chapters was performed using SPSS Statistics 
(version 19, IBM Corp., NY, USA). The Wilcoxon signed-rank test was used for 
comparisons of phospholipid classes between the mitochondrial and microsomal 
fractions. To examine the relationship between age and phospholipids, or age and total 
protein content, linear regression was used with sex as a second independent variable, 
with significance set a level of p < 0.05. Normality of the dependent variable was 
assessed by examining the histograms of the residuals, and non-normal data was 
transformed where required. Positively skewed residuals were transformed using 
logarithmic or reciprocal transformations depending on the level of skew present while 
negatively skewed data used the reflection of these transformations. Outliers were 
identified as being greater than three standard deviations from the mean of the 
standardised residuals, and were dealt with by either transformation of the dependent 
variable or removal from the analysis. Normality of the dependent variable was assessed 
by examining the histograms of the standardised residuals, and non-normal data was 
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transformed where required. Influential data points were identified by a cook’s distance 
of greater than one and were removed from the analysis. Where the dependent variable 
was transformed, data is displayed in figures as untransformed scatterplots with 
transformed beta-coefficients and p value to allow direct comparison between 
phospholipids. As this was an exploratory study a correction for multiple comparisons 
was not applied.  
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Chapter 4  The Dorsolateral Prefrontal Cortex 
This chapter is an amended version of the published manuscript: Norris SE, Friedrich 
MG, Mitchell TW, Truscott, RJW, Else PL, (2015) Human prefrontal cortex 
phospholipids containing docosahexaenoic acid increase during normal adult aging, 
whereas those containing arachidonic acid decrease. Neurobiology of Aging, 
36(4)1659-69. 
4.1 Introduction 
This chapter will examine the changes seen during normal ageing in PC, PE and PS 
phospholipids present in the mitochondrial and microsomal membranes of the 
dorsolateral prefrontal cortex.  
The dorsolateral prefrontal cortex (henceforth referred to as the prefrontal cortex) is 
located in the middle frontal gyrus (see Chapter 1 Figure 1-2), and has connections to 
many brain regions including the orbitofrontal cortex, the thalamus, the hippocampus, 
and the primary and secondary association areas of the neocortex [188]. The functions 
of this region include executive functions such as working memory, cognitive 
flexibility, as well as planning and inhibition [188]. 
Changes to phospholipid composition have been particularly well-studied in different 
parts of the frontal and prefrontal cortex in AD [85–87,92,93,111,113,115,116,189]. 
Both Svennerholm [88] and Söderberg et al. [90,93] have reported losses of total 
phospholipid with age in whole human neocortex and frontal cortex respectively over 
the adult lifespan. Losses of PC and PE within the frontal cortex with advanced age 
have also been reported by Söderberg et al. [93].  
Thus, the aim of this chapter was to expand on the limited knowledge available on age-
related changes in phospholipids of the mitochondrial and microsomal membranes of 
the human prefrontal cortex. 
4.2 Results  
4.2.1 Age-related changes to total protein content in subcellular fractions  
No changes with age in total protein concentration (mg/g tissue) were seen in the whole 
tissue homogenate, or in the mitochondrial and microsomal membranes. 
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4.2.2 Major phospholipid classes of mitochondrial and microsomal fractions 
The three major phospholipid classes PC, PE and PS showed similar abundances in the 
mitochondrial and microsomal membranes when expressed as a percentage of total 
phospholipid (Figure 4-1). Overall, PC represented approximately 56%, PE 29% and PS 
15% of total phospholipid. Small differences in abundance were seen between the 
membrane fractions, including a slightly higher level of PE in the mitochondria (p < 
0.001) and a marginally higher level of PC in the microsomal membranes (p < 0.01). No 
significant differences were seen in the abundance of PS between the two membrane 
fractions.  
No differences were observed between the mitochondrial and microsomal fractions for 
any phospholipid class or in total phospholipid content when analysed as a quantified 
amount (i.e. pmol phospholipid/µg of membrane protein). Additionally, no age-related 
changes were seen for any of the three phospholipid classes or total phospholipids in 
either the mitochondrial or microsomal fraction when expressed as either percent of 
total phospholipid class or as quantified amounts. 
 
 
Figure 4-1: Percent composition of the three major phospholipid classes within the 
mitochondrial (left) and microsomal (right) fractions in normal human prefrontal cortex. 
Values are the mean ± SEM for the entire cohort. The microsomal membranes showed 
significantly higher amounts of total phosphatidylcholine (PC) compared to 
mitochondria (p < 0.01, Wilcoxon signed-rank test), while the mitochondria contained 
more phosphatidylethanolamine (PE) (p < 0.001, Wilcoxon signed-rank test). There 
were no differences between membrane fractions for phosphatidylserine (PS). 
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4.2.3 Changes in mitochondrial phospholipids with age  
4.2.3.1 Phosphatidylcholines 
The composition of PC, PE and PS phospholipids detected in the mitochondrial 
membranes of the entorhinal cortex can be seen in (Figure 4-2). The most abundant 
phospholipid found in the mitochondrial membranes of the prefrontal cortex was PC 
16:0_18:1, representing approximately 25% of all phospholipids measured. From ages 
20 to 100 years, PC 16:0_18:1 increased from 41% to 44% of all PC molecules 
analysed, representing a 7% increase from its initial abundance over the 80 year period 
(Figure 4-3, Table 4-1). Six other PCs also changed with age in abundance when 
expressed as percent composition (percent of total PC), including PC 16:0_22:6, PC 
18:0_18:2, PC 16:0_18:2, PC 14:0_16:0, lyso-PC 16:0, and PC 15:0_16:0/O-16:0_16:0. 
Of these six phospholipids only lyso-PC 16:0 decreased in abundance over the adult 
lifespan. 
Analysis of quantified phospholipids (as pmol/µg of membrane protein) found that PC 
16:0_18:0 and lyso-PC 16:0 decreased with age, while PC O-16:1_18:0 increased in 
quantified amount with age (Table 4-2). 
4.2.3.2 Phosphatidylethanolamines 
Ten mitochondrial PEs changed in their percent composition with age in the human 
prefrontal cortex (Figure 4-4 & Table 4-1). Decreases with age were seen in the second-
most abundant mitochondrial PE, PE 18:0_20:4, which declined from approximately 
19% of total mitochondrial PE to 15% from ages 20 to 100. Considering the abundance 
of this phospholipid, this represents the largest change with age seen in any 
mitochondrial PE. A second highly abundant mitochondrial PE, PE 18:0_22:4, also 
decreased by 24% from ages 20 to 100. Decreases with age were also seen in PE 
18:0_18:1 and PE 16:0_18:1, two moderately abundant phospholipids that together 
comprise approximately 6.7% of total mitochondrial PEs (Figure 4-2). PE 16:0_20:4, 
PE 17:0_22:6/O-18:0_22:6 and PE O-16:1_22:4 also decreased across the adult lifespan 
in the prefrontal cortex, but these phospholipids are only of low abundance in the 
mitochondria.  
Increases with age were reported for three mitochondrial PEs, PE 18:1_22:6, PE O-
18:1_22:6 and PE O-18:1_22:5, which increased in abundance by 42%, 60%, and 133%  
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Figure 4-2: Phospholipids detected within PC, PE and PS in the mitochondrial fraction 
of human prefrontal cortex (as a percent of total phospholipid within each class). 
Phospholipids were quantified as described in materials and methods. Values are mean 
across the cohort ± SEM.
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Figure 4-3: Mitochondrial PCs changing significantly with age (as a percent of total PC) 
in normal human prefrontal cortex (n = 30-36).  Regression model was adjusted for sex: 
males (●), females (○). T indicates dependent variable transformed for linear regression, 
with transformed beta-coefficient and p-value reported on original scatterplot for 
comparison. Regression parameters are shown in Table 4-1. 
 
 
Table 4-1: Mitochondrial phospholipids (percent of phospholipid within phospholipid 
class) changing significantly with age in the human prefrontal cortex. 
Phospholipid Slope 
95% CI  
β df t P value Lower Upper 
Phosphatidylcholine 
Lyso-PC 16:0 -0.0025 -0.0043 -0.0008 -0.522 2,33 -2.946 0.006** 
PC 14:0_16:0  0.0022 0.0003 0.0042 0.408 2,33 2.397 0.022* 
PC 16:0_18:1 0.0339 0.0119 0.0559 0.543 2,31 3.148 0.0036** 
PC 16:0_18:2L 0.0016 0.0002 0.0030 0.453 2,30 2.295 0.029* 
PC 16:0_22:6 0.0058 0.0008 0.0108 0.430 2,33 2.338 0.026* 
PC 18:0_18:2I 0.0028 0.0002 0.0054 0.415 2,27 2.207 0.036* 
PC 15:0_16:0 
 /O-16:0_16:0IR 0.0017 0.0002 0.0032 0.448 2,28 2.274 0.031* 
Phosphatidylethanolamine 
PE 16:0_18:1 -0.0184 -0.0284 -0.0084 -0.689 2,21 -3.842 0.0009*** 
PE 16:0_20:4 -0.0077 -0.0152 -0.0001 -0.376 2,32 -2.066 0.047* 
PE 18:0_18:1 -0.0147 -0.0246 -0.0049 -0.606 2,21 -3.103 0.005** 
PE 18:0_20:4I -0.0002 -0.0003 -0.00002 -0.424 2,33 -2.299 0.028* 
PE 18:0_22:4I -0.0006 -0.0011 -0.0001 -0.555 2,27 -2.705 0.012** 
PE 18:1_22:6 0.0105 0.0060 0.0150 0.723 2,30 4.773 0.00004*** 
PE 17:0_22:6 
 /O-18:0_22:6 -0.0096 -0.0158 -0.0033 -0.615 2,23 -3.167 0.004** 
PE O-16:1_22:4 -0.0026 -0.0052 -0.0001 -0.390 2,33 -2.089 0.045* 
PE O-18:1_22:5 0.0147 0.0039 0.0256 0.548 2,31 2.763 0.0095** 
PE O-18:1_22:6 0.0109 0.0065 0.0153 0.702 2,31 5.041 0.00002*** 
Phosphatidylserine 
PS 18:0_20:4 -0.0198 -0.0327 -0.0069 -0.588 2,25 -3.163 0.004** 
PS 18:0_22:6 0.1605 0.0229 0.2981 0.425 2,30 2.383 0.024* 
Phospholipid molecular species were detected using nanoelectrospray ionisation mass 
spectrometry and quantified as described in materials and methods. Regression was 
adjusted for gender. Superscript indicates dependent variable transformed for linear 
regression, with transformed regression output reported: L logarithm, I reciprocal, IR 
reflect and reciprocal. * P <0.05 ** P <0.01 *** P <0.001   
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Table 4-2: Quantified mitochondrial phospholipids (pmol/µg total membrane protein) 
changing significantly with age in the human prefrontal cortex. 
Phospholipid Slope 
95% CI  
β df t P value Lower Upper 
Phosphatidylcholine 
Lyso-PC 16:0 -0.0070 -0.0120 -0.0020 -0.512 2,33 -2.871 0.007** 
PC 16:0_18:0 -0.0216 -0.0428 -0.0003 -0.384 2,31 -2.073 0.047* 
PC O-16:1_18:0 0.0118 0.0024 0.0211 0.538 2,20 2.627 0.016* 
Phosphatidylethanolamine 
PE 18:0_22:4 -0.0404 -0.0750 -0.0057 -0.503 2,27 -2.391 0.024* 
PE 18:1_22:6IR 0.0005 0.0001 0.0009 0.456 2,32 2.563 0.015* 
PE 17:0_22:6 
 /O-18:0_22:6 -0.0106 -0.0194 -0.0018 -0.516 2,23 -2.494 0.020* 
PE O-18:1_22:5 0.0174 0.0040 0.0309 0.526 2,31 2.646 0.013* 
PE O-18:1_22:6 0.0122 0.0047 0.0197 0.540 2,33 3.323 0.002** 
Phosphatidylserine 
PS 18:0_20:4 -0.0091 -0.0181 -0.00002 -0.427 2,25 -2.065 0.049* 
PS 18:0_22:4 -0.0017 -0.0031 -0.0002 -0.440 2,30 -2.337 0.026* 
PS 18:1_20:1I -0.0037 -0.0071 -0.0002 -0.424 2,28 -2.188 0.037* 
Phospholipid molecular species were detected using nanoelectrospray ionisation mass 
spectrometry and quantified as described in materials and methods. Regression was 
adjusted for gender. Superscript indicates dependent variable transformed for linear 
regression, with transformed regression output reported: I reciprocal, IR reflect and recipr 
ocal. * P <0.05 ** P <0.01 *** P <0.001  
CHAPTER 4 
 
65 | P a g e  
 
 
CHAPTER 4 
 
66 | P a g e  
 
 
Figure 4-4: Mitochondrial PEs changing significantly with age (as a percent of total PE) 
in normal human prefrontal cortex (n = 24-36).  Regression model was adjusted for sex: 
males (●), females (○). T indicates dependent variable transformed for linear regression, 
with transformed beta-coefficient and p-value reported on original scatterplot for 
comparison. Regression parameters are shown in Table 4-1. 
respectively across the 80 year period. While seemingly substantial increases were seen 
in PE O-18:1_22:5 with age, this phospholipid is only of low abundance and comprises 
less than 2% of total mitochondrial PE (Figure 4-2) and 0.4% of total mitochondrial 
phospholipid. 
Analysis of the quantified data (pmol/µg membrane protein) showed similar trends for 
all PE phospholipids measured. PE 18:0_22:4 and PE 17:0_22:6/O-18:0_22:6 continued 
to decrease significantly with age, while PE 18:1_22:6, PE O-18:1_22:6 and PE O-
18:1_22:6 all maintained age-related increases (Table 4-2). 
4.2.3.3 Phosphatidylserines 
Two PS phospholipids, PS 18:0_22:6 and PS 18:0_20:4, changed with age in their 
percent composition in the mitochondrial membranes of the human prefrontal cortex 
(Figure 4-5, Table 4-1). PS 18:0_22:6 is the principal PS found in mitochondrial 
membranes, representing just over half of all mitochondrial PS (Figure 4-2) and 8.3% of 
total mitochondrial phospholipids. PS 18:0_22:6 increased by 34% in abundance over 
80 years, rising from approximately 44% of total PS phospholipids at age 20 to 57% at 
100 years of age. This represents the largest change with age in abundance for any 
mitochondrial phospholipid.  
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Figure 4-5: Mitochondrial PSs changing significantly with age (as a percent of total PC) 
in normal human prefrontal cortex (n = 28-33).  Regression model was adjusted for sex: 
males (●), females (○). Regression parameters are shown in Table 4-1. 
In contrast, PS 18:0_20:4 decreased with age by 85% when expressed as a percent of 
total PS (Figure 4-5, Table 4-1) and by 70% quantitatively (pmol/µg membrane protein, 
Table 4-2) over the age range studied. Two other mitochondrial PSs changed across the 
80 year period in their quantitative amount, with PS 18:0_22:4 decreasing and PS 
18:1_20:1 increasing with age (Table 4-2). 
4.2.4 Changes in microsomal phospholipids with age  
4.2.4.1 Phosphatidylcholines 
The composition of PC, PE and PS phospholipids detected in the microsomal 
membranes of the prefrontal cortex can be seen in (Figure 4-6). Age-related changes in 
PC phospholipids in microsomal membranes of the prefrontal cortex were small, with 
only three relatively minor phospholipids changing significantly with age in their 
percent composition (Figure 4-7, Table 4-3). These included PC 16:0_20:4, PC 
16:0_18:2, and PC 14:0_16:0. PC 16:0_20:4 decreased in abundance with age by 14% 
from age 20 to 100, while PC 16:0_18:2 and PC 14:0_16:0 increased by 32% and 14% 
respectively. These three phospholipids are of low to moderate abundance, however, 
comprising only 3.3% of the total microsomal phospholipid when combined.   
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Figure 4-6: Phospholipids detected within PC, PE and PS in the microsomal fraction of 
human prefrontal cortex (as a percent of total phospholipid within each class).  
Phospholipids were quantified as described in materials and methods. Values are mean 
across the cohort ± SEM. 
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Figure 4-7: Microsomal PCs changing significantly with age (as a percent of total PC) 
in normal human prefrontal cortex (n = 30-34). Males (●), females (○).Regression 
model was adjusted for sex: males (●), females (○). T indicates dependent variable 
transformed for linear regression, with transformed beta-coefficient and p-value 
reported on original scatterplot for comparison. Regression parameters are shown in 
Table 4-3. 
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Table 4-3: Microsomal phospholipids (percent of phospholipid within phospholipid 
class) changing significantly with age in the human prefrontal cortex. 
Phospholipid Slope 
95% CI  
β df t P value Lower Upper 
Phosphatidylcholine 
PC 14:0_16:0 0.0021 0.0004 0.0037 0.437 2,32 2.575 0.015* 
PC 16:0_18:2I 0.0017 0.0002 0.0032 0.426 2,27 2.295 0.030* 
PC 16:0_20:4 -0.0062 -0.0120 -0.0004 -0.422 2,31 -2.198 0.036* 
Phosphatidylethanolamine 
Lyso-PE 22:4 -0.0055 -0.0091 -0.0018 -0.493 2,32 -3.032 0.005** 
Lyso-PE 22:6 -0.0079 -0.0132 -0.0026 -0.515 2,33 -3.015 0.005** 
PE 16:0_20:4 -0.0047 -0.0083 -0.0011 -0.539 2,29 -2.644 0.013* 
PE 18:0_18:1L -0.0020 -0.0031 -0.0009 -0.693 2,26 -3.830 0.0007*** 
PE 18:0_22:5 -0.0255 -0.0422 -0.0087 -0.561 2,29 -3.107 0.004** 
PE 18:1_18:1L -0.0019 -0.0030 -0.0007 -0.588 2,30 -3.294 0.003** 
PE 18:1_22:6 0.0069 0.0014 0.0122 0.494 2,32 2.581 0.015* 
PE 17:0_22:4 
 /O-18:0_22:4 -0.0040 -0.0068 -0.0011 -0.498 2,30 -2.821 0.008** 
PE O-16:1_22:4I -0.0009 -0.0014 -0.0004 -0.599 2,33 -3.558 0.001** 
PE O-18:1_20:4I -0.0007 -0.0014 -0.0001 -0.491 2,31 -2.444 0.020* 
Phosphatidylserine 
PS 18:0_22:6 0.1915 0.0217 0.3614 0.424 2,32 2.297 0.028* 
Phospholipid molecular species were detected using nanoelectrospray ionisation mass 
spectrometry and quantified as described in materials and methods. Regression was 
adjusted for gender. Superscript indicates dependent variable transformed for linear 
regression, with transformed regression output reported: L logarithm, I reciprocal.  
* P <0.05 ** P <0.01 *** P <0.001  
 
 
Table 4-4: Quantified microsomal phospholipids (pmol/µg total membrane protein) 
changing significantly with age in the human prefrontal cortex. 
Phospholipid Slope 
95% CI  
β df t P value Lower Upper 
Phosphatidylethanolamine 
PE 15:0_22:6 
 /O-16:0_22:6 0.0070 0.0007 0.0133 0.395 1,32 2.275 0.030* 
Phospholipid molecular species were detected using nanoelectrospray ionisation mass 
spectrometry and quantified as described in materials and methods. Regression was 
adjusted for gender.  * P <0.05  
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Analysis of the quantified data for PC phospholipids (as pmol/µg of membrane protein) 
showed similar trends to those reported for the percent data, but no PC reached 
statistical significance in the microsomal fraction.  
4.2.4.2 Phosphatidylethanolamines 
Ten microsomal PEs showed significant age-related changes in the prefrontal cortex 
(Figure 4-8, Table 4-3). PE 18:1_18:1, PE 18:0_18:1 and PE 18:0_22:5 are all 
moderately abundant PEs present in the microsomes, and these phospholipids decreased 
in abundance by 30%, 31% and 61% respectively from ages 20 to 100. The remaining 
six microsomal PEs that decreased with age were of low abundance, and included lyso-
PE 22:6, PE 16:0_20:4, PE O-18:1_20:4, PE 17:0_22:4/O-18:0_22:4, lyso-PE 22:4 and 
PE O-16:1_22:4. The only microsomal PE to increase in abundance with age was PE 
18:1_22:6, a phospholipid which is also of low abundance in the microsomal 
membranes (0.6% of all microsomal phospholipids). All of the major microsomal PEs, 
including PE 16:0_22:6, PE 18:0_22:6, PE 18:0_20:4 and PE 18:0_22:4 (Figure 4-6), 
showed no changes with age in the human prefrontal cortex.  PE 15:0_22:6/O-
16:0_22:6 was the only microsomal phospholipid that increased in quantitative amount 
(pmol of phospholipid/µg of membrane protein) in the prefrontal cortex (Table 4-4). 
The quantified PE data showed similar trends to those reported for the percent data, but 
none of these phospholipids reached statistical significance.  
4.2.4.3 Phosphatidylserines 
Only a single microsomal PS phospholipid, PS 18:0_22:6, changed in its percent 
composition with age in the human prefrontal cortex (Figure 4-9, Table 4-3). This 
phospholipid is the primary PS found in microsomal membranes representing 
approximately 50% of all microsomal PS (Figure 4-6) and 7.5% of all phospholipids. 
PS 18:0_22:6 increased by 35% in abundance from ages 20 to 100 (Figure 4-9, Table 
4-3).  
No age-related changes were found for any PS phospholipids in the quantified 
microsomal data (pmol/µg of membrane protein). 
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Figure 4-8: Microsomal PEs changing significantly with age (as a percent of total PC) 
in normal human prefrontal cortex (n = 29-36).  Regression model was adjusted for sex: 
males (●), females (○). T indicates dependent variable transformed for linear regression, 
with transformed beta-coefficient and p-value reported on original scatterplot for 
comparison. Regression parameters are shown in Table 4-3. 
 
 
 
Figure 4-9: Microsomal PSs changing significantly with age (as a percent of total PC) in 
normal human prefrontal cortex (n = 35).  Regression model was adjusted for sex: males 
(●), females (○). Regression parameters are shown in Table 4-3.  
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4.3 Discussion 
This chapter examined age-related changes in the major phospholipids present in both 
the mitochondrial and microsomal membranes of normal human prefrontal cortex over 
the adult lifespan. A diverse range of molecular phospholipids were found to undergo 
changes with age in both membrane fractions, with none of these changes being limited 
to a particular class of phospholipid.  
The largest age-related change for a single molecular phospholipid was seen in PS 
18:0_22:6 in both the mitochondrial and microsomal membranes (Figure 4-5 & Figure 
4-9). This one phospholipid makes up around 8.3% and 7.5% of the total phospholipid 
present in mitochondrial and microsomal membranes respectively, and a substantial 
age-related increase of approximately one third in abundance was found in both 
membrane fractions. Several other phospholipids containing 22:6 (DHA) also increased 
with age in both membrane fractions, including mitochondrial PC 16:0_22:6 (Figure 
4-3, Table S3) and PE O-18:1_22:6 (Figure 4-4, Table S3), and both mitochondrial and 
microsomal PE 18:1_22:6 (Figure 4-4 & Figure 4-8; Table 4-1 & Table 4-3 ). 
Significant increases in DHA have been reported previously in early childhood 
development [70]. DHA is known to incorporate itself preferentially into amino 
phospholipids such as PE or PS in the brain [190]. The importance of PS containing 
DHA in neuronal survival has been shown in vitro with decreased cell death reported in 
neuro-2A cells supplemented with both DHA and serine together over DHA alone, 
indicating that accumulation of DHA in PS is responsible for this protective effect 
[191]. Further evidence for the importance of DHA in the human brain has been seen in 
patients with Zellweger syndrome, a peroxisomal disorder where depletion of long 
chain PUFA such as DHA results in severe brain abnormalities and death within the 
first year of life [58]. Depletion of DHA in the human frontal cortex has been reported 
in AD [92,93], but several other studies have also reported no changes in DHA levels 
with the disease [86,87,108,121].  
In the present chapter many phospholipids containing a 20:4 fatty acid decreased 
significantly in abundance with age in both the mitochondrial and microsomal fractions. 
Although double bond position cannot be definitively determined by the mass 
spectrometry technique used in this thesis, 20:4 can be putatively classified as the n-6 
PUFA AA as the n-3 isomer has not been detected in any previous studies of the human 
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brain. The primary AA-containing phospholipid decreasing with age in the 
mitochondrial membranes was PE 18:0_20:4, a phospholipid which comprises 16% of 
total PE (Figure 4-2). Mitochondrial PE 18:0_20:4 declined by 25% in abundance 
across the 80 year period studied (Figure 4-4, Table 4-1). Other less abundant 
mitochondrial phospholipids containing a AA fatty acid that also declined in abundance 
with age included PE 16:0_20:4, which showed a 20% loss from ages 20 to 100 (Figure 
4-4, Table 4-1), and PS 18:0_20:4 which declined by 82% (Figure 4-5, Table 4-1). 
Microsomal phospholipids containing AA that decreased with age included PE 
16:0_20:4 and PE O-18:1_20:4 (Figure 4-8, Table 4-3). PE 18:0_20:4 showed a trend 
towards decreasing with age within the microsomal membranes but failed to reach 
statistical significance (β=-0.416, p=0.051). Interestingly several 22:4-containing 
phospholipids also decreased in abundance with age, including mitochondrial PE O-
16:1_22:4 (34% loss, Figure 4-4, Table 4-1), and microsomal PE O-16:1_22:4 (46% 
loss), PE 17:0_22:4/O-18:0_22:4 (33% loss), and lyso-PE 22:4 (54% loss, Figure 4-8, 
Table 4-3). 22:4 can be putatively classified as an n-6 fatty acid (adrenic acid) based on 
its synthesis via the elongation and desaturation pathway (see Chapter 2 section 2.1.4) 
[56].  
Because of the age-related changes identified for phospholipids containing either DHA, 
AA or adrenic acid further regressions with age were carried out for both the 
mitochondrial and microsomal membranes (Table 4-5 & Table 4-6 respectively). 
Increases with age were seen in the abundance of DHA in the combined phospholipids, 
which was driven by a rise in PS-DHA in both membrane fractions. In contrast, AA 
decreased in both mitochondrial and microsomal combined phospholipids, with 
decreases seen in mitochondrial PE-AA and microsomal PE-AA and PS-AA. Adrenic 
acid did not show many statistically significant decreases with age in any of the three 
phospholipid classes in either membrane fraction aside from a reduction in 
mitochondrial PC. Interestingly, when the two n-6 fatty acids were combined with 
mitochondrial PC one of the most statistically significant changes in this study was seen 
(Table 4-5). Previous studies have also reported significant decreases with age in n-6 
fatty acids in the human frontal cortex across the adult lifespan [94,95]. Contrary to the 
present study, Carver et al. [94] reported no changes for DHA with age while 
McNamara [95] described significant decreases. Other age-related changes reported in  
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Table 4-5: Linear regression of the most abundant polyunsaturated fatty acids (percent 
of total fatty acids within phospholipid class) in the mitochondrial membranes with age 
in human prefrontal cortex 
Mitochondrial 
fatty acids Slope 
95% CI β df t P value Lower Upper 
Combined phospholipids       
20:4IR -0.0007 -0.0011 -0.0002 -0.515 2,33 -2.913 0.006** 
22:4 -0.0057 -0.0197 0.0083 -0.159 2,33 -0.827 0.414 
20:4 + 22:4 -0.0189 -0.0347 -0.0030 -0.424 2,33 -2.425 0.021* 
22:6 0.0369 0.0075 0.0663 0.431 2,33 2.554 0.015* 
Phosphatidylcholine       
20:4 -0.0077 -0.0227 0.0073 -0.205 2,33 -1.047 0.303 
22:4L -0.0045 -0.0075 -0.0015 -0.518 2,33 -3.049 0.004** 
20:4 + 22:4LR 0.0023 0.0013 0.0034 0.676 2,33 4.444 0.00009*** 
22:6 0.0023 -0.0026 0.0072 0.185 2,33 0.939 0.354 
Phosphatidylethanolamine      
20:4I -0.0003 -0.0005 -0.00002 -0.411 2,33 -2.215 0.034* 
22:4 0.0046 -0.0299 0.0391 0.054 2,33 0.274 0.786 
20:4 + 22:4 0.00009 -0.00006 0.0002 0.241 2,33 1.237 0.225 
22:6 0.0345 -0.0205 0.0895 0.246 2,33 1.279 0.210 
Phosphatidylserine       
20:4 -0.0059 -0.0119 0.0002 -0.322 2,33 -1.980 0.056 
22:4 0.0261 -0.0070 0.0591 0.301 2,33 1.604 0.118 
20:4 + 22:4 -0.0146 -0.0308 0.0015 -0.345 2,30 -1.848 0.074 
22:6 0.0803 0.0115 0.1490 0.425 2,30 2.383 0.024* 
Fatty acids calculated from phospholipid molecular species data. Regression was 
adjusted for gender. Superscript indicates dependent variable transformed for linear 
regression: L logarithm, LR reflect and logarithm, I reciprocal, IR reflect and reciprocal.  * 
P <0.05 ** P <0.01 *** P <0.001 
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Table 4-6: Linear regression of most abundant polyunsaturated fatty acids (percent of 
total fatty acids within phospholipid class) in the microsomal membranes with age in 
human prefrontal cortex 
Microsomal 
fatty acids Slope 
95% CI β df t P value Lower Upper 
Combined phospholipids 
20:4 -0.0151 -0.0256 -0.0046 -0.507 2,33 -2.931 0.006** 
22:4 0.0071 -0.0026 0.0168 0.285 2,33 1.484 0.147 
20:4 + 22:4 -0.0080 -0.0209 0.0049 -0.244 2,33 -1.266 0.215 
22:6 0.0464 0.0224 0.0703 0.645 2,33 3.941 0.0004*** 
Phosphatidylcholine 
20:4 -0.0122 -0.0256 0.0013 -0.350 2,33 -1.844 0.074 
22:4 0.0013 -0.0104 0.0131 0.046 2,33 0.233 0.817 
20:4 + 22:4IR -0.0006 -0.0011 -0.0002 -0.492 2,33 -2.760 0.009** 
22:6 0.0023 -0.0022 0.0067 0.201 2,33 1.028 0.312 
Phosphatidylethanolamine 
20:4I -0.0003 -0.0005 -0.0002 -0.631 2,32 -3.972 0.0004*** 
22:4IR 0.0004 0.00004 0.0008 0.348 2,33 1.834 0.076 
20:4 + 22:4 -0.0059 -0.0371 0.0252 -0.084 2,31 -0.390 0.699 
22:6 0.0294 -0.0037 0.0626 0.375 2,31 1.809 0.080 
Phosphatidylserine 
20:4I -0.0042 -0.0079 -0.0004 -0.413 2,32 -2.239 0.032* 
22:4 -0.0096 -0.0350 0.0158 -0.155 2,31 -0.722 0.445 
20:4 + 22:4 -0.0181 -0.0445 0.0083 -0.275 2,31 -1.398 0.172 
22:6 0.0958 0.0108 0.1807 0.424 2,31 2.297 0.028* 
Fatty acids calculated from phospholipid molecular species data. Regression was 
adjusted for gender. Superscript indicates dependent variable transformed for linear 
regression: I reciprocal, IR reflect and reciprocal.  * P <0.05 ** P <0.01 *** P <0.001 
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the literature includes a loss of total phospholipid in human frontal cortex [88,90,93], a 
result which was not seen in this study in either the mitochondrial or microsomal 
membranes. In a later study, Söderberg et al. [93] reported a significant age-related 
decline in total PC phospholipids in frontal grey matter, a finding which was also not 
replicated in the present study.  
Several significant age-related changes also occurred in highly abundant phospholipids 
containing saturated and/or monounsaturated fatty acids. The most abundant 
phospholipid of this type was mitochondrial PC 16:0_18:1, which increased from 
approximately 41% of total mitochondrial PC phospholipids at age 20 to 44% by 100 
years of age (Figure 4-3, Table 4-1). The next most abundant mitochondrial 
phospholipid showing significant age-related changes was PE 18:0_18:1, which 
declined by 30% in abundance over the 80 year period studied, followed by PE 
16:0_18:1 with a 37% loss. In the microsomal membranes the most abundant 
phospholipids of this type showing significant changes with age were PE’s 18:0_18:1 
and 18:1_18:1, both of which contribute approximately 1% each to total phospholipids 
detected (Figure 4-8, Table 4-3). Both of these microsomal PE phospholipids declined 
in abundance by 35% and 32% respectively from ages 20 to 100. While these findings 
are noteworthy, the specific functions of phospholipids containing saturated and/or 
monounsaturated fatty acids in the human brain are mostly unknown. Current in vitro 
evidence suggests a potential role for such phospholipids as modulators of membrane 
bilayer fluidity [192,193].  
In summary, many different phospholipids changed significantly with age in the 
mitochondrial and microsomal membranes of normal human prefrontal cortex, and 
these changes were not confined to a particular class of phospholipid in either 
membrane fraction. Notable phospholipids increasing over the adult lifespan included 
mitochondrial and microsomal PS 18:0_22:6 and other phospholipids containing DHA. 
Decreases were seen in phospholipids containing AA or adrenic acid, including the 
highly abundant mitochondrial PE 18:0_20:4. While increases in DHA have previously 
been reported in early childhood, to our knowledge this is first time age-related changes 
have been reported for individual phospholipids during normal adult ageing in the 
human brain, as well as being the first report of increases in phospholipids containing 
DHA over the adult lifespan.  
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Chapter 5 The Hippocampus 
This chapter is an amended version of the published manuscript: Hancock SE, 
Friedrich MG, Mitchell TW, Truscott, RJW, Else PL, (2015) Decreases are seen in 
the human hippocampus over the adult lifespan in phospholipids containing adrenic 
and arachidonic acids, Lipids, 50(9);861-872 
5.1 Introduction 
This chapter will examine the changes seen during normal ageing in PC, PE and PS 
phospholipids present in the mitochondrial and microsomal membranes of the 
hippocampus. 
The hippocampus is located in the medial temporal lobe of the brain and belongs to the 
limbic system (see Chapter 1, Figure 1-2). It has important roles in the consolidation of 
short-term memory to long-term [194,195], as well as spatial navigation [196]. The 
hippocampus is one of the earliest sites where atrophy is exhibited in the development 
of AD [197,198]. Less severe atrophy of this region is also seen during normal ageing 
[199]. The presence of Aβ deposits characteristic of AD within the medial temporal 
region is thought to accelerate atrophy within the hippocampus and other brain 
structures of the medial temporal region [200]. Additionally, the hippocampus is 
believed to be one of the initial sites of the development of NFTs [7].  
The phospholipids of the hippocampus have been examined for their role in the 
pathogenesis of AD in several studies over the past few decades [86,111,113,121–123], 
but very few studies have examined the changes occurring in hippocampal 
phospholipids during normal ageing [90,93]. Decreases in total phospholipids with age 
have been reported after age 60 in the hippocampus [90], alongside reductions in total 
PC and PE [93]. No age-related changes have previously been reported for the fatty 
acids of either PC or PE phospholipids in the human hippocampus [93].  
Therefore, the aim of this chapter was to expand on the current knowledge of the 
changes occurring to the PC, PE and PS phospholipids of the human hippocampus 
during normal ageing.  
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5.2 Results 
5.2.1 Age-related changes to total protein content in subcellular fractions  
Statistically significant age-related declines were seen in the total protein content of the 
microsomal fraction of the hippocampus, but no changes with age were found for either 
the whole tissue homogenate or mitochondrial fraction (Figure 5-1, Table 5-1). Total 
protein decreased in the microsomal membranes from 2.5 µg/mg wet weight of tissue to 
1.9 µg/mg wet weight of tissue from ages 20 to 100, representing a decrease of 48%. A 
trend was seen for a decline in total protein with age within the whole tissue 
homogenate, but this failed to reach statistical significance (β = -0.356, p = 0.055). 
5.2.2 Major phospholipid classes of mitochondrial and microsomal fractions 
The ratio of the three major phospholipid classes PC, PE and PS showed a similar 
distribution between the mitochondrial and microsomal membranes (Figure 5-2). 
Overall, PC comprised 43%, PE 36% and PS 21% of total phospholipids measured in 
each fraction with some small differences in phospholipid content between the two 
membrane fractions. A slightly higher percentage of PE was present in the mitochondria 
(p < 0.001) while the microsomes contained more PC (p < 0.001). There were no 
differences in the percent abundance of PS between the two membrane fractions. The 
percent contribution of total PC, PE, PS, and total phospholipids were also examined for 
any age-related changes in the mitochondrial and microsomal fractions, with no 
significant age-related changes seen.  
The quantified amount of each phospholipid class (as pmol/µg membrane protein) 
between the two membrane fractions was also analysed, with the microsomal fraction 
found to contain higher amounts of PC (p < 0.001) and PS (p = 0.005). Total quantified 
phospholipids were also greater in the microsomes than in the mitochondria (p = 0.001). 
Regression of quantified phospholipids (pmol/µg membrane protein) with age showed 
no statistically significant age-related changes for any phospholipid class in either 
membrane fraction, including total quantified phospholipids. 
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Figure 5-1: Linear regression of age against total protein amount (mg/g wet tissue) 
measured in whole tissue homogenate and subcellular fractions derived from normal 
human hippocampus. Total protein was measured using BCA assay as described in 
methods and materials. Regression model was adjusted for sex: males (●), females (○). 
T indicates dependent variable transformed for linear regression, with transformed beta-
coefficient and p-value reported on original scatterplot for comparison. Regression 
parameters are shown in Table 5-1. 
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Table 5-1: Linear regression of total protein (mg/g of tissue) with age in the whole 
tissue homogenate and subcellular fractions of normal human hippocampus 
Phospholipid Slope 
95% CI  
β df t P value Lower Upper 
Whole tissue 
 homogenateI -0.00002 -0.00004 -0.0000004 -0.356 2,33 -1.994 0.055 
Mitochondria -0.0082 -0.0430 0.0267 -0.087 2,33 -0.479 0.635 
MicrosomesL -0.0016 -0.0027 -0.0006 -0.484 2,33 -3.164 0.003** 
Total protein amount measured using BCA Assay. Regression was adjusted for gender. 
Superscript indicates dependent variable transformed for linear regression, with 
transformed regression output reported: L logarithm ** P <0.01  
 
 
 
Figure 5-2: Percent composition of the three major phospholipid classes within the 
mitochondrial (left) and microsomal (right) fractions in normal human hippocampus. 
Values are the mean ± SEM for the entire cohort. The microsomal membranes showed 
significantly higher amounts of total phosphatidylcholine (PC) compared to 
mitochondria (p < 0.001, Wilcoxon signed-rank test), while the mitochondria contained 
more phosphatidylethanolamine (PE) (p < 0.001, Wilcoxon signed-rank test). There 
were no differences between fractions for phosphatidylserine (PS).  
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5.2.3 Changes in mitochondrial phospholipids with age  
5.2.3.1 Phosphatidylcholines 
The composition of PC, PE and PS phospholipids detected in the mitochondrial 
membranes of the hippocampus can be seen in (Figure 5-3).Three mitochondrial PCs 
changed with age in the human hippocampus (Figure 5-4, Table 5-2). PC 16:0_18:1, the 
most abundant phospholipid present in mitochondrial membranes, increased from 
40.8% of total mitochondrial PC at age 20 to 42.5% at age 100, representing a 4% 
increase from its initial abundance. PC 16:0_18:2 also increased in abundance with age, 
but this phospholipid is only present in low-to-moderate amounts within mitochondrial 
membranes (Figure 5-3). The only mitochondrial PC to decrease with age was PC 
18:0_20:4, which declined in abundance by 24% from ages 20 to 100 (Figure 5-4, Table 
5-2).  
Regression of quantified phospholipids (pmol phospholipid/µg total protein) with age 
was also performed, with no mitochondrial PCs showing any statistically significant 
age-related changes (Table 5-3). 
5.2.3.2 Phosphatidylethanolamines 
Age-related changes were seen in several mitochondrial PEs (Figure 5-5, Table 5-2). PE 
18:0_22:4 was the most abundant mitochondrial PE to decrease with age, declining by 
13% in abundance over the 80 year period. This phospholipid is the third-most abundant 
mitochondrial PE, comprising approximately 8% of total mitochondrial PE (Figure 5-3) 
and 3% of total mitochondrial phospholipid. Three other mitochondrial PEs decreased 
with age: PE 16:0_22:4, PE O-16:1_20:2 and PE O-18:1_22:3 (Figure 5-5, Table 5-2). 
PE 16:0_22:4 is a moderately abundant mitochondrial PE, which contributes up to 1.5% 
of mitochondrial PE (Figure 5-3) and 0.6% of total mitochondrial phospholipid. This 
phospholipid decreased by 19% in abundance from ages 20 to 100 (Figure 5-5, Table 
5-2). The remaining phospholipid to decline with age, PE O-16:1_20:2, is only of low 
abundance in the mitochondrial membranes, comprising just over 0.4% of total 
mitochondrial phospholipid. 
Three mitochondrial PEs increased in percent abundance over the 80 year period: PE 
18:1_22:6 lyso-PE 22:6 and lyso-PE 18:1. PE 18:1_22:6 is a moderately abundant 
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Figure 5-3: Phospholipids detected within PC, PE and PS in the mitochondrial fraction 
of human hippocampus (as a percent of total phospholipid within each class).  
Phospholipids were quantified as described in materials and methods. Values are mean 
across the cohort ± SEM. 
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Figure 5-4: Mitochondrial PCs changing significantly with age (as a percent of total PC) 
in normal human hippocampus (n = 33-36).  Regression model was adjusted for gender: 
males (●), females (○). Regression parameters are shown in Table 5-2. 
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Table 5-2: Mitochondrial phospholipids (percent of phospholipid within phospholipid 
class) changing significantly with age in the human hippocampus. 
Phospholipid Slope 
95% CI  
β df t P value Lower Upper 
Phosphatidylcholine 
PC 16:0_18:1 0.0230 0.0005 0.0456 0.405 2,31 2.083 0.046* 
PC 16:0_18:2 0.0033 0.0005 0.0060 0.459 2,31 2.416 0.022* 
PC 18:0_20:4 -0.0127 -0.0211 -0.0042 -0.496 2,33 -3.049 0.005** 
Phosphatidylethanolamine 
Lyso-PE 18:1 0.0034 0.0005 0.0062 0.438 2,33 2.411 0.022* 
Lyso-PE 22:6 0.0037 0.0005 0.0069 0.431 2,33 2.338 0.026* 
PE 16:0_22:4 -0.0039 -0.0071 -0.0007 -0.453 2,30 -2.510 0.018* 
PE 18:0_22:4I -0.0002 -0.0004 -0.00002 -0.371 2,33 -2.221 0.033* 
PE 18:1_22:6 0.0074 0.0040 0.0108 0.668 2,32 4.442 0.0001*** 
PE O-16:1_20:2 -0.0055 -0.0098 -0.0013 -0.502 2,29 -2.654 0.013* 
Phosphatidylserine 
PS 18:0_20:1L -0.0019 -0.0039 -0.00001 -0.383 2,32 -2.048 0.0489* 
PS 18:0_20:4 -0.0161 -0.0253 -0.0070 -0.614 2,30 -3.589 0.0016** 
PS 18:0_22:4 -0.0186 -0.0362 -0.0009 -0.381 2,32 -2.138 0.040* 
PS 18:0_22:6 0.1167 0.0014 0.2320 0.384 2,32 2.062 0.047* 
PS 18:1_20:0 -0.0049 -0.0094 -0.0005 -0.416 2,32 -2.259 0.031* 
Phospholipid molecular species were detected using nanoelectrospray ionisation mass 
spectrometry and quantified as described in materials and methods. Regression was 
adjusted for gender. Superscript indicates dependent variable transformed for linear 
regression, with transformed regression output reported: L logarithm, I reciprocal.  
* P <0.05 ** P <0.01 *** P <0.001  
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Table 5-3: Quantified mitochondrial phospholipids (pmol/µg total membrane protein) 
changing significantly with age in the human hippocampus. 
Phospholipid Slope 
95% CI  
β df t P value Lower Upper 
Phosphatidylethanolamine 
PE O-16:1_20:2 -0.0097 -0.0158 -0.0035 -0.588 2,29 -3.200 0.003** 
Phosphatidylserine 
PS 18:0_18:1L -0.0024 -0.0045 -0.0002 -0.427 2,32 -2.266 0.030* 
PS 18:0_20:1 -0.0111 -0.0170 -0.0053 -0.654 2,31 -3.864 0.0005*** 
PS 18:0_20:2 -0.0116 -0.0206 -0.0025 -0.497 2,24 -2.630 0.015* 
PS 18:0_20:4 -0.0278 -0.0407 -0.0149 -0.709 2,30 -4.403 0.0001*** 
PS 18:1_20:0 -0.0052 -0.0103 -0.0001 -0.394 2,32 -2.097 0.044* 
Phospholipid molecular species were detected using nanoelectrospray ionisation mass 
spectrometry and quantified as described in materials and methods. Regression was 
adjusted for gender. Superscript indicates dependent variable transformed for linear 
regression, with transformed regression output reported: L logarithm.  
* P <0.05 ** P <0.01 *** P <0.001  
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Figure 5-5: Mitochondrial PEs changing significantly with age (as a percent of total PE) 
in normal human hippocampus (n = 32-36).  Regression model was adjusted for sex: 
males (●), females (○). T indicates dependent variable transformed for linear regression, 
with transformed beta-coefficient and p-value reported on original scatterplot for 
comparison. Regression parameters are shown in Table 5-2.  
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phospholipid in the mitochondrial membranes, comprising approximately 1% of total 
mitochondrial phospholipids. PE 18:1_22:6 increased from 2.3% of total mitochondrial 
PE to 2.9% from ages 20 to 100, representing an increase in abundance of 26%. The 
two other lyso-PEs showing increases with age, lyso-PE 22:6 and lyso-PE 18:1, 
comprised less than 1.7% of total mitochondrial PE when combined (Figure 5-3).  
Analysis of the quantified phospholipids (pmol phospholipid/µg membrane protein) 
showed similar trends for all mitochondrial PEs identified as changing significantly in 
their percent abundance with age, but only a single mitochondrial PE reached statistical 
significance: PE O-16:1_20:2 (Table 5-3). PE O-16:1_20:2 decreased with age from 
1.150 pmol/µg membrane protein to 0.374 pmol/µg membrane protein from ages 20 to 
100.  
5.2.3.3 Phosphatidylserines 
Within the mitochondrial membranes, five PS phospholipids changed in percent 
abundance with age (Figure 5-6, Table 5-2). The most abundant phospholipid to show 
an age-related change was PS 18:0_22:6, which increased from 37.0% of total 
mitochondrial PS to 46.3% from ages 20 to 100. The remaining four phospholipids all 
decreased with age in the mitochondrial membranes. PS 18:0_22:4, a moderately 
abundant mitochondrial phospholipid, declined by 17% over the 80 year period (Figure 
5-6, Table 5-2). PS 18:0_20:4, PS 18:0_20:1 and PS 18:1_20:0 are all low abundance 
mitochondrial phospholipids, and decreased respectively by 39%, 30% and 35% from 
age 20 to 100.  
Three of these mitochondrial PSs also declined significantly in quantified amount (pmol 
phospholipid/µg membrane protein) with age: PS 18:0_20:4, PS 18:0_20:1 and PS 
18:1_20:0 (Table 5-3). A further two mitochondrial PS also decreased significantly in 
quantified amount with age, PS 18:0_18:1 and PS 18:0_20:2. 
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Figure 5-6: Mitochondrial PSs changing significantly with age (as a percent of total PS) 
in normal human hippocampus (n = 33-35). Regression model was adjusted for sex: 
males (●), females (○). T indicates dependent variable transformed for linear regression, 
with transformed beta-coefficient and p-value reported on original scatterplot for 
comparison. Regression parameters are shown in Table 5-2. 
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5.2.4 Changes in microsomal phospholipids with age  
5.2.4.1 Phosphatidylcholines 
The composition of PC, PE and PS phospholipids detected in the microsomal 
membranes of the hippocampus can be seen in (Figure 5-7).Two microsomal PCs 
changed with age (Figure 5-8, Table 5-4). Decreases with age were observed in PC 
18:0_18:1, the third most abundant microsomal PC. PC 18:0_18:1 comprises 10% of 
total microsomal PC (Figure 5-7) and 4% of total microsomal phospholipids, and 
declined by 15% from ages 20 to 100 (Figure 5-8, Table 5-4). An age-related increase 
of 35% in abundance was found for PC 15:0_16:0/O-16:0_16:0 (Figure 5-8, Table 5-4), 
but this phospholipid comprises only 0.2% of total microsomal phospholipid.  
PC 15:0_16:0/O-16:0_16:0 also increased in quantified amount with age within the 
microsomal membranes, doubling from 0.78 pmol/µg membrane protein at age 20 to 1.6 
pmol/µg membrane protein by age 100 (Table 5-5). 
5.2.4.2 Phosphatidylethanolamines 
Three microsomal PEs changed with age in their percent composition (percent of total 
microsomal PE) in the hippocampus (Figure 5-9, Table 5-4). The most abundant 
microsomal PE showing age-related changes was PE 18:0_22:4, which decreased by 
18% in abundance across the 80 year period. PE 18:0_22:4 is the third most abundant 
microsomal PE, comprising 8% of total microsomal PE (Figure 5-7). The two 
remaining microsomal PEs increased significantly in percent abundance with age. PE 
18:1_22:6, a moderately abundant microsomal PE, increased from 1.9% of microsomal 
PE to 2.5% from ages 20 to 100, representing an increase of 27% in abundance (Figure 
5-9, Table 5-4). PE 15:0_22:6/O-16:0_22:6 rose by a little over 70% across the 80 year 
period, but this phospholipid is only of low abundance in microsomal membranes 
(Figure 5-7). PE 15:0_22:6/O-16:0_22:6 also increased with age in quantified amount, 
rising from 0.8 pmol/µg membrane protein at age 20 to 1.5 pmol/µg membrane protein 
at age 100 (Table 5-5).  
5.2.4.3 Phosphatidylserines 
Only a single PS phospholipid changed in its percent composition with age in the 
microsomal membranes: PS 18:0_20:4 (Figure 5-10, Table S3). PS 18:0_20:4 decreased 
from 3.3% of microsomal PS to 2.3% over the 80 year period studied, representing a 
loss of one-third in abundance.  
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Figure 5-7: Phospholipids detected within PC, PE and PS in the microsomal fraction of 
human hippocampus (as a percent of total phospholipid with each class). Phospholipids 
were quantified as described in materials and methods. Values are mean across the 
cohort ± SEM. 
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Figure 5-8: Microsomal PCs changing significantly with age (as a percent of total PC) 
in normal human hippocampus (n = 36).  Regression model was adjusted for sex: males 
(●), females (○). T indicates dependent variable transformed for linear regression, with 
transformed beta-coefficient and p-value reported on original scatterplot for 
comparison. Regression parameters are shown in Table 5-4. 
 
Table 5-4: Microsomal phospholipids (percent of phospholipid within phospholipid 
class) changing significantly with age in the human hippocampus. 
Phospholipid Slope 
95% CI  
β df t P value Lower Upper 
Phosphatidylcholine 
PC 18:0_18:1 -0.0212 -0.0380 -0.0044 -0.461 2,33 -2.566 0.015* 
PC 15:0_16:0 
 /O-16:0_16:0I 0.0008 0.0004 0.0012 0.642 2,33 4.059 0.0003*** 
Phosphatidylethanolamine 
PE 18:0_22:4 -0.0190 -0.0360 -0.0020 -0.396 2,33 -2.275 0.030* 
PE 18:1_22:6 0.0065 0.0027 0.0104 0.588 2,32 3.443 0.0016** 
PE 15:0_22:6 
 /O-16:0_22:6 0.0036 0.0006 0.0067 0.460 2,31 2.460 0.020* 
Phosphatidylserine 
PS 18:0_20:4 -0.0123 -0.0239 -0.0008 -0.426 2,29 -2.184 0.037* 
Phospholipid molecular species were detected using nanoelectrospray ionisation mass 
spectrometry and quantified as described in materials and methods. Regression was 
adjusted for gender. Superscript indicates dependent variable transformed for linear 
regression, with transformed regression output reported: I reciprocal. * P <0.05  
** P <0.01 *** P <0.001  
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Table 5-5: Quantified microsomal phospholipids (pmol/µg total membrane protein) 
changing significantly with age in the human hippocampus. 
Phospholipid Slope 
95% CI  
β df t P value Lower Upper 
Phosphatidylcholine 
PC 14:0_16:0L 0.0019 0.00006 0.0038 0.382 2,33 2.102 0.043* 
PC 16:0_18:2 0.0195 0.0057 0.0332 0.491 2,30 2.889 0.006** 
PC 18:1_18:1 0.0017 0.00005 0.0034 0.363 2,33 2.098 0.044* 
PC 15:0_16:0 
 /O-16:0_16:0 0.0107 0.0030 0.0183 0.483 2,33 2.835 0.003** 
PC 15:0_18:1 
 /O-16:0_18:1I 0.0013 0.0002 0.0025 0.439 2,31 2.324 0.027* 
Phosphatidylethanolamine 
PE 18:1_20:3I 0.0021 -0.0006 0.0037 0.522 2,29 2.922 0.007** 
PE 15:0_22:6 
 /O-16:0_22:6 0.0090 0.0005 0.0174 0.405 2,31 2.151 0.039* 
PE O-18:1_22:5 0.0228 0.0010 0.0446 0.398 2,33 2.128 0.041* 
Phospholipid molecular species were detected using nanoelectrospray ionisation mass 
spectrometry and quantified as described in materials and methods. Regression was 
adjusted for gender. Superscript indicates dependent variable transformed for linear 
regression, with transformed regression output reported: L logarithm, I reciprocal. * P 
<0.05 ** P <0.01 *** P <0.001 
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Figure 5-9: Microsomal PEs changing significantly with age (as a percent of total PE) in 
normal human hippocampus (n = 34-36).  Regression model was adjusted for sex: males 
(●), females (○). Regression parameters are shown in Table 5-4. 
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Figure 5-10: Microsomal PSs changing significantly with age (as a percent of total PS) 
in normal human hippocampus (n = 32).  Regression model was adjusted for sex: males 
(●), females (○). Regression parameters are shown in Table 5-4. 
There were no microsomal PSs that changed significantly in quantified amount over the 
80 year period (pmol phospholipid/µg membrane protein, Table 5-5). 
5.3 Discussion  
Examination of the mitochondrial and microsomal membranes of the human 
hippocampus showed that many phospholipids underwent significant changes during 
normal ageing. These changes were not limited to any single class of phospholipid or a 
single membrane fraction. Rather, the age-related changes in the hippocampus occurred 
in a broad range of phospholipids in both the mitochondrial and microsomal 
membranes, with many of these changes occurring in low-to-moderately abundant 
phospholipids. In particular, phospholipids containing a 22:4 fatty acid (adrenic acid) 
underwent consistent age-related decreases in both membrane fractions across the 80 
year period studied, while those containing a 22:6 fatty acid (DHA) increased across the 
adult lifespan. 
PE 18:0_22:4 is the third most abundant PE in both the mitochondria and microsomes 
(Figure 5-3 & Figure 5-7), and a decrease of approximately 13% and 18% in percent 
abundance with age was found in both membranes fractions respectively (Figure 5-5 & 
Figure 5-9, Table 5-2 & Table 5-4). Several other phospholipids with a 22:4 fatty acid 
also declined in percent abundance with age in the mitochondrial membranes: PE 
16:0_22:4 and PS 18:0_22:4 declined by 19% and 17% respectively from ages 20 to 
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100 (Figure 5-5 & Figure 5-6, Table 5-2). The 22:4 fatty acid can be putatively assigned 
as being adrenic acid, an n-6 PUFA, based on its synthesis via the elongation and 
desaturation pathway (see Chapter 2, Figure 2-4) [56]. Adrenic acid is the product of 
elongation of the n-6 PUFA 20:4 (AA) by two carbons. Two isomers of 20:4 can exist: 
an n-3 and an n-6 isomer (AA) which differ only by the position of their double bonds. 
As discussed in Chapter 4 (section 4.3), the mass spectrometry method used in this 
thesis cannot determine double bond position. However, previous studies of fatty acids 
within the phospholipids of human hippocampus that used gas chromatography have not 
detected any n-3 20:4, so we can assume that the 20:4 detected is primarily AA 
[90,93,122,123]. Many phospholipids containing AA also decreased with age in the 
mitochondrial and microsomal membranes. Common between both membrane fractions 
was a decline in the percent abundance of PS 18:0_20:4 with age, by 39% and 30% in 
mitochondrial and microsomal membranes respectively (Figure 5-6 & Figure 5-10, 
Table 5-2 & Table 5-4). Age-related decreases were also seen in mitochondrial PC 
18:0_20:4, which declined by 24% over the 80 year period (Figure 5-4, Table 5-2). 
Due to these age-related declines in mitochondrial and microsomal phospholipids 
containing the n-6 fatty acids adrenic acid or AA, additional regressions were conducted 
to check for changes in fatty acid content with age in the hippocampus (Table 5-6 & 
Table 5-7). Decreases with age in AA were seen in the combined phospholipids of the 
mitochondrial membranes (Table 5-6). When phospholipids containing either AA or 
adrenic acid were pooled together, an even greater loss with age was revealed in the 
combined mitochondrial phospholipids. In the microsomal membranes, only the pooled 
AA and adrenic acid declined with age in the combined phospholipids (Table 5-7). 
Together, these results indicate that there is a significant loss of long-chain n-6 fatty 
acids in both membrane fractions within the hippocampus over the adult lifespan. 
Despite significant age-related losses of PE 18:0_22:4 in both membrane fractions 
(Figure 5-5 & Figure 5-9) there were no changes seen with age to either PE-adrenic acid 
or to pooled PE-AA and PE-adrenic acid in either the mitochondrial or microsomal 
membranes (Table 5-6 & Table 5-7). Instead most of the age-related declines in adrenic 
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Table 5-6: Linear regression of most abundant polyunsaturated fatty acids (percent of 
total fatty acids within phospholipid class) in the mitochondrial membranes with age in 
human hippocampus 
Mitochondrial 
fatty acids Slope 
95% CI β df t P value Lower Upper 
Combined phospholipids       
20:4LR -0.0022 -0.0044 -0.00003 -0.385 2,33 -2.065 0.047* 
22:4 -0.0084 -0.0178 -0.0009 -0.324 2,33 -1.835 0.076 
20:4 + 22:4 LR -0.0038 -0.0070 -0.0006 -0.429 2,33 -2.443 0.020* 
22:6 0.0211 -0.0065 0.0486 0.299 2,33 1.556 0.129 
Phosphatidylcholine       
20:4 -0.0077 -0.0165 0.0010 -0.320 2,32 -1.794 0.082 
22:4 0.0003 -0.0033 0.0038 0.028 2,33 0.146 0.885 
20:4 + 22:4 -0.0071 -0.0178 0.0037 -0.243 2,32 -1.341 0.189 
22:6 0.0006 -0.0036 0.0047 0.057 2,33 0.289 0.775 
Phosphatidylethanolamine      
20:4 -0.0068 -0.0247 0.0110 -0.151 2,33 0.781 0.440 
22:4 -0.0127 -0.0298 0.0044 -0.285 2,33 0.140 0.140 
20:4 + 22:4 -0.0195 -0.0437 0.0047 -0.315 2,33 -1.642 0.110 
22:6 0.0245 -0.0021 0.0512 0.356 2,33 1.877 0.069 
Phosphatidylserine       
20:4LR -0.0081 -0.0127 -0.0035 -0.614 2,30 -3.589 0.001** 
22:4I -0.0004 0.0008 -0.00001 -0.352 2,33 -1.969 0.057 
20:4 + 22:4L -0.0015 -0.0025 -0.0004 -0.494 2,33 -2.869 0.007** 
22:6 0.0804 0.0302 0.1305 0.568 2,31 3.265 0.003** 
Fatty acids calculated from phospholipid molecular species data. Regression was 
adjusted for gender. Superscript indicates dependent variable transformed for linear 
regression: L logarithm, LR reflect and logarithm, I reciprocal. * P <0.05 ** P <0.01  
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Table 5-7: Linear regression of most abundant polyunsaturated fatty acids (percent of 
total fatty acids within phospholipid class) in the microsomal membranes with age in 
human hippocampus 
Microsomal 
fatty acids Slope 
95% CI β df t P value Lower Upper 
Combined phospholipids 
20:4 -0.0060 -0.0169 0.0049 -0.201 2,33 -1.125 0.269 
22:4 -0.0103 -0.0208 -0.0003 -0.363 2,33 -1.986 0.055 
20:4 + 22:4 -0.0163 -0.0300 -0.0026 -0.395 2,33 -2.249 0.021* 
22:6 -0.0014 -0.0250 0.0223 -0.023 2,32 -0.118 0.907 
Phosphatidylcholine 
20:4 -0.0012 -0.0165 0.0141 -0.031 2,33 -0.164 0.871 
22:4 -0.0035 -0.0147 -0.0078 -0.124 2,33 -0.626 0.536 
20:4 + 22:4 -0.0047 -0.0131 0.0037 -0.195 2,33 -1.134 0.265 
22:6 -0.0004 -0.0042 0.0034 -0.046 2,33 -0.232 0.818 
Phosphatidylethanolamine 
20:4 -0.0071 -0.0255 0.0113 -0.154 2,32 -0.783 0.440 
22:4 -0.0131 -0.0309 0.0047 -0.287 2,33 -1.150 0.143 
20:4 + 22:4 -0.0173 -0.0407 0.0061 -0.292 2,32 -1.504 0.142 
22:6 0.0025 -0.0254 0.0305 0.037 2,32 0.186 0.854 
Phosphatidylserine 
20:4 -0.0004 -0.0097 0.0089 -0.016 2,33 -0.087 0.931 
22:4 -0.0095 -0.0189 -0.0001 -0.373 2,30 -2.072 0.047* 
20:4 + 22:4 -0.0112 -0.0265 -0.0041 -0.260 2,31 -1.492 0.146 
22:6 -0.0394 -0.0173 0.0961 0.274 2,33 1.413 0.167 
Fatty acids calculated from phospholipid molecular species data. Regression was 
adjusted for gender. * P <0.05  
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acid and AA were seen in PS, with mitochondrial and microsomal PS-adrenic acids 
declining significantly over the 80 year period, alongside considerable losses of 
mitochondrial PS-AA. In the mitochondria this loss of PS-adrenic acid and PS-AA were 
driven predominantly by declines in PS 18:0_22:4 and PS 18:0_20:4 respectively 
(Figure 5-6, Table 5-2), while in the microsomal membranes there were losses with age 
of PS 18:0_22:4 (Figure 5-10, Table 5-4). These results emphasise that age-related 
changes in individual phospholipids are not necessarily reflected in the total 
contribution of a given fatty acid within a class of phospholipid. Previous studies using 
combinations of thin-layer chromatography and gas chromatography to examine the 
changes with age to phospholipids and their fatty acids as separate entities would not 
have seen these age-related changes.  
Interestingly we saw substantial increases in mitochondrial PS 18:0_22:6 over the adult 
lifespan in the human hippocampus (Figure 5-6, Table 5-2). This finding is similar to 
what was reported in Chapter 4 (section 4.2) for the mitochondrial and microsomal 
fractions of the human prefrontal cortex. In Chapter 4 (section 4.3) the importance of 
DHA within PS phospholipids of the human brain was discussed. Several other low-
abundance phospholipids containing DHA also increased with age in both membrane 
fractions of the hippocampus, including mitochondrial and microsomal PE 18:1_22:6 
(Figure 5-5 & Figure 5-9, Table 5-2 & Table 5-4), mitochondrial lyso-PE 22:6 (Figure 
5-4, Table 5-2) and microsomal PE 15:0_22:6/O-16:0_22:6 (Figure 5-9, Table 5-4). 
Increases in mitochondrial PS-DHA were also seen with age in the human hippocampus 
(Table 5-6), but this age-related increase in DHA was not reflected in combined 
mitochondrial phospholipids. This suggests that the increase in DHA across the adult 
lifespan within the hippocampus is not as extensive as that seen in the human prefrontal 
cortex, but that this smaller increase in mitochondrial PS-DHA still may exhibit a 
neuroprotective effect leading to increased longevity.  
The largest change in any single phospholipid of the human hippocampus occurred in 
mitochondrial PC 16:0_18:1, the predominant phospholipid present in the mitochondrial 
membranes (Figure 5-7). Mitochondrial PC 16:0_18:1 increased from 40.8% of total 
mitochondrial PC to 42.5% from ages 20 to 100, representing a 4% increase in initial 
abundance over the 80 year period (Figure 5-4, Table 5-2). In the previous chapter, we 
also saw age-related increases in mitochondrial PC 16:0_18:1 within the prefrontal 
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cortex. As discussed in Chapter 4 section 4.3, the role of this particular molecular 
phospholipid is largely unknown; however, its high abundance could suggest a 
structural or scaffolding role in cellular membranes. Evidence is also available that 
suggests a role for PC 16:0_18:1 in modulating membrane fluidity [192,193], as well as 
participating in the formation of lipid raft domains [201].  
Two previous studies have examined changes in the phospholipids of the human 
hippocampus during normal ageing. Similar to the present study, Söderberg et al. [90] 
reported decreases in total protein concentration (mg/g of wet tissue) in the human 
hippocampus with age. However, unlike this thesis Söderberg et al. [90] did not perform 
a fractionation step and so was unable to pinpoint the loss of protein with age to a 
particular subcellular fraction (Figure 5-2). Both studies by Söderberg et al. [90,93] 
reported decreases with age in the concentration of total phospholipids (mg/g wet 
tissue) in the hippocampus from ages 50-60 years, a finding that was not seen in this 
region in the present thesis. Between the two studies by Söderberg et al. there were 
conflicting results for age-related changes to phospholipid classes. Söderberg et al. [90] 
reported no changes in concentration to either total PC or PE with age in the 
hippocampus, while Söderberg et al. [93] found age-related decreases in both total PC 
and PE. In the present chapter, no changes with age were seen for any phospholipid 
class, either in percent abundance or quantified amount. Söderberg et al. [93] also 
examined changes in hippocampal PC and PE fatty acids with no age-related changes 
with age being found.  
In summary, there were several phospholipids containing either adrenic acid or AA that 
decreased with age in the mitochondrial and microsomal membranes of the human 
hippocampus. The most abundant phospholipid of this type was PE 18:0_22:4 in both 
membrane fractions, which decreased by approximately 13-18% in abundance from 
ages 20 to 100. Analysis of total fatty acids found that both adrenic acid and AA 
decreased with age in the combined phospholipids in both membrane fractions, but no 
age-related changes were seen specifically in the PE class for either fatty acid. Similar 
to our previous finding for the human prefrontal cortex in Chapter 4, significant age-
related increases were seen in mitochondrial PS 18:0_22:6 within the hippocampus.  
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Chapter 6 The Entorhinal Cortex 
The following chapter is an amended version of the manuscript submitted for 
publication: Hancock SE, Friedrich MG, Mitchell TW, Truscott RJW, Else PL 
(2015), “The phospholipid composition of the human entorhinal cortex remains 
relatively stable over 80 years of adult aging”. 
6.1 Introduction 
This chapter will examine the changes seen during normal ageing in PC, PE and PS 
phospholipids present in the mitochondrial and microsomal membranes of the 
entorhinal cortex.  
The entorhinal cortex is located in the medial temporal lobe in the anterior portion of 
the parahippocampal gyrus, and is considered to be the interface between the 
hippocampal formation and the neocortex (see Chapter 1, Figure 1-2). Within the 
hippocampal formation, there are circuits of interconnected neurons between the layers 
of the entorhinal cortex and regions of the hippocampus that form the perforant pathway 
involved in encoding episodic memory [202]. There is some disagreement in the 
literature as to whether this region is subject to significant age-related changes during 
normal ageing, with some studies finding significant declines in volume with age 
[17,19] while others have reported no age-related changes [203]. The entorhinal cortex 
also undergoes a loss in volume during the earliest stages of AD [203–205]. Both the 
Aβ plaques and tau NFTs characteristic of AD appear in this region in early stages of 
the disease [7]. Despite the significant changes occurring in the entorhinal cortex in AD 
surprisingly few studies have looked at alterations to phospholipid composition 
specifically in the entorhinal cortex [116], although others have examined the entire 
parahippocampal gyrus [121,123]. To date, there have been no studies conducted that 
test if any changes occur in the phospholipids of this region during normal ageing.  
Therefore, the aim of this chapter was to characterise the age-related changes occurring 
to the phospholipid composition of the mitochondrial and microsomal membranes of the 
human entorhinal cortex.   
CHAPTER 6 
 
103 | P a g e  
 
6.2 Results 
6.2.1 Age-related changes to total protein content in subcellular fractions  
No changes with age in total protein concentration (mg/g tissue) were seen in the whole 
tissue homogenate, or in the mitochondrial and microsomal membranes. 
6.2.2 Major phospholipid classes of mitochondrial and microsomal fractions 
Each of the three phospholipids classes measured in this study (PC, PE and PS) reported 
as a fraction of total phospholipid detected in the mitochondrial and microsomal 
membranes are shown in Figure 6-1. The most abundant of the three phospholipid 
classes in both membrane fractions was PC, making up around 50% of the total 
phospholipids detected, followed by PE at 30% and PS at just under 20%.  
When the percent composition of each phospholipid class was compared with each 
fraction, the mitochondria contained slightly less PC compared to the microsomes (p < 
0.05), and slightly more PE (p < 0.001). No differences were seen in PS content 
between the fractions. The quantified amounts of each phospholipid class (as pmol of 
phospholipid/µg membrane protein) were also analysed, with approximately 20% more  
 
 
Figure 6-1: Percent composition of the three major phospholipid classes within the 
mitochondrial (left) and microsomal (right) fractions in normal human entorhinal 
cortex.  Values are the mean ± SEM for the entire cohort. The microsomal membranes 
showed significantly higher amounts of total phosphatidylcholine (PC) compared to 
mitochondria (p < 0.05, Wilcoxon signed-rank test), while the mitochondria contained 
more phosphatidylethanolamine (PE) (p < 0.001, Wilcoxon signed-rank test). There 
were no differences between fractions for phosphatidylserine (PS). 
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Figure 6-2: Phospholipid classes changing significantly with age (as a percent of total 
phospholipid) in normal human entorhinal cortex (n = 36).  Regression model was 
adjusted for sex: males (●), females (○). Regression parameters are shown in Table 6-1. 
 
 
 
Table 6-1: Phospholipid classes changing significantly with age in the normal human 
entorhinal cortex 
Phospholipid Slope 
95% CI  
β df t P value Lower Upper 
Percent composition (% total phospholipid) 
Mitochondrial PC 0.0700 0.0061 0.1339 0.394 2,33 2.232 0.033* 
Mitochondrial PE  -0.0487 -0.0953 -0.0019 -0.367 2,33 -2.122 0.042* 
Phospholipid molecular species were detected using nanoelectrospray ionisation mass 
spectrometry and quantified as described in materials and methods. Regression was 
adjusted for gender. * P <0.05  
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PC, PS and total phospholipid being present in the microsomal fraction (p < 0.01, data 
not shown).  
Regressions with age were carried out for each of the phospholipids classes in both the 
mitochondrial and microsomal membranes. Mitochondrial PC increased by 12% in 
abundance over the 80 years (Figure 6-2, Table 6-1). Conversely, mitochondrial PE 
declined by 11% in abundance from ages 20 to 100. No changes with age were reported 
for any of the quantified phospholipid classes (as pmol of phospholipid/µg membrane 
protein) in either membrane fraction, including total mitochondrial and microsomal 
phospholipid.  
6.2.3 Changes in mitochondrial phospholipids with age  
6.2.3.1 Phosphatidylcholines 
The composition of PC, PE and PS phospholipids detected in the mitochondrial 
membranes of the entorhinal cortex can be seen in Figure 6-3. A significant age-related 
increase was found for the most abundant phospholipid of the mitochondrial fraction: 
PC 16:0_18:1 (Figure 6-4, Table 6-2). PC 16:0_18:1 increased from 42% of total 
mitochondrial PC at age 20 to 44% at age 100. Due to the high abundance of this 
phospholipid, this represents one of the largest age-related changes for any single 
mitochondrial phospholipid in the human entorhinal cortex.  
Only one other mitochondrial PC increased with age in its percent composition, PC 
16:0_18:2, which increased in abundance by 73% across the 80 years. However, this 
phospholipid is relatively low in abundance, making up only 0.5% of total 
mitochondrial PC. Only PC 16:0_18:2 maintained its age-related increase when 
analysed as quantified data (pmol of phospholipid/µg membrane protein, Table 6-3). 
6.2.3.2 Phosphatidylethanolamines 
A total of six mitochondrial PEs increased in abundance over the 80 year period studied 
when expressed as a percent of total PE (Figure 6-5, Table 6-2). Four of these 
phospholipids contained a 22:6 fatty acid: PE 16:0_22:6, PE 18:1_22:6, PE O-
18:1_22:6, and PE 17:0_22:6/O-18:0_22:6. Only three mitochondrial PEs containing a 
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Figure 6-3: Phospholipids detected within PC, PE and PS in the mitochondrial fraction 
of human entorhinal cortex (as a percent of total phospholipid within each class).  
Phospholipids were quantified as described in materials and methods. Values are mean 
across the cohort ± SEM. 
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Figure 6-4: Mitochondrial PCs changing significantly with age (as a percent of total PC) 
in normal human entorhinal cortex (n = 30-36).  Regression model was adjusted for sex: 
males (●), females (○). Regression parameters are shown in Table 6-2. 
22:6 fatty acid did not show any age-related increases. These were lyso-PE 22:6, PE 
15:0_22:6/O-16:0_22:6 and PE 18:0_22:6, the most abundant PE present in the 
mitochondria (Figure 6-3). 
PE 16:0_22:6 is the fourth-most abundant mitochondrial PE, comprising just under 6% 
of total mitochondrial PE (Figure 6-3) and 1.8% of total mitochondrial phospholipid. 
An increase of 17% in abundance was observed for this phospholipid over the 80 year 
period (Figure 6-5, Table 6-2). Of the remaining 22:6-containing mitochondrial PEs, PE 
18:1_22:6 increased by 18%, PE O-18:1_22:6 by 15%, and PE 17:0_22:6/O-18:0_22:6 
by 251% from ages 20 to 100. Though seemingly large increases in abundance were 
seen in PE 17:0_22:6/O-18:0_22:6 with age, this phospholipid is of low abundance in 
the mitochondria, making up only 0.7% of total mitochondrial PE (Figure 6-3). Aside 
from these age-related increases seen in 22:6-containing PEs, two other mitochondrial 
PEs increased with age in their percent composition: PEs 16:0_18:1 (25%), 16:0_20:1 
(30%) (Figure 6-5, Table 6-2).  
Only PE 17:0_22:6/O-18:0_22:6 maintained an increase with age when analysed as a 
quantified amount (pmol of phospholipid/µg membrane protein, Table 6-3). Two other 
mitochondrial PEs decreased in quantified amount with age in the human entorhinal 
cortex, PE 18:0_22:4 and PE O-18:1_22:4.  
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Table 6-2: Mitochondrial phospholipids (percent of phospholipid within phospholipid 
class) changing significantly with age in the human entorhinal cortex. 
Phospholipid Slope 
95% CI  
β df t P value Lower Upper 
Phosphatidylcholine 
PC 16:0_18:1 0.0298 0.0086 0.0511 0.482  2,32 2.861 0.007** 
PC 16:0_18:2 0.0067 0.0023 0.0111 0.547  2,29 3.131 0.004** 
Phosphatidylethanolamine 
PE 16:0_18:1 0.0091 0.0022 0.0161 0.470 2,31 2.690 0.011* 
PE 16:0_20:1 0.0026 0.000003 0.0053 0.386 2,27 2.054 0.0498* 
PE 16:0_22:6 0.0109 0.0020 0.0197 0.450 2,31 2.505 0.018* 
PE 18:1_22:6 0.0049 0.0009 0.0089 0.452 2,30 2.511 0.018* 
PE 17:0_22:6 
 /O-18:0_22:6 0.0085 0.0029 0.0141 0.612 2,26 3.116 0.004** 
PE O-18:1_22:6 0.0033 0.00002 0.0067 0.328 2,32 2.051 0.0485* 
Phospholipid molecular species were detected using nanoelectrospray ionisation mass 
spectrometry and quantified as described in materials and methods. Regression was 
adjusted for gender. * P <0.05 ** P <0.01  
 
 
 
Table 6-3: Quantified mitochondrial phospholipids (pmol/µg total membrane protein) 
changing significantly with age in the human entorhinal cortex. 
Phospholipid Slope 
95% CI  
β df t P value Lower Upper 
Phosphatidylcholine 
PC 16:0_18:2 0.0138 0.0030 0.0246 0.483 2,32 2.614 0.014* 
Phosphatidylethanolamine 
PE 18:0_22:4 -0.0502 -0.0882 -0.0123 -0.488 2,33 -2.702 0.011* 
PE 17:0_22:6 
 /O-18:0_22:6 0.0099 0.0010 0.0188 0.482 2,30 2.297 0.030* 
PE O-18:1_22:4 -0.0085 -0.0165 -0.0005 -0.384 2,33 -2.160 0.038* 
Phosphatidylserine 
PS 18:0_22:4 -0.0253 -0.0484 -0.0022 -0.404 2,33 -2.226 0.033* 
Phospholipid molecular species were detected using nanoelectrospray ionisation mass 
spectrometry and quantified as described in materials and methods. Regression was 
adjusted for gender. * P <0.05   
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Figure 6-5: Mitochondrial PEs changing significantly with age (as a percent of total PE) 
in normal human entorhinal cortex (n = 30-36).  Regression model was adjusted for sex: 
males (●), females (○). Regression parameters are shown in Table 6-2. 
6.2.3.3 Phosphatidylserines 
No PS phospholipids changed with age in either percent abundance (percent of total PS) 
or quantified amount (pmol phospholipid/µg membrane protein) in the mitochondrial 
fraction. 
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6.2.4 Changes in microsomal phospholipids with age  
6.2.4.1  Phosphatidylcholines 
The percent composition of each microsomal phospholipid within PC, PE and PS can be 
seen in Figure 6-6. There were three microsomal PCs observed to undergo age-related 
changes, all of which increased in abundance (Figure 6-7, Table 6-4). The most 
abundant of these was PC 18:1_18:1, a phospholipid that is found in moderate amounts 
in the microsomal membranes of the human entorhinal cortex (Figure 6-6). PC 
18:1_18:1 increased from 2.7% of microsomal PC to 3.6% from ages 20 to 100 (Figure 
6-7, Table 6-4). The remaining two microsomal PCs increasing in abundance with age 
were PC 14:0_16:0 and PC 15:0_16:0/O-16:0_16:0, which rose by 23% and 38% in 
abundance over the 80 year period. However, both of these phospholipids are only of 
low abundance making up less than 1% of the total microsomal phospholipid when 
combined.  
No age-related changes were observed for the quantified microsomal PC phospholipids 
(pmol phospholipid/µg membrane protein) in the entorhinal cortex. 
6.2.4.2 Phosphatidylethanolamines 
Analysis of the microsomal PEs of the entorhinal cortex found three phospholipids that 
changed with age (Figure 6-8, Table 6-4). Two of these phospholipids increased with 
age, PE 18:1_22:6 and PE 16:0_22:5, by 28% and 25% in abundance respectively over 
the 80 years. PE 16:0_20:1 decreased by 22% in abundance over the same period. All 
three phospholipids are of low abundance in the microsomal membranes, however, 
making up less than 1.4% of the total microsomal phospholipid when combined (Figure 
6-6). 
Only a single microsomal PE changed with age when quantified phospholipids (pmol 
phospholipid/µg membrane protein) were analysed (Table 6-5). PE 18:1_22:4 increased 
from 2.0 pmol/µg membrane protein at age 20 to 2.6 pmol phospholipid/µg membrane 
protein at age 100.  
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Figure 6-6: Phospholipids detected within PC, PE and PS in the microsomal fraction of 
human entorhinal cortex (as a percent of total phospholipid within each class).  
Phospholipids were quantified as described in materials and methods. Values are mean 
across the cohort ± SEM.  
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Figure 6-7: Microsomal PCs changing significantly with age (as a percent of total PC) 
in normal human entorhinal cortex (n = 30-36). Regression model was adjusted for sex: 
males (●), females (○). Regression parameters are shown in Table 6-4. 
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Table 6-4: Microsomal phospholipids (percent of phospholipid within phospholipid 
class) changing significantly with age in the human entorhinal cortex. 
Phospholipid Slope 
95% CI  
β df t P value Lower Upper 
Phosphatidylcholine 
PC 14:0_16:0 0.0030 0.0002 0.0058 0.400 2,32 2.168 0.038* 
PC 18:1_18:1 0.0115 0.0020 0.0211 0.443 2,32 2.452 0.020* 
PC 15:0_16:0 
 /O-16:0_16:0 0.0021 0.0008 0.0033 0.570 2,31 3.271 0.003** 
Phosphatidylethanolamine 
PE 16:0_20:1 -0.0029 -0.0055 -0.0003 -0.456 2,24 -2.273 0.032* 
PE 16:0_22:5 0.0043 0.0006 0.0080 0.409 2,28 2.395 0.024* 
PE 18:1_22:6 0.0069 0.0024 0.0115 0.517 2,31 3.096 0.004** 
Phosphatidylserine 
PS 18:0_22:4 -0.0203 -0.0382 -0.0023 -0.418 2,32 -2.301 0.028* 
PS 18:1_20:1 0.0071 0.0011 0.0131 0.440 2,32 2.421 0.021* 
Phospholipid molecular species were detected using nanoelectrospray ionisation mass 
spectrometry and quantified as described in materials and methods. Regression was 
adjusted for gender. * P <0.05 ** P <0.01   
 
 
Table 6-5: Quantified microsomal phospholipids (pmol/µg total membrane protein) 
changing significantly with age in the human entorhinal cortex. 
Phospholipid Slope 
95% CI  
β df t P value Lower Upper 
Phosphatidylethanolamine 
PE 18:1_22:4 0.0264 0.0020 0.0508 0.413 2,29 2.216 0.035* 
Phospholipid molecular species were detected using nanoelectrospray ionisation mass 
spectrometry and quantified as described in materials and methods. Regression was 
adjusted for gender. * P <0.05  
 
  
CHAPTER 6 
 
114 | P a g e  
 
 
 
 
 
Figure 6-8: Microsomal PEs changing significantly with age (as a percent of total PE) in 
normal human entorhinal cortex (n = 30-36). Regression model was adjusted for sex: 
males (●), females (○). Regression parameters are shown in Table 6-4. 
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6.2.4.3 Phosphatidylserines 
Only two PS phospholipids changed with age in the microsomal fraction: PS 18:0_22:4 
and PS 18:1_20:1 (Figure 6-9, Table 6-4). PS 18:0_22:4, a moderately abundant 
phospholipid making up 7% of microsomal PS (Figure 6-6) and 1.4% of total 
microsomal phospholipids, decreased in percent composition by 20% from ages 20 to 
100 (Figure 6-8, Table 6-4). PS 18:1_20:1 increased its percent composition, by 180% 
over the 80 year period. While a seemingly large increase with age, PS 18:1_20:1 is 
only found in low amounts in microsomal membranes, making up only 0.7% of 
microsomal PS (Figure 6-6). 
No microsomal PS changed in quantified amount (pmol phospholipid/µg membrane 
protein) with age in the human entorhinal cortex. 
 
 
 
 
Figure 6-9: Microsomal PSs changing significantly with age (as a percent of total PS) in 
normal human entorhinal cortex (n = 30-36). Regression model was adjusted for sex: 
males (●), females (○). Regression equations are presented in Table 6-4. 
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6.3 Discussion  
In the present chapter, a number of phospholipids underwent changes in the 
mitochondrial and microsomal membranes of the human entorhinal cortex during 
normal ageing. Similar to what was reported for the prefrontal cortex (Chapter 4) and 
hippocampus (Chapter 5), the changes observed in the entorhinal cortex were not 
limited to a particular class of phospholipid, nor were they limited to either the 
mitochondrial or microsomal fraction. Many age-related increases were seen 
specifically in mitochondrial PE phospholipids containing a 22:6 fatty acid (DHA), a 
finding similar to that previously reported in the prefrontal cortex (Chapter 4) and, to a 
lesser extent, the hippocampus (Chapter 5).  
The most interesting age-related change in the phospholipids of the entorhinal cortex 
was found within the mitochondrial PE phospholipids. Four of the six mitochondrial 
PEs that changed significantly in percent composition with age contained a DHA: PE 
16:0_22:6, PE 18:1_22:6, PE O-18:1_22:6, and PE 17:0_22:6/O-18:0_22:6 (Figure 6-5, 
Table 6-2). There were only three PE phospholipids containing a 22:6 fatty acid that did 
not change with age in the mitochondrial fraction: lyso-PE 22:6, PE 15:0_22:6/O-
16:0_22:6 and the most abundant mitochondrial PE, PE 18:0_22:6. As discussed in 
previous chapters, the 22:6 fatty acid can be putatively classified as the n-3 fatty acid 
DHA based on its synthesis via the elongation and desaturation pathway (see Chapter 2, 
Figure 2-4) [56]. DHA is the most abundant n-3 fatty acid present in the brain; other n-3 
fatty acids such as 20:5 (EPA) are typically only found in trace amounts in the human 
brain. Indeed, no phospholipids with this fatty acid were found in any of the three 
regions examined so far. DHA has a number of important biological roles in neuronal 
cellular membranes, including neurite growth, membrane fluidity, synaptic transmission 
and the production of anti-inflammatory eicosanoids [77]. The importance of 
phospholipids containing DHA with a PS head group in neuron survival and longevity 
was discussed previously in Chapter 4, but no changes with age to PS 18:0_22:6 were 
observed in the entorhinal cortex in either membrane fraction. Conversely, the specific 
cellular role of PE phospholipids containing DHA is widely unknown. The only 
available evidence suggests a role for some PE-DHA fatty acids as preferential 
precursors for the synthesis of PS-DHA phospholipids via PSS2 [46]. PSS2 is located in 
the mitochondria-region of the endoplasmic reticulum and is highly expressed in both 
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brain and testes in mammals. Increases in PS synthesis via serine-base exchanges have 
been reported in aged rats in the cerebellum and cerebral cortex, both with and without 
the addition of exogenous calcium [47]; however, if this also occurs in humans then we 
would expect levels of PE-DHA to decrease with age with a corresponding increase in 
PS-DHA. More research is needed to elucidate the mechanism and significance of PE-
DHA phospholipids increasing with age in this region of the brain. 
Due to the number of mitochondrial PEs containing DHA increasing in their percent 
composition with age, additional analysis was carried out to examine if any changes 
with age occurred to the most abundant PUFA across both the mitochondrial (Table 
6-6) and microsomal membranes (Table 6-7). Surprisingly no age-related changes were 
seen in DHA in any of the phospholipid classes in the mitochondrial membranes despite 
the finding that many mitochondrial PEs containing DHA increased with age (Table 
6-6). Examination of individual mitochondrial PE phospholipids showed that the lack of 
age-related changes to total PE-DHA could be attributed to a lack of age-related 
changes in the most abundant mitochondrial PE phospholipid, PE 18:0_22:6. This PE 
makes up 31% of total mitochondrial PE (Figure 6-3), which is nearly three times the 
combined amount of the four mitochondrial PE-DHA phospholipids that increased with 
age. Interestingly there were also decreases reported for total mitochondrial PC-22:4 
fatty acids with age despite no single mitochondrial PC with a 22:4 fatty acid changing 
significantly with age (Figure 6-4). These results emphasise that significant age-related 
changes in specific phospholipids may be masked by examining fatty acids in isolation 
using techniques such as GC. 
The phospholipid that underwent one of the largest age-related changes in the entorhinal 
cortex was mitochondrial PC 16:0_18:1, the most abundant phospholipid present in this 
fraction (Figure 6-3). While only a 6% increase in abundance was found for PC 
16:0_18:1 over the 80 year period (Figure 6-4, Table 6-2), this phospholipid comprises 
approximately 42% of total mitochondrial PC (Figure 6-3) and 21% of total 
mitochondrial phospholipids, making this one of the largest changes in membrane 
composition reported in this region. A similar age-related change in the abundance of 
PC 16:0_18:1 was reported in the mitochondria of the prefrontal cortex (Chapter 4)  
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Table 6-6: Linear regression of most abundant polyunsaturated fatty acids (percent of 
total fatty acids within phospholipid class) in the mitochondrial membranes with age in 
human entorhinal cortex 
Mitochondrial 
fatty acids Slope 
95% CI β df t P value Lower Upper 
Combined phospholipids       
20:4 -0.0039 -0.0148 0.0069 -0.144 2,32 -0.739 0.465 
22:4 -0.0145 -0.0256 -0.0034 -0.441 2,32 -2.653 0.012* 
20:4 + 22:4 -0.0184 -0.0338 -0.0031 -0.417 2,32 -2.447 0.020* 
22:6 -0.0011 -0.0250 0.0228 -0.019 2,32 -0.096 0.924 
Phosphatidylcholine       
20:4 -0.0007 -0.0108 0.0094 -0.028 2,31 -0.140 0.889 
22:4 -0.0098 -0.0191 -0.0004 -0.387 2,32 -2.129 0.041* 
20:4 + 22:4 -0.0105 -0.0200 -0.0010 -0.400 2,31 -2.264 0.031* 
22:6 -0.0013 -0.0051 0.0026 -0.130 2,32 -0.665 0.511 
Phosphatidylethanolamine      
20:4 -0.0029 -0.0219 0.0161 -0.061 2,32 -0.310 0.758 
22:4 -0.0134 -0.0369 0.0101 -0.216 2,32 -1.162 0.254 
20:4 + 22:4 -0.0163 -0.0448 0.0121 -0.222 2,32 -1.168 0.252 
22:6 0.0202 -0.0080 0.0482 0.278 2,32 1.460 0.154 
Phosphatidylserine       
20:4 0.0036 -0.0025 0.0097 0.231 2,31 1.197 0.240 
22:4 -0.0095 -0.0206 0.0017 -0.321 2,31 -1.722 0.094 
20:4 + 22:4 -0.0059 -0.0160 0.0042 -0.219 2,31 -1.183 0.245 
22:6 0.0432 -0.0418 0.0128 0.196 2,30 1.034 0.308 
Fatty acids calculated from phospholipid molecular species data. Regression was 
adjusted for gender. * P <0.05 ** P <0.01 *** P <0.001   
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Table 6-7: Linear regression of most abundant polyunsaturated fatty acids (percent of 
total fatty acids within phospholipid class) in the microsomal membranes with age in 
human entorhinal cortex 
Mitochondrial 
fatty acids Slope 
95% CI β df t P value Lower Upper 
Combined phospholipids       
20:4 -0.0056 -0.0149 0.0037 -0.239 2,32 -1.235 0.226 
22:4 -0.0056 -0.0138 0.0026 -0.260 2,32 -1.383 0.176 
20:4 + 22:4 -0.0112 -0.0252 0.0028 -0.307 2,32 -1.632 0.113 
22:6 -0.0008 -0.0262 0.0247 -0.012 2,32 -0.060 0.952 
Phosphatidylcholine       
20:4 -0.0021 -0.0114 0.0072 -0.092 2,31 -0.470 0.641 
22:4 -0.0027 -0.0062 0.0008 -0.314 2,30 -1.586 0.123 
20:4 + 22:4 -0.0027 -0.0128 0.0075 -0.104 2,32 -0.537 0.595 
22:6 -0.00003 -0.0046 0.0045 -0.002 2,32 -0.012 0.990 
Phosphatidylethanolamine      
20:4 -0.0145 -0.0341 0.0051 -0.270 2,32 -1.506 0.142 
22:4 -0.0051 -0.0190 0.0088 -0.136 2,30 -0.750 0.459 
20:4 + 22:4 -0.0089 -0.0354 0.0177 -0.134 2,32 -0.680 0.501 
22:6 0.0152 -0.0118 0.0422 0.220 2,32 1.148 0.259 
Phosphatidylserine       
20:4 -0.0007 -0.0080 0.0065 -0.041 2,32 -0.207 0.837 
22:4 -0.0125 -0.0230 -0.0020 -0.440 2,32 -2.417 0.022* 
20:4 + 22:4 -0.0132 -0.0233 -0.0031 -0.476 2,32 -2.660 0.012* 
22:6 0.0319 -0.0520 0.1157 0.148 2,32 0.774 0.445 
Fatty acids calculated from phospholipid molecular species data. Regression was 
adjusted for gender. * P <0.05 ** P <0.01 *** P <0.001 
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and the hippocampus (Chapter 5). As discussed previously in Chapter 4 and Chapter 5, 
the function of this particular phospholipid is currently unknown, but its high abundance 
in both the mitochondrial and microsomal membranes suggests a structural role. 
However, it has been hypothesised that this particular phospholipid could play a role in 
modulating the fluidity of the membrane bilayer [192,193] as well as participate in the 
formation of lipid rafts [201].  
Despite reports of decreases in the volume of the entorhinal cortex during normal 
ageing [17,19] there have been no published studies to date that have examined age-
related changes to the phospholipids of this region, which prevent any comparisons 
being made with this study. The entorhinal cortex has also not been extensively studied 
for changes in membrane phospholipids in AD despite this region displaying losses in 
volume and significant tau and Aβ deposition in the early to mid-stages of the disease 
[203–205]. Only one study has specifically examined the entorhinal cortex for any 
changes its phospholipids in AD, finding no changes in either total PC, PE or PS 
phospholipid [116]. However, a further two other studies have examined the entire 
parahippocampal gyrus, looking at total phospholipid-fatty acids [121] and fatty acids 
separated by phospholipid class [123]. Skinner et al. [121] reported increases in total 
18:1 and 22:4 in AD, with no changes being reported for DHA. Conversely, Prasad et 
al. [123] observed decreases in several PE-fatty acids in the 
hippocampus/parahippocampal gyrus, including both AA and DHA. Although the 
current evidence is relatively sparse, if the loss of PE-DHA in the entorhinal cortex and 
greater parahippocampal gyrus is indeed indicative of AD then the rise in several PE 
phospholipids containing DHA seen in the present chapter during normal ageing in the 
entorhinal cortex could be protective against the disease. More extensive research will 
be needed to see if there is a substantial loss of DHA in AD specifically in the 
entorhinal cortex to confirm this hypothesis. 
In summary, there were many age-related increases seen in the entorhinal cortex in both 
the mitochondrial and microsomal membranes, including the rise of several 
mitochondrial PE phospholipids containing DHA. These PE-DHA phospholipids 
included PE 16:0_22:6, PE 18:1_22:6, PE O-18:1_22:6, and PE 17:0_22:6/O-
18:0_22:6; however, the most abundant DHA-containing mitochondrial PE, PE 
18:0_22:6, did not change with age. These contralateral changes in mitochondrial PEs 
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containing DHA led to no significant age-related changes being observed overall for 
total mitochondrial PE-DHA. Out of the three regions analysed so far, the entorhinal 
cortex has displayed the fewest number of changes to phospholipids during normal, 
adult ageing in both the mitochondrial and microsomal membranes.  
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Chapter 7 The Cerebellum  
7.1 Introduction 
This chapter will examine age-related changes in PC, PE and PS phospholipids in the 
mitochondrial and microsomal membranes of the human cerebellum. 
Latin for the “the little brain”, the cerebellum is located at the bottom of the brain (see 
Chapter 1, Figure 1-2) and has a primary role in the coordination and precision of motor 
activity The cytoarchitecture of the cerebellum consists of three layers: a superficial 
molecular layer, a layer of Purkinje cells and a granular layer comprised of small, 
densely-packed granular cells. The cerebellum is thought to be largely spared during the 
pathogenesis of AD, with only small amounts of Aβ plaques characteristic of the 
disease being found in the molecular layer of the cerebellum [206,207]. The NFTs also 
characteristic of AD are largely absent in the cerebellum in affected individuals 
[206,207]. Likewise, many studies examining changes in phospholipids within the 
cerebellum during the pathogenesis of AD have found few to no changes as a result of 
the disease [85,111,112,115,116,123]. A recent stereological study found no changes in 
either Purkinje or granule cell number or density in AD, but a significant reduction in 
total cerebellar volume was seen in the AD group [208]. Due to the small amount of 
reported changes in the cerebellum in AD described above this region is often used as a 
control brain region.  
Significant losses in cerebellar volume have also been reported during normal ageing, 
particularly in advanced age, using both stereological and in vivo imaging techniques 
[209]. Despite these reported changes, only a single study has looked at any changes to 
membrane lipids with age [90]. Söderberg et al. [90] found no changes during normal 
ageing in the levels of total phospholipid, PC or PE. Therefore, the aim of this chapter 
was to identify if any changes are occurring to the molecular phospholipids of the 
mitochondrial and microsomal membranes of the human cerebellum during normal 
ageing.   
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7.2 Results  
7.2.1 Changes in total protein concentration during normal ageing  
The total protein content (mg/g wet tissue) of both the mitochondrial and microsomal 
fractions declined significantly with age (Figure 7-1, Table 7-1). Mitochondrial protein 
concentration fell by 54%, decreasing from 7.9 to 3.7 mg protein/g wet tissue from ages 
20 to 100, while microsomal protein decreased from 1.5 to 0.9 mg/g wet tissue, a loss of 
38%. The concentration of total protein within the whole tissue showed a trend towards 
decreased abundance with advanced age, but this failed to reach statistical significance 
(p = 0.076). 
7.2.2 Major phospholipid classes of mitochondrial and microsomal fractions 
The proportion of PC, PE and PS detected in the mitochondrial and microsomal 
fractions (as a percent of total phospholipid) is shown in Figure 7-2. The most abundant 
phospholipid class present in the two membrane fractions was PC, which comprised 
around 45% of total phospholipids in the two fractions, followed by PE at 
approximately 35% of total phospholipids and PS at 20%. The microsomal membranes 
contained more PC than the mitochondrial (p < 0.001) while the mitochondrial 
membranes contained more PE and PS (p < 0.001). The quantified amount (pmol/µg 
membrane protein) of each phospholipid in all three classes was also analysed, with 
higher levels of total PC (p < 0.01) , PE and PS (p < 0.001) found in the mitochondria, 
as well as higher levels of total quantified phospholipid (p < 0.001). Each phospholipid 
class was also assessed for any changes with age in both the mitochondrial and 
microsomal membranes, with no age-related effect found in either membrane fraction 
for any phospholipid class measured as percent abundance (% total phospholipid) or as 
quantified phospholipids (pmol phospholipid/µg membrane protein). Likewise, no 
statistically significant changes with age were found in either membrane fraction for 
total quantified phospholipid. 
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Figure 7-1: Linear regression of total protein amount (mg/g wet tissue) measured in 
whole tissue homogenate and subcellular fractions derived from normal human 
cerebellum against age. Total protein was measured using BCA assay as described in 
methods and materials. Regression model was adjusted for sex: males (●), females (○). 
T indicates dependent variable transformed for linear regression, with transformed beta-
coefficient and p-value reported on original scatterplot for comparison. Regression 
parameters are shown in Table 7-1.  
CHAPTER 7 
 
125 | P a g e  
 
Table 7-1: Significant linear regression results of total protein (mg/g of tissue) with age 
in the subcellular fractions of neurologically normal human cerebellum 
Phospholipid Slope 
95% CI  
β df t P value Lower Upper 
Whole tissue 
homogenateI -0.00002 -0.00005 -0.0000002 -0.331 2,33 -1.833 0.076 
Mitochondria -0.0534 -0.0913 -0.0155 -0.472 2,33 -2.865 0.007** 
Microsomes -0.0072 -0.0126 -0.0018 -0.462 2,33 -2.708 0.011* 
Total protein amount measured using BCA Assay. Regression was adjusted for gender. 
Superscript indicates dependent variable transformed for linear regression, with 
transformed regression output reported: I reciprocal. * P <0.05 ** P <0.01 
 
 
 
 
Figure 7-2: Relative percentage contribution of the three major phospholipid classes 
within the mitochondrial (left) and microsomal (right) fractions in neurologically 
normal cerebellum. Values are the mean ± SEM for the entire cohort. The microsomal 
membranes showed significantly higher amounts of total phosphatidylcholine (PC) 
compared to mitochondria (p < 0.001, Wilcoxon signed-rank test), while the 
mitochondria contained more phosphatidylethanolamine (PE) (p < 0.001, Wilcoxon 
signed-rank test) and phosphatidylserine (PS) (p<0.001, Wilcoxon signed-rank test). 
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7.2.3 Changes in mitochondrial phospholipids with age  
7.2.3.1 Phosphatidylcholines 
The percent composition of all phospholipids detected in the mitochondrial membranes 
is shown in Figure 7-3. Four mitochondrial PCs underwent statistically significant 
changes with age in the human cerebellum (Figure 7-4, Table 7-2). The most abundant 
mitochondrial PC to change with age was PC 16:0_22:6, which increased from 3.6% of 
total mitochondrial PC at age 20 to 4.3% at 100 years of age. This represents an 
increase of 20% from its initial abundance. Only one other mitochondrial PC showed an 
age-related increase, PC 16:0_18:2, which rose by 39% in abundance over the 80 year 
period. However, PC 16:0_18:2 is only of low abundance in the mitochondrial 
membranes, comprising only 1.1% of mitochondrial PC (Figure 7-3) and 0.5% of total 
mitochondrial phospholipid. 
The remaining statistically significant mitochondrial PCs decreased with age as follows: 
PC 16:0_22:4 by 25%, and PC 16:0_20:1 by 27% over the 80 year period (Figure 7-4, 
Table 7-2). PC 16:0_22:4 is a moderately abundant phospholipid, comprising 2.9% of 
mitochondrial PC, while PC 16:0_20:1 is of lower abundance making up less than 1.5% 
of mitochondrial PC (Figure 7-3). Of these four mitochondrial PCs only PC 16:0_18:2 
maintained its increase with age when analysed as quantified amount (pmol 
phospholipid/µg membrane protein; Table 7-3). 
7.2.3.2 Phosphatidylethanolamines 
Within the mitochondria, eleven PEs changed in percent composition with age (Figure 
7-5, Table 7-2). The mitochondrial PE with the largest age-related change was PE 
18:0_22:6, the most abundant PE present in the mitochondria (Figure 7-3). 
Mitochondrial PE 18:0_22:6 increased from 26.0% of total mitochondrial PE to 31.5% 
over the 80-year period. Four other mitochondrial PEs containing a 22:6 fatty acid also 
increased with age: PE 16:0_22:6, PE 18:1_22:6, PE O-18:1_22:6 and PE 15:0_22:6/O-
16:0_22:6 (Figure 7-5, Table 7-3). PE 16:0_22:6, the third-most abundant mitochondrial 
PE, increased by 34% in percent composition from ages 20 to 100. Both PE 18:1_22:6 
and O-18:1_22:6 are moderately abundant phospholipids (Figure 7-3) that increased by 
33% and 22% in abundance respectively over the 80 year period (Figure 7-5, Table 
7-2). PE 15:0_22:6/O-16:0_22:6 more than tripled in abundance from ages 20 to 100, 
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Figure 7-3: Phospholipids detected within PC, PE and PS in the mitochondrial fraction 
of human cerebellum (as a percent of total phospholipid within each class). 
Phospholipids were quantified as described in materials and methods. Values are mean 
across the cohort ± SEM.  
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Figure 7-4: Mitochondrial PCs changing significantly with age (as a percent of total PC) 
in normal human cerebellum (n = 33-35).  Regression model was adjusted for sex: 
males (●), females (○). T indicates dependent variable transformed for linear regression, 
with transformed beta-coefficient and p-value reported on original scatterplot for 
comparison. Regression parameters are shown in Table 7-2.  
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Table 7-2: Mitochondrial phospholipids (percent of phospholipid within phospholipid 
class) changing significantly with age in the human cerebellum. 
Phospholipid Slope 
95% CI  
β df t P value Lower Upper 
Phosphatidylcholine 
PC 16:0_18:2 0.0045 0.0004 0.0086 0.412 2,31 2.218 0.034* 
PC 16:0_20:1 -0.0053 -0.0104 -0.0002 -0.410 2,30 -2.126 0.042* 
PC 16:0_22:4I -0.0010 -0.0019 -0.00003 -0.391 2,32 -2.102 0.044* 
PC 16:0_22:6 0.0091 0.0019 0.0164 0.478 2,31 2.575 0.015* 
Phosphatidylethanolamine 
Lyso-PE 22:4 -0.0035 -0.0069 -0.0001 -0.394 2,33 -2.116 0.042* 
PE 16:0_22:6 0.0197 0.0114 0.0279 0.708 2,30 4.883 0.00003*** 
PE 18:0_18:1 -0.0114 -0.0186 -0.0041 -0.539 2,32 -3.205 0.003** 
PE 18:0_20:4 -0.0606 -0.0931 -0.0281 -0.600 2,32 -3.799 0.0006*** 
PE 18:0_22:4 -0.0214 -0.0332 -0.0096 -0.616 2,33 -3.694 0.0008*** 
PE 18:0_22:6 0.0688 0.0132 0.1244 0.460 2,33 2.518 0.017* 
PE 18:1_22:6 0.0106 0.0054 0.0158 0.606 2,33 4.122 0.0002*** 
PE 15:0_22:6 
 /O-16:0_22:6 0.0210 0.0097 0.0323 0.669 2,32 3.785 0.0006*** 
PE 17:0_22:4 
 /O-18:0_22:4 -0.0095 -0.0157 -0.0034 -0.542 2,33 -3.171 0.003** 
PE O-16:1_22:5 -0.0124 -0.0188 -0.0060 -0.647 2,33 -3.936 0.0004*** 
PE O-18:1_22:6 0.0065 0.0007 0.0123 0.421 2,33 2.268 0.030* 
Phosphatidylserine 
PS 18:0_18:1 -0.1269 -0.2293 -0.0246 -0.445 2,33 -2.523 0.017* 
PS 18:0_22:4L -0.0025 -0.0036 -0.0015 -0.735 2,32 -4.856 0.00003*** 
PS 18:0_22:6L 0.0022 0.0012 0.0032 0.681 2,33 4.451 0.00009*** 
Phospholipid molecular species were detected using nanoelectrospray ionisation mass 
spectrometry and quantified as described in materials and methods. Regression was 
adjusted for gender. Superscript indicates dependent variable transformed for linear 
regression, with transformed regression output reported: L logarithm, I reciprocal. * P 
<0.05 ** P <0.01 *** P <0.001  
  
CHAPTER 7 
 
130 | P a g e  
 
 
 
 
Table 7-3: Quantified mitochondrial phospholipids (pmol/µg membrane protein) 
changing significantly with age in the human cerebellum. 
Phospholipid Slope 
95% CI  
β df t P value Lower Upper 
Phosphatidylcholine 
PC 16:0_18:2 0.0092 0.0024 0.0160 0.494 2,31 2.768 0.009** 
Phosphatidylethanolamine 
PE 16:0_22:6I 0.0004 0.00004 0.0008 0.422 2,31 2.243 0.032* 
PE 18:0_22:4 -0.0230 -0.0451 -0.0007 -0.380 2,32 -2.101 0.044* 
PE 18:1_22:6I 0.0008 0.0002 0.0015 0.473 2,33 2.642 0.013* 
PE 15:0_22:6 
 /O-16:0_22:6 0.0260 0.0095 0.0425 0.610 2,32 3.219 0.003** 
PE 17:0_22:4 
 /O-18:0_22:4 -0.0106 -0.0197 -0.0015 -0.434 2,33 -2.363 0.024* 
PE O-16:1_22:5 -0.0122 -0.0203 -0.0042 -0.544 2,33 -3.098 0.004** 
PE O-18:1_22:6I 0.0006 0.00001 0.0012 0.388 2,33 2.079 0.046* 
Phosphatidylserine 
PS 18:0_22:4 -0.0237 -0.0448 -0.0026 -2.284 2,32 -2.284 0.029* 
PS 18:0_22:6 0.1998 0.0585 0.3410 2.877 2,33 2.877 0.007** 
Phospholipid molecular species were detected using nanoelectrospray ionisation mass 
spectrometry and quantified as described in materials and methods. Regression was 
adjusted for gender. Superscript indicates dependent variable transformed for linear 
regression, with transformed regression output reported: I reciprocal.  
* P <0.05 ** P <0.01  
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but this phospholipid is only present in low amounts in the mitochondria (Figure 7-3). 
The remaining statistically significant mitochondrial PEs all decreased in abundance 
over the 80 year period. The second-most abundant mitochondrial PE, PE 18:0_20:4, 
fell from 19.0% of mitochondrial PE to 14.2% from ages 20 to 100 (Figure 7-5, Table 
7-2). Two moderately abundant mitochondrial PEs decreased in abundance over the 80 
year period: PE 18:0_22:4 by 39% and PE 18:0_18:1 by 28%. The remaining three 
mitochondrial PEs decreasing with age, PE 17:0_22:4/O-18:0_22:4, PE O-16:1_22:5 
and lyso-PE 22:4 are all low abundance phospholipids, making up just over 1.0% of 
total mitochondrial phospholipid when combined. 
Seven of these mitochondrial PEs maintained age-related changes when examined as 
quantified amount (pmol/µg membrane protein, Table 7-3). Increases with age were 
seen in quantified PE 16:0_22:6, PE 18:1_22:6, PE O-18:1_226, and PE 15:0_22:6/O-
16:0_22:6. Phospholipids decreasing in both percent abundance and quantified amount 
with age included PE 18:0_22:4, PE 17:0_22:4/O-18:0_22:4 and PE O-16:1_22:5 
7.2.3.3 Phosphatidylserines 
There were three mitochondrial PSs that changed significantly with age in the 
cerebellum (Figure 7-6, Table 7-2). PS 18:0_22:6, the most abundant mitochondrial PS 
(Figure 7-3), increased considerably from 34.3% of total mitochondrial PS to 51.4% 
from ages 20 to 100 (Figure 7-6, Table 7-2). The remaining two PS phospholipids, PS 
18:0_18:1 and PS 18:0_22:4 both decreased in abundance with age in the mitochondria, 
by 30% and 37% respectively over the 80 year period. PS 18:0_18:1 is the second most 
abundant PS in the mitochondria, making up 28.9% of total mitochondrial PS (Figure 
7-3) and 6.3% of total mitochondrial phospholipid. PS 18:0_22:4 is a moderately 
abundant phospholipid, comprising approximately 6.3% of total mitochondrial PS.  
Two of these three mitochondrial PSs also showed changes with age in quantified 
amount (pmol/µg membrane protein; Table 7-3). PS 18:0_22:6 retained its increase with 
age in the mitochondria, rising from 20.5 pmol/µg membrane protein to 36.5 pmol/µg 
membrane protein from ages 20 to 100, representing a 78% increase from its initial 
abundance. PS 18:0_22:4 also maintained a loss with advanced age, decreasing by 35% 
in abundance over the 80 year period. 
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Figure 7-5: Mitochondrial PEs changing significantly with age (as a percent of total PE) 
in normal human cerebellum (n = 33-36). Regression model was adjusted for sex: males 
(●), females (○). Regression parameters are shown in Table 7-2 
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Figure 7-6: Mitochondrial PSs changing significantly with age (as a percent of total PS) 
in normal human cerebellum (n = 35-36). Regression model was adjusted for sex: males 
(●), females (○). T indicates dependent variable transformed for linear regression, with 
transformed beta-coefficient and p-value reported on original scatterplot for 
comparison. Regression parameters are shown in Table 7-2. 
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7.2.4 Changes in microsomal phospholipids with age  
7.2.4.1 Phosphatidylcholines 
All phospholipids detected in the microsomal fraction are presented as a percent of 
phospholipid within each phospholipid class in Figure 7-7. There were seven 
microsomal PCs that changed with age in the cerebellum, with two of these 
phospholipids increasing with age (Figure 7-8, Table 7-4). The second-most abundant 
phospholipid present in microsomal membranes, PC 16:0_16:0, increased from 11.8% 
to 15.3% of total microsomal PC from ages 20 to 100. Only one other microsomal PC 
increased with age in the cerebellum: PC 16:0_18:2. However, this phospholipid is only 
of low abundance in the microsomes, making up less than 1.2% of microsomal PC 
(Figure 7-7) and 0.6% of total microsomal phospholipids. PC 16:0_18:2 increased by 
54% in abundance over the 80 year period studied (Figure 7-8, Table 7-4).  
The remaining five phospholipids, PC 18:0_18:1, PC 16:0_22:4, PC 16:0_20:1, PC 
18:1_22:6, and lyso-PC 18:1, all decreased in abundance with age (Figure 7-8, Table 
7-4). PC 18:0_18:1 is the third-most abundant microsomal PC (Figure 7-7), and it 
decreased by 18% from ages 20 to 100 (Figure 7-8, Table 7-4). PC 16:0_22:4, a 
moderately abundant microsomal phospholipid, decreased from 2.7% of microsomal PC 
to 2.1% from ages 20 to 100. The remaining three significant microsomal PCs, PC 
16:0_20:1, PC 18:1_22:6 and lyso-PC 18:1 are all of low abundance within microsomal 
membranes, and they decreased in abundance by 23%, 59% and 10% respectively over 
the 80 year period. There were no microsomal PCs that changed significantly with age 
when analysed as quantified mount (pmol phospholipid/µg membrane protein). 
7.2.4.2 Phosphatidylethanolamines 
There were eight microsomal PEs that changed in their percent composition with age 
(Figure 7-9, Table 7-4). The most abundant PE in microsomes, PE 18:0_22:6, increased 
with age, rising from 26.0% of total microsomal PE to 31.1% from ages 20 to 100. 
Three other microsomal PEs containing a 22:6 fatty acid also increased with age, 
including PE 16:0_22:6, PE 18:1_22:6 and PE 15:0_22:6/O-16:0_22:6. PE 16:0_22:6 is 
the third-most abundant microsomal PE, making up 6.2% of microsomal PE (Figure 
7-7) and 2.1% of the total microsomal phospholipid. PE 16:0_22:6 increased by 25% in 
percent abundance over the 80 year period (Figure 7-9, Table 7-4). PE  
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Figure 7-7: Phospholipids detected within PC, PE and PS in the microsomal fraction of 
human cerebellum (as a percent of total phospholipid within each class). Phospholipids 
were quantified as described in materials and methods. Values are mean across the 
cohort ± SEM.  
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Figure 7-8: Microsomal PCs changing significantly with age (as a percent of total PC) 
in normal human cerebellum (n = 32-36). Regression model was adjusted for sex: males 
(●), females (○). T indicates dependent variable transformed for linear regression, with 
transformed beta-coefficient and p-value reported on original scatterplot for 
comparison. Regression parameters are shown in Table 7-4 
 
Table 7-4: Microsomal phospholipids (percent of phospholipid within phospholipid 
class) changing significantly with age in the human cerebellum. 
Phospholipid Slope 
95% CI  
β df t P value Lower Upper 
Phosphatidylcholine 
Lyso-PC 18:1I -0.0007 -0.0013 -0.00004 -0.395 2,32 -2.166 0.038* 
PC 16:0_16:0 0.0431 0.0147 0.0715 0.527 2,33 3.088 0.004** 
PC 16:0_18:2 0.0061 0.0019 0.0102 0.521 2,32 2.980 0.005** 
PC 16:0_20:1 -0.0043 -0.0086 -0.0001 -0.399 2,31 -2.089 0.045* 
PC 16:0_22:4 -0.0081 -0.0145 -0.0018 -0.446 2,29 -2.608 0.014* 
PC 18:0_18:1 -0.0182 -0.0351 -0.0014 -0.402 2,32 -2.203 0.035* 
PC 18:1_22:6 -0.0040 -0.0072 -0.0009 -0.469 2,33 -2.620 0.013* 
Phosphatidylethanolamine 
PE 16:0_22:4 -0.0052 -0.0088 -0.0017 -0.534 2,32 -3.023 0.005** 
PE 16:0_22:6 0.0171 0.0072 0.0269 0.597 2,30 3.550 0.001** 
PE 18:0_18:1 -0.0110 -0.0181 -0.0039 -0.530 2,33 -3.125 0.004** 
PE 18:0_20:4 -0.0348 -0.0595 -0.0102 -0.502 2,33 -2.872 0.007** 
PE 18:0_22:4 -0.0202 -0.0335 -0.0069 -0.548 2,32 -3.094 0.004** 
PE 18:0_22:6 0.0641 0.0075 0.1206 0.427 2,33 2.305 0.028* 
PE 18:1_22:6 0.0084 0.0039 0.0130 0.589 2,33 3.757 0.0007*** 
PE 15:0_22:6 
 /O-16:0_22:6 0.0099 0.0015 0.0183 0.428 2,33 2.403 0.022* 
Phosphatidylserine 
PS 18:0_18:1 -0.1699 -0.2468 -0.0929 -0.662 2,32 -4.498 0.00008*** 
PS 18:0_20:1 -0.0206 -0.0403 -0.0009 -0.396 2,31 -2.136 0.041* 
PS 18:0_20:2L -0.0026 -0.0047 -0.0004 -0.472 2,27 -2.412 0.023* 
PS 18:0_22:4L -0.0018 -0.0033 -0.0003 -0.445 2,33 -2.428 0.021* 
PS 18:0_22:6 0.2064 0.1160 0.2968 0.692 2,32 4.652 0.00005*** 
PS 18:1_20:1 0.0179 0.0077 0.0281 0.570 2,32 3.574 0.001** 
Phospholipid molecular species were detected using nanoelectrospray ionisation mass 
spectrometry and quantified as described in materials and methods. Regression was 
adjusted for gender. Superscript indicates dependent variable transformed for linear 
regression, with transformed regression output reported: L logarithm, I reciprocal.  
* P <0.05 ** P <0.01 *** P <0.001  
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Table 7-5: Quantified microsomal phospholipids (pmol/µg membrane protein) changing 
significantly with age in the human cerebellum. 
Phospholipid Slope 
95% CI  
β df t P value Lower Upper 
Phosphatidylethanolamine 
PE 16:0_22:4 -0.0044 -0.0087 -0.0002 -0.398 2,30 -2.139 0.041* 
Phosphatidylserine 
PS 18:0_18:1L -0.0031 -0.0055 -0.0006 -0.454 2,33 -2.568 0.015* 
PS 18:0_20:1 -0.0142 -0.0251 -0.0033 -0.464 2,31 -2.658 0.012* 
PS 18:0_20:2I -0.0030 -0.0051 -0.0008 -0.536 2,27 -2.834 0.009** 
PS 18:0_22:4L -0.0024 -0.0045 -0.0002 -0.419 2,33 -2.263 0.030* 
PS 18:0_22:5 -0.0212 -0.0389 -0.0036 -0.548 2,22 -2.493 0.021* 
PS 18:1_20:1 0.0017 0.0002 0.0033 0.413 2,32 2.241 0.032* 
Phospholipid molecular species were detected using nanoelectrospray ionisation mass 
spectrometry and quantified as described in materials and methods. Regression was 
adjusted for gender. Superscript indicates dependent variable transformed for linear 
regression, with transformed regression output reported: L logarithm, I reciprocal.  
* P <0.05 ** P <0.01  
18:1_22:6 is a moderately abundant phospholipid comprising 2.9% of microsomal PE 
(Figure 7-7), and it increased in abundance by 26% from ages 20 to 100 (Figure 7-9, 
Table 7-4). The final microsomal PE containing a 22:6 fatty acid that increased with 
age, PE 15:0_22:6/O-16:0_22:6, showed a large increase in abundance with age of 61%. 
However, this phospholipid is only present in low amounts in the microsomes 
comprising less than 1.7% of microsomal PE (Figure 7-7) and 0.6% of total microsomal 
phospholipids.  
Four microsomal PEs decreased in abundance with age in the cerebellum (Figure 7-9, 
Table 7-4). The most abundant microsomal PE to decline with age in was PE 18:0_20:4, 
the second-most abundant PE in the microsomes (Figure 7-7). This phospholipid 
comprised 16.0% of microsomal PE and 5.3% of the total microsomal phospholipid and 
declined by 16% in abundance over the 80 year period studied (Figure 7-9, Table 7-4). 
Two moderately abundant microsomal PEs decreased with age, PE 18:0_22:4 and PE 
18:0_18:1, decreasing by 36% and 27% respectively over the 80 year period. The final 
microsomal PE to decline with age was PE 16:0_22:4, a low abundance phospholipid 
which fell by 38% from ages 20 to 100. 
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Figure 7-9: Microsomal PEs changing significantly with age (as a percent of total PE) in 
normal human cerebellum (n = 33-36). Regression model was adjusted for sex: males 
(●), females (○). Regression parameters are shown in Table 7-4. 
Only a single microsomal PE maintained its decrease with age when analysed as 
quantified amount (pmol/µg membrane protein), PE 16:0_22:4 (Table 7-5). This 
phospholipid decreased from 0.9 pmol/µg membrane protein at age 20 to 0.5 pmol/µg 
membrane protein at 100 years of age. 
7.2.4.3 Phosphatidylserines 
Six microsomal PSs changed with age in the cerebellum (Figure 7-10, Table 7-4). The 
most abundant PS in the microsomes, PS 18:0_22:6, increased from 34.5% of 
microsomal PS to 51.0%. Only one other microsomal PS increased significantly with 
age, PS 18:1_20:1, which doubled in abundance over the 80 year period studied. PS 
18:1_20:1 is a low abundance phospholipid, however, making up only 1.9% of 
microsomal PS (Figure 7-7) and 0.3% of the total microsomal phospholipid.  
Four microsomal PS phospholipids decreased with age (Figure 7-10, Table 7-4). The 
second-most abundant microsomal PS, PS 18:0_18:1, shrank by 38% from ages 20 to 
100. PS 18:0_22:4 and PS 18:0_20:1, both moderately abundant microsomal PS 
phospholipids, decreased by 28% and 56% in abundance over the 80 year period 
respectively. The final PS phospholipid to change with age, PS 18:0_20:2, is of low 
abundance in microsomal membranes, comprising just about 1% of microsomal PS 
(Figure 7-7) and 0.2% of total microsomal phospholipid. PS 18:0_20:1 decreased from 
its initial abundance by 38% from ages 20 to 100. 
Five of these microsomal PS phospholipids also changed with age in their quantified 
amount (pmol/µg membrane protein; Table 7-5). These included PS 18:0_18:1, PS 
18:0_20:1, PS 18:0_20:2, PS 18:0_22:4 and PS 18:1_20:1. A sixth microsomal PS was 
also found to decline in quantified amount with age, PS 18:0_22:5, which decreased 
from 2.9 pmol/µg membrane protein to 1.2 pmol/µg membrane protein from ages 20 to 
100. 
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Figure 7-10: Microsomal PSs changing significantly with age (as a percent of total PS) 
in normal human cerebellum (n = 30-36). Regression model was adjusted for sex: males 
(●), females (○). T indicates dependent variable transformed for linear regression, with 
transformed beta-coefficient and p-value reported on original scatterplot for 
comparison. Regression parameters are shown in Table 7-4.  
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7.3 Discussion 
There were many changes in PC, PE and PS phospholipids in the mitochondrial and 
microsomal membranes of the human cerebellum during normal ageing. In effect, the 
cerebellum experienced the highest number of changes to its phospholipids with age 
compared to any other region of the brain studied so far in this thesis. Of particular note 
were age-related increases in both mitochondrial and microsomal PS 18:0_22:6 and PE 
18:0_22:6 over the 80 year period, as well as age-related increases in many other 
phospholipids containing DHA in both membrane fractions.  
Both mitochondrial and microsomal PS 18:0_22:6 increased by approximately half their 
initial abundance from ages 20 to 100 (Figure 7-6, Figure 7-10). PS 18:0_22:6 is the 
most abundant PS present in both the mitochondrial and microsomal membranes, 
making up approximately 42% of mitochondrial and microsomal PS (Figure 7-3, Figure 
7-7), and approximately 8-9% of total phospholipid in each fraction. Due to the high 
abundance of PS 18:0_22:6, these age-related increases in mitochondrial and 
microsomal PS 18:0_22:6 represent a substantial shift in the phospholipid composition 
of both membrane fractions in the cerebellum during normal ageing. Increases of a 
similar magnitude in PS 18:0_22:6 with age were also previously seen in the 
mitochondrial and microsomal membranes of the prefrontal cortex (Chapter 4), and in 
the mitochondria of the human hippocampus (Chapter 5). Other highly abundant 
phospholipids containing DHA also increased with age, including both mitochondrial 
and microsomal PE 18:0_22:6, a phospholipid that is equally as abundant as PS 
18:0_22:6 (Figure 7-3, Figure 7-7). Both mitochondrial and microsomal PE 18:0_22:6 
increased by one-fifth in abundance from ages 20 to 100 (Figure 7-5, Figure 7-9). This 
is the first instance of increasing amounts of mitochondrial and microsomal PE 
18:0_22:6 with age in any brain region studied so far. Other phospholipids with DHA 
showing age-related increases included both mitochondrial and microsomal PE 
16:0_22:6, PE 18:1_22:6, and PE 15:0_22:6/O-16:0_22, and microsomal PE O-
18:1_22:6. The essentiality of DHA within the brain was established in Chapter 2 
(section 2.1.4). As discussed in Chapter 4, DHA preferentially incorporates itself into 
phospholipids with a PS head group during biosynthesis in the brain [210], and 
increased PS 18:0_22:6 within neural cells is thought to promote longevity and decrease 
cellular apoptosis [191]. Unlike PS 18:0_22:6 there is little information available on the 
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possible role of PE 18:0_22:6 within cellular membranes, aside from its preference as a 
substrate for the synthesis of PS phospholipids with DHA by PSS2 (Chapter 6). 
Increases in PS synthesis by both PSS1 and PSS2 have been reported in the cerebellum 
of aged rats [47]; however, if this were also true for humans then we would expect to 
see a corresponding decrease in PE 18:0_22:6 and/or PC 16:0_22:6 with age and not the 
age-related increases observed for these phospholipids in this chapter 
Due to the increased levels of phospholipids containing DHA in the mitochondrial and 
microsomal membranes of the cerebellum in older individuals, additional regressions 
with age were carried on the dominate PUFA in this region for both mitochondrial 
(Table 7-6) and microsomal (Table 7-7) membranes. Increases in total DHA were seen 
in both the PE and PS classes, as well as in the combined phospholipids of both the 
mitochondrial and microsomal membranes (Table 7-6 & Table 7-7). The increases in 
DHA with age in the combined phospholipids of the mitochondria occur at nearly twice 
the rate of that seen in the corresponding microsomal membranes. Looking at individual 
phospholipid classes, this disparity in the rate of increases in DHA between the two 
membrane fractions arises from PE-DHA phospholipids and not from PS-DHA. Both 
mitochondrial and microsomal PS phospholipids have a similar rate of increase with 
age, with both mitochondrial and microsomal PS-DHA increasing in amount within the 
PS class by 0.10% per year. Mitochondrial PE-DHA increased within the PE class by 
0.09% per year (Table 7-6), however, a rate that is one-third higher than that seen for 
microsomal PE-DHA (0.06% per year, Table 7-7). Between the two membrane fractions 
a similar number of phospholipids increased with age, with the mitochondrial fraction 
only experiencing one more significant PE-DHA phospholipid: PE O-18:1_22:6 (Figure 
7-5, Table 7-2). PE O-18:1_22:6 is not of high abundance within either the 
mitochondrial membranes, however, so it is unlikely that this single phospholipid is 
responsible for the large differences seen in the rate of increase between the 
mitochondrial and microsomal PE-DHA. Rather, each PE-DHA phospholipid in the 
mitochondrial fraction increased at a slightly higher rate per year than its microsomal 
counterpart (Table 7-2, Table 7-4). The only phospholipid class to not show any age-
related changes in DHA in both the mitochondrial and microsomal fractions was PC, a 
phospholipid class that contains negligible amounts of DHA.  
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Table 7-6: Linear regression of most abundant polyunsaturated fatty acids (percent of 
total fatty acids within phospholipid class) in the mitochondrial membranes with age in 
human cerebellum 
Mitochondrial 
fatty acids Slope 
95% CI β df t P value Lower Upper 
Combined phospholipids       
20:4 -0.0114 -0.0227 0.00001 -0.379 2,32 -2.034 0.050 
22:4 -0.0185 -0.0276 -0.0094 -0.666 2,33 -4.146 0.0002*** 
20:4 + 22:4  -0.0304 -0.0471 -0.0137 -0.615 2,32 -3.717 0.0008*** 
22:6 0.0567 0.0337 0.0797 0.749 2,33 5.023 0.00002*** 
Phosphatidylcholine       
20:4 0.0049 -0.0050 0.0147 0.196 2,33 1.002 0.324 
22:4 -0.0137 -0.0252 -0.00210 -0.423 2,33 -2.403 0.022* 
20:4 + 22:4 -0.0088 -0.0180 0.0004 -0.327 2,33 -1.939 0.061 
22:6 0.0061 -0.0011 0.0133 0.320 2,33 1.711 0.096 
Phosphatidylethanolamine      
20:4 -0.0359 -0.0566 -0.0151 -0.589 2,32 -3.523 0.001** 
22:4I -0.0006 -0.0010 -0.0003 0.594 2,33 3.512 0.001** 
20:4 + 22:4 -0.0582 -0.0865 -0.0300 -0.675 2,32 -4.194 0.0002*** 
22:6 0.0930 0.0545 0.1315 0.734 2,33 4.916 0.00002*** 
Phosphatidylserine       
20:4 -0.0034 -0.0120 0.0052 -0.158 2,33 -0.802 0.429 
22:4 -0.0229 -0.0394 -0.0064 -0.506 2,33 -2.825 0.008** 
20:4 + 22:4 -0.0263 -0.0458 -0.0068 -0.494 2,33 -2.744 0.0097** 
22:6 0.1050 0.0625 0.1474 0.742 2,32 5.036 0.00002*** 
Fatty acids calculated from phospholipid molecular species data. Regression was 
adjusted for gender. Superscript indicates dependent variable transformed for linear 
regression: I reciprocal.  * P <0.05 ** P <0.01 *** P <0.001 
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Table 7-7: Linear regression of most abundant polyunsaturated fatty acids (percent of 
total fatty acids within phospholipid class) in the microsomal membranes with age in 
human cerebellum 
Microsomal 
fatty acids Slope 
95% CI β df t P value Lower Upper 
Combined phospholipids 
20:4 -0.0039 -0.0132 0.0054 -0.166 2,33 -0.853 0.400 
22:4 -0.0142 -0.0242 -0.0041 -0.511 2,33 -2.872 0.007** 
20:4 + 22:4 -0.0181 -0.0332 -0.0029 -0.422 2,33 -2.428 0.021* 
22:6 0.0319 0.0073 0.0564 0.477 2,33 2.637 0.013* 
Phosphatidylcholine 
20:4 -0.0023 -0.0135 0.0089 -0.079 2,33 -0.417 0.679 
22:4 -0.0055 -0.0135 0.0025 -0.270 2,33 -1.392 0.173 
20:4 + 22:4 -0.0078 -0.0180 0.0024 -0.288 2,33 -1.559 0.129 
22:6 -0.0033 -0.0117 -0.0050 -0.154 2,33 -0.812 0.423 
Phosphatidylethanolamine 
20:4 -0.0151 -0.0339 0.0038 -0.311 2,33 -1.625 0.114 
22:4 -0.0223 -0.0422 -0.0024 -0.419 2,33 -2.281 0.029* 
20:4 + 22:4 -0.0374 -0.0660 -0.0088 -0.478 2,33 -2.657 0.012* 
22:6 0.0642 0.0308 0.0976 0.644 2,33 3.910 0.0004*** 
Phosphatidylserine 
20:4 -0.0011 -0.0104 0.0082 -0.046 2,32 -0.238 0.814 
22:4 -0.0193 -0.0341 -0.0046 -0.481 2,33 -2.664 0.012* 
20:4 + 22:4 -0.0207 -0.0406 -0.0009 -0.394 2,33 -2.126 0.041* 
22:6 0.1032 0.0580 0.1484 0.692 2,33 4.652 0.00005*** 
Fatty acids calculated from phospholipid molecular species data. Regression was 
adjusted for gender. * P <0.05 ** P <0.01 *** P <0.001 
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In the brain regions previously analysed in this thesis decreases with age were 
commonly seen in phospholipids containing either 20:4 or 22:4 fatty acids. Both 22:4 
and 20:4 fatty acids can be putatively classified as the n-6 fatty acids adrenic acid and 
AA (Chapter 4, section 4.3). Decreases in adrenic acid and, less frequently, in AA with 
age were also seen across all three classes of phospholipid in both the mitochondrial and 
microsomal fractions of the cerebellum, (Table 7-6, Table 7-7). Losses of adrenic acid 
with age were seen in all three phospholipid classes individually, as well as in the 
combined phospholipids classes, in both membrane fractions with the exception of 
microsomal PC. Only mitochondrial PE reported losses of AA with age, however, 
despite the significant losses seen in both mitochondrial and microsomal PE 18:0_20:4 
(Figure 7-5, Figure 7-9). Combining the two n-6 fatty acids together resulted in losses in 
both membrane fractions, with only mitochondrial and microsomal PC remaining 
unaffected (Table 7-6, Table 7-7).  
The cerebellum is often used as a control tissue in the study of changes in membrane 
lipids during AD, a finding presumed to be due largely to the absence of any significant 
burden of intra- and extracellular protein aggregates compared with other brain regions 
[206,207]. Indeed, very few changes have been seen in the membrane lipids of 
cerebellum during the pathogenesis of AD compared with other regions 
[85,111,112,115,116,123]. Only in the white matter of the cerebellum have significant 
losses of phospholipids been reported in AD [85]. Only a single study has examined 
changes in cerebellar phospholipids during normal ageing, finding no changes to total 
PC or PE with advanced age [90]. No changes with age to either total PC or PE 
phospholipids in either the mitochondrial or microsomal membranes were observed in 
the current chapter, a finding that agrees with the previous study. However, numerous 
changes to molecular phospholipids were seen in all three phospholipids classes both 
membrane fractions. Indeed, the cerebellum underwent the most numerous changes to 
its molecular phospholipids during ageing compared to any region analysed so far in 
this thesis. The sheer number of changes to phospholipids of the cerebellum during 
normal ageing combined with its substantial cytoarchitectural differences to the rest of 
the brain suggest that the cerebellum may not be the ideal choice as a control tissue for 
studying the effects of age-related neurodegenerative diseases such as AD.  
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In summary, there were many changes seen in the PC, PE and PS phospholipids of the 
mitochondrial and microsomal membranes of the human cerebellum during normal 
ageing. Significant age-related increases were seen in mitochondrial and microsomal PS 
18:0_22:6 and mitochondrial and microsomal PE 18:0_22:6, as well as many other 
phospholipids containing DHA. This led to increases with age in total DHA in PE, PS 
and combined phospholipids in both the mitochondria and microsomes. Age-related 
decreases were reported for total adrenic acid in all classes and membrane fraction 
except for microsomal PC. Despite significant losses of mitochondrial and microsomal 
PE 18:0_20:4 with age, no age-related changes were seen in either mitochondrial or 
microsomal PE-AA. The multitude of changes to the phospholipids of the human 
cerebellum during normal ageing compared with the other three brain regions studied 
suggests that the cerebellum may not be a good choice for examining the changes 
occurring to phospholipids in age-related neurodegenerative diseases such as AD. 
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Chapter 8 The Motor Cortex 
8.1 Introduction 
This chapter will investigate age-related changes to the PC, PE and PS of the 
mitochondrial and microsomal membranes in the human motor cortex. 
The motor cortex is a brain region classified by closely related anatomical and 
functional areas. It is located in the posterior region of the frontal lobe anterior to the 
central sulcus (see Chapter 1, Figure 1-2). This area of the brain is also known as the 
agranular frontal cortex because it lacks an internal granular layer (layer IV). Another 
cytoarchitectural marker of the motor cortex is the presence of large neurons known as 
Betz cells that, along with other cortical neurons, extend long axons down the 
corticospinal tract. Many neurons from the motor cortex terminate in the brain stem, 
while others form reciprocal circuits between the motor cortex and somatosensory 
cortex that allow the translation of sensory information into motor action (reviewed by 
Rizzolatti et al. [211]). 
There is some disagreement within the literature as to whether this region undergoes 
changes in grey matter volume and/or cortical thickness during normal ageing. Some 
studies have reported age-related changes in grey matter volume and/or cortical 
thickness within this region [16,18–23,212], while others have found the motor cortex 
to be relatively spared of these changes during normal ageing [24–26,213]. As 
discussed by Lemaître et al. [16], studies which have reported age-related declines in 
grey matter volume and/or cortical thickness within the motor cortex have contained 
large numbers of participants over the age of 60 years, suggesting that any changes 
occurring in this region happen late in life. The motor cortex also experiences very few 
changes in grey matter volume and/or cortical thickness until the later stages of AD 
[214–216], which corresponds to a later appearance of Aβ aggregates and tau NFTs 
within this region [7]. For these reasons, the motor cortex is often used as a control 
region when studying the pathogenesis of AD, although not as commonly as the 
cerebellum. 
Currently, there are no published studies on whether the phospholipids of the primary 
motor cortex undergo significant changes during normal ageing. A single study has 
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examined the total phospholipid-fatty acids of an anatomically and functionally related 
brain region, the premotor area (BA 4), finding no changes with age [96]. Considering 
the relative stability of this region during both normal ageing and the pathogenesis of 
AD, it was hypothesised that very few changes would be detected in this region. 
Therefore, the aim of this chapter was to examine whether any changes occur to the 
phospholipids of the motor cortex with age in both the mitochondrial and microsomal 
membranes. 
8.2 Results  
8.2.1 Changes in total protein concentration during normal ageing  
No age-related effects were observed for total protein concentration in the whole tissue 
homogenate, or in either the mitochondrial or microsomal fractions. 
8.2.2 Major phospholipid classes of mitochondrial and microsomal fractions 
Each of the three phospholipid classes measured in the mitochondrial and microsomal 
membranes of the motor cortex expressed as a percent of total detected phospholipid is 
shown in Figure 8-1. Approximately 56% of detected phospholipids in both membrane 
fractions were PC phospholipids, while PE and PS made up 27% & 17% respectively. 
The microsomal membranes contained slightly higher amounts of total PS compared to 
the mitochondrial membranes (p < 0.01). No statistically significant differences were 
seen between the membrane fractions for either PC or PE. Analysis of the quantified 
phospholipid classes (as pmol phospholipid/µg membrane lipid) showed similar results 
to the percent composition data. There was more PS in the microsomal fraction (p < 
0.05), with no significant differences seen in PC or PE between the two membrane 
fractions. Total quantified phospholipids were also increased in the microsomal fraction 
(p < 0.05).  
Total PC, PE, PS were also assessed for any age-related changes in both mitochondrial 
and microsomal membranes. No age-related changes to any class in either membrane 
fraction was observed when analysed as a percent of total detected phospholipid or as 
quantified phospholipids. Likewise, there were no changes with age total quantified 
phospholipids in either membrane fraction. 
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Figure 8-1: Percent composition of the three major phospholipid classes within the 
mitochondrial (left) and microsomal (right) fractions in neurologically normal motor 
cortex. Values are the mean ± SEM for the entire cohort. The microsomal membranes 
showed significantly higher amounts of total phosphatidylserine (PS) compared to 
mitochondria (p < 0.01, Wilcoxon signed-rank test). No statistically significant 
difference was seen for phosphatidylcholine (PC) or phosphatidylethanolamine (PE) 
between the mitochondria and microsomes. 
8.2.3 Changes in mitochondrial phospholipids with age  
8.2.3.1 Phosphatidylcholine 
The composition of the PC, PE and PS phospholipids detected in the mitochondrial 
fraction can be seen in Figure 8-2. Three PCs changed with age when analysed as a 
percent of total mitochondrial PC: PC 16:0_20:4, PC 16:0_22:4 and PC 16:0_18:2 
(Figure 8-3, Table 8-1). All three phospholipids are moderately abundant within 
mitochondrial membranes, comprising 3.6%, 2.0% and 1.3% of total mitochondrial PC 
respectively (Figure 8-2). Both PC 16:0_20:4 and PC 16:0_22:4 declined with age 
within mitochondrial membranes, with decreases of 17% and 41% in abundance seen 
respectively (Figure 8-3, Table 8-1). PC 16:0_18:2 increased with age, rising from 0.9% 
of total mitochondrial PC at age 20 to 1.5% at age 100, representing an increase of 59% 
from its initial abundance. 
Only PC 16:0_22:4 retained its decrease with age within the mitochondria when 
analysed as quantified phospholipid (pmol of phospholipid/µg membrane protein). PC 
16:0_22:4 decreased from 5.3 to 2.3 pmol/µg membrane protein over the 80 year period 
(Table 8-2) 
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Figure 8-2: Phospholipids detected within PC, PE and PS in the mitochondrial fraction 
of human motor cortex (as a percent of total phospholipid within each class). 
Phospholipids were quantified as described in materials and methods. Values are mean 
across the cohort ± SEM. 
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Figure 8-3: Mitochondrial PCs changing significantly with age (as a percent of total PC) 
in normal human motor cortex (n = 30-34). Regression model was adjusted for sex: 
males (●), females (○). T indicates dependent variable transformed for linear regression, 
with transformed beta-coefficient and p-value reported on original scatterplot for 
comparison. Regression parameters are shown in Table 8-1  
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Table 8-1: Mitochondrial phospholipids (percent of phospholipid within phospholipid 
class) changing significantly with age in the human motor cortex. 
Phospholipid Slope 
95% CI  
β df t P value Lower Upper 
Phosphatidylcholine 
PC 16:0_18:2 0.0068 0.0019 0.0117 0.525 2,31 2.824 0.008** 
PC 16:0_20:4 -0.0080 -0.0151 -0.0008 -0.416 2,30 -2.263 0.031* 
PC 16:0_22:4I -0.0021 -0.0038 -0.0006 -0.558 2,27 -2.779 0.0098** 
Phospholipid molecular species were detected using nanoelectrospray ionisation mass 
spectrometry and quantified as described in materials and methods. Regression was 
adjusted for gender. Superscript indicates dependent variable transformed for linear 
regression, with transformed regression output reported: I reciprocal.  
* P <0.05 ** P <0.01  
 
 
 
Table 8-2: Quantified mitochondrial phospholipids (pmol/µg total membrane protein) 
changing significantly with age in the human motor cortex. 
Phospholipid Slope 
95% CI  
β df t P value Lower Upper 
Phosphatidylcholine 
PC 16:0_22:4 -0.0370 -0.0707 -0.0034 -0.460 2,27 -2.260 0.032* 
Phosphatidylethanolamine 
PE O-18:1_20:4 -0.0048 -0.0096 -0.00003 -0.394 2,31 -2.052 0.049* 
Phospholipid molecular species were detected using nanoelectrospray ionisation mass 
spectrometry and quantified as described in materials and methods. Regression was 
adjusted for gender. ** P <0.01 
  
CHAPTER 8 
 
155 | P a g e  
 
8.2.3.2 Phosphatidylethanolamines 
No mitochondrial PEs changed with age within the motor cortex when analysed as a 
percent of total PE, or when analysed as quantified mitochondrial PE (pmol of 
phospholipid/µg membrane protein) 
8.2.3.3 Phosphatidylserines 
Similarly to mitochondrial PE, no mitochondrial PS phospholipids changed with age in 
either their percent composition (percent of total mitochondrial PS) or quantified 
amount (pmol/µg membrane protein) in the motor cortex. 
8.2.4 Changes in microsomal phospholipids with age  
8.2.4.1  Phosphatidylcholines 
The composition of PC, PE and PS phospholipids within the microsomal membranes 
can be seen in Figure 8-4. Within microsomal PC there were three phospholipids that 
changed with age in the motor cortex (Figure 8-5, Table 8-3). PC 18:0_20:4, PC 
14:0_16:0 and PC 16:0_18:2 are all moderately abundant phospholipids within 
microsomal membranes. PC 18:0_20:4 comprises 1.7% of total microsomal PC (Figure 
8-4), and it decreased by 28% in abundance from ages 20 to 100 (Figure 8-5, Table 
8-3). Levels of both PC 14:0_16:0 and PC 16:0_18:2 rose with age within the 
microsomes, with increases of 15% and 51% seen respectively over the 80 year period. 
Only PC 18:0_20:4 maintained its decrease with age within the microsomal membranes 
of the motor cortex when analysed as quantified phospholipid (pmol/µg membrane 
protein; Table 8-4). PC 18:0_20:4 decreased by 39% in quantified amount from ages 20 
to 100 years of age.  
8.2.4.2 Phosphatidylethanolamines 
Five microsomal PEs changed with age within the motor cortex, with four of these 
phospholipids increasing in abundance with age (Figure 8-6, Table 8-3). PE O-
18:1_22:6 is a moderately abundant microsomal PE present at 2.0% of total microsomal 
PE (Figure 8-4) and 0.5% of the total microsomal phospholipid. PE O-18:1_22:6 
increased from its initial abundance by 16% from ages 20 to 100 (Figure 8-6, Table 
8-3). PE O-18:1_22:5, PE 15:0_22:6/O-16:0_22:6 and PE 15:0_22:4/O-16:0_22:4 also 
increased in abundance with age, by 75%, 83% and 86% respectively over the 80 year  
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Figure 8-4: Phospholipids detected within PC, PE and PS in the microsomal fraction of 
human motor cortex (as a percent of total phospholipid with each class). Phospholipids 
were quantified as described in materials and methods. Values are mean across the 
cohort ± SEM.  
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Figure 8-5: Microsomal PCs changing significantly with age (as a percent of total PC) 
in normal human m motor cortex (n = 30-35). Regression model was adjusted for sex: 
males (●), females (○). Regression parameters are shown in Table 8-3. 
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Table 8-3: Microsomal phospholipids (percent of phospholipid within phospholipid 
class) changing significantly with age in the human motor cortex. 
Phospholipid Slope 
95% CI  
β df t P value Lower Upper 
Phosphatidylcholine 
PC 14:0_16:0 0.0024 0.0001 0.0047 0.409 2,32 2.168 0.038* 
PC 16:0_18:2 0.0064 0.0018 0.0110 0.505 2,32 2.818 0.008** 
PC 18:0_20:4 -0.0066 -0.0113 -0.0019 -0.521 2,27 -2.892 0.007** 
Phosphatidylserine 
PE 15:0_22:4 
 /O-16:0_22:4IR 0.0020 0.0002 0.0039 0.424 2,29 2.300 0.029* 
PE 15:0_22:6 
 /O-16:0_22:6 0.0053 0.00008 0.0106 0.415 2,27 2.083 0.047* 
PE O-16:1_22:4 -0.0039 -0.0068 -0.0011 -0.518 2,32 -2.854 0.008** 
PE O-18:1_22:5 0.0104 0.0004 0.0205 0.378 2,32 2.111 0.043* 
PE O-18:1_22:6 0.0038 0.0001 0.0076 0.377 2,32 2.097 0.044* 
Phospholipid molecular species were detected using nanoelectrospray ionisation mass 
spectrometry and quantified as described in materials and methods. Regression was 
adjusted for gender. Superscript indicates dependent variable transformed for linear 
regression, with transformed regression output reported: IR reflect and reciprocal.  
* P <0.05 ** P <0.01  
 
 
 
Table 8-4: Quantified microsomal phospholipids (pmol/µg total membrane protein) 
changing significantly with age in the human motor cortex. 
Phospholipid Slope 
95% CI  
β df t P value Lower Upper 
Phosphatidylcholine 
PC 18:0_20:4 -0.0197 -0.0332 -0.0061 -0.504 2,27 -2.974 0.006** 
Phospholipid molecular species were detected using nanoelectrospray ionisation mass 
spectrometry and quantified as described in materials and methods. Regression was 
adjusted for gender. ** P <0.01   
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Figure 8-6: Microsomal PEs changing significantly with age (as a percent of total PC) 
in normal human m motor cortex (n = 30-35). Regression model was adjusted for sex: 
males (●), females (○). T indicates dependent variable transformed for linear regression, 
with transformed beta-coefficient and p-value reported on original scatterplot for 
comparison. Regression parameters are shown in Table 8-3 
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period. However these three phospholipids are only of low abundance in microsomal 
membranes, comprising only 2.7% of total microsomal PE when combined (Figure 
8-4). The final microsomal PE to show a change with age, PE O-16:1_22:4, decreased 
in abundance from ages 20 to 100 by 45%. Similarly, PE O-16:1_22:4 is only of low 
abundance within microsomal membranes, comprising only 0.5% of total microsomal 
PE (Figure 8-4) 
No microsomal PEs showed statistically significant changes with age when analysed as 
quantified phospholipid (pmol/µg membrane protein). 
8.2.4.3 Phosphatidylserines 
No microsomal PS phospholipids changed with age in the motor cortex in either percent 
composition (percent of total microsomal PS) or quantified amount (pmol/µg membrane 
protein). 
8.3 Discussion 
There were very few changes seen with age in the phospholipids that make up the 
mitochondrial and microsomal membranes of the human motor cortex compared to the 
previously four brain regions examined. All of the changes that occurred in the 
mitochondrial and microsomal membranes of the motor cortex took place in 
phospholipids that were of low-to-moderate abundance.  
Notably, there were no age-related changes reported for any PS phospholipids in the 
motor cortex in either the mitochondrial or microsomal membranes. A similar trend was 
seen in the entorhinal cortex (Chapter 6), where no mitochondrial PS phospholipids 
changed with age, but the motor cortex is the only brain region examined to show no 
changes to both mitochondrial and microsomal PS. PS is synthesised in the ER, 
primarily within the MAM [217]. The MAM is commonly found in the mitochondrial 
fraction using the subcellular fractionation method employed in this study [41,218]. 
Phospholipids synthesised within the MAM are sent to the mitochondrial membranes by 
means of the close association between the two membranes [219]. As outlined in 
Chapter 2 (2.1.3), PS is produced in the MAM by serine-exchange with PC and PE by 
PSS1 and PSS2 respectively. Mitochondrial membranes also lack the ability to 
synthesise PE phospholipids de novo, and only a small amount of de novo synthesis of 
PE is conducted within the MAM. Instead, PSD converts PS into PE for use in the inner 
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and outer mitochondrial membranes [219]. Taken together, this relative lack of change 
in PS phospholipids within either the mitochondrial or microsomal membranes as well 
as no changes to PE phospholipids within the mitochondria suggests that homeostasis of 
PS metabolism is unperturbed in both mitochondrial and microsomal membranes within 
the motor cortex of the human brain over the adult lifespan. This combined with the 
lack of changes with age to the grey matter volume and/or cortical thickness of the 
motor cortex described in the introduction of this chapter (section 8.1) could also 
suggest that maintenance and regulation of these PS synthesis and degradation pathways 
could be crucial in preserving grey matter in healthy brain ageing.  
Unlike the previous four regions analysed there did not seem to be any definite trend 
towards either losses with age of phospholipids containing adrenic acid (22:4) or AA 
(20:4), or increases with age in phospholipids containing DHA (22:6) in either 
membrane fraction within the motor cortex. Similar to the previously analysed brain 
regions, further linear regression of the most abundant PUFA with age was conducted to 
confirm these results for both mitochondrial (Table 8-5) and microsomal (Table 8-6) 
membranes. No changes with age were observed for either AA, adrenic acid, AA 
combined with adrenic or DHA in any phospholipid class or combined phospholipids in 
the mitochondrial fraction (Table 8-5). However, in the microsomes losses with age 
were found for AA in both PC and PE (Table 8-6). While this age-related loss of 
microsomal PC-AA could be explained by the loss of microsomal PC 18:0_20:4 seen 
with age (Figure 8-5, Table 8-3), no single PE phospholipid containing AA was 
identified as changing significantly with age in the microsomal fraction (Figure 8-6, 
Table 8-3). This finding implies that the loss of PE-AA with age seen in the microsomal 
fraction is likely the net result of small losses of many microsomal PE phospholipids 
containing AA with age, rather than being limited to a single, dominant phospholipid 
molecular species. Both AA and adrenic acid are long-chain n-6 PUFA, and AA 
combined with adrenic acid within microsomal PC and PE also declined with age 
(Table 8-6). This suggests that there is a loss of long chain n-6 PUFA with age within 
PC and PE in the microsomal membranes of the motor cortex, but the lack of change in 
AA and adrenic acid within the combined phospholipids suggests that there is no 
decline overall in total membrane long-chain n-6 PUFA with age  
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Table 8-5 Linear regression of the most abundant polyunsaturated fatty acids (percent of 
total fatty acids within phospholipid class) in the mitochondrial membranes with age in 
human motor cortex 
Mitochondrial 
fatty acids Slope 
95% CI β df t P value Lower Upper 
Combined phospholipids       
20:4 -0.0023 -0.0138 0.0092 -0.080 2,32 -0.405 0.688 
22:4 -0.0078 -0.0188 0.0031 -0.290 2,32 -1.458 0.155 
20:4 + 22:4 -0.0101 -0.0242 0.0039 -0.280 2,32 -1.466 0.152 
22:6 -0.00005 -0.0351 0.0350 -0.001 2,32 -0.003 0.998 
Phosphatidylcholine       
20:4 0.0032 -0.0086 0.0150 0.111 2,32 -1.047 0.303 
22:4 -0.0089 -0.0186 0.0008 -0.363 2,32 -1.860 0.072 
20:4 + 22:4 -0.0057 -0.0172 0.0059 -0.201 2,32 -1.000 0.325 
22:6 0.0012 -0.0076 0.0100 0.056 2,32 0.275 0.785 
Phosphatidylethanolamine      
20:4 -0.0137 -0.0318 0.0044 -0.291 2,31 -1.540 0.134 
22:4 -0.0085 -0.0358 0.0189 -0.129 2,32 -0.632 0.532 
20:4 + 22:4 -0.0192 -0.0485 0.0102 -0.261 2,31 -1.332 0.193 
22:6 0.0035 -0.0381 0.0451 0.035 2,31 0.171 0.865 
Phosphatidylserine       
20:4 -0.0005 -0.0043 0.0032 -0.058 2,32 -0.283 0.779 
22:4 -0.0017 -0.0213 0.0180 -0.036 2,32 -0.175 0.862 
20:4 + 22:4 -0.0022 -0.0223 0.0179 -0.046 2,32 -0.224 0.825 
22:6 0.0111 -0.0981 0.1203 0.042 2,32 0.207 0.837 
Fatty acids calculated from phospholipid molecular species data. Regression was 
adjusted for gender.  
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Table 8-6 Linear regression of the most abundant polyunsaturated fatty acids (percent of 
total fatty acids within phospholipid class) in the microsomal membranes with age in 
human motor cortex 
Microsomal 
fatty acids Slope 
95% CI β df t P value Lower Upper 
Combined phospholipids       
20:4 -0.0081 -0.0196 0.0033 -0.278 2,32 -1.447 0.158 
22:4 -0.0042 -0.0141 0.0057 -0.169 2,32 -0.867 0.392 
20:4 + 22:4 -0.0012 -0.0281 0.0039 -0.276 2,32 -1.542 0.133 
22:6 0.0050 -0.0507 0.0607 0.037 2,32 0.184 0.855 
Phosphatidylcholine       
20:4 -0.0081 -0.0158 -0.0003 -0.400 2,32 -2.108 0.043* 
22:4 -0.0007 -0.0066 0.0051 -0.050 2,32 0.233 0.817 
20:4 + 22:4 -0.0088 -0.0160 -0.0017 -0.426 2,32 -2.509 0.017* 
22:6 -0.0014 -0.0095 0.0066 -0.075 2,32 -0.365 0.717 
Phosphatidylethanolamine      
20:4 -0.0166 -0.0315 -0.0017 -0.400 2,31 -2.271 0.030* 
22:4 -0.0120 -0.0275 0.0036 -0.314 2,31 -1.569 0.127 
20:4 + 22:4 -0.0284 -0.0524 -0.0043 -0.431 2,32 -2.405 0.022* 
22:6 0.0268 -0.0152 0.0688 -0.259 2,32 1.300 0.203 
Phosphatidylserine       
20:4 -0.0012 -0.0047 0.0024 -0.135 2,32 -0.660 0.514 
22:4 0.0009 -0.0218 0.0236 0.016 2,32 0.080 0.937 
20:4 + 22:4 0.0003 -0.0231 0.0226 -0.005 2,32 -0.023 0.982 
22:6 0.0083 -0.0983 0.1150 0.032 2,32 0.159 0.875 
Fatty acids calculated from phospholipid molecular species data. Regression was 
adjusted for gender.  * P <0.05  
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This relative lack of change in either the PUFA component of phospholipids combined 
with the few age-related changes seen in both mitochondrial and microsomal 
phospholipids suggests that the membrane composition of the motor cortex is the most 
stable during normal ageing compared to the other four brain regions examined in this 
thesis. As discussed in the introduction to this chapter, the greater motor area is thought 
to remain relatively unchanged in grey matter volume and thickness throughout ageing, 
and only exhibits losses in these structures with advanced age [16]. The motor cortex 
also remains relatively unchanged during the pathogenesis of AD, with losses of grey 
matter thickness and/or volume during the pathogenesis of AD not seen in the motor 
cortex until the very late stages of the diseases [214–216]. Likewise, the characteristic 
Aβ aggregates and tau NFTs also fail to appear in the motor cortex until the later stages 
of the disease [7]. The only study to examine changes in phospholipids with age in the 
motor cortex looked at total phospholipid fatty acids in a closely related region, the 
premotor area (BA 4) [96], finding no changes with age to any fatty acids in this region. 
The results of the present study combined with the relative lack of changes to grey 
matter thickness and/or volume reported in the motor cortex during both normal ageing 
and in diseases of ageing such as AD suggest that this region may be a good control for 
comparing and contrasting both age-related and AD-related changes to phospholipids. 
Indeed, the lack of age-related changes in the motor cortex make this region more 
suitable than the cerebellum, the other commonly used control region, which was found 
to undergo numerous changes in its phospholipids during normal ageing (Chapter 7).  
In summary, there were very few changes occurring to the mitochondrial and 
microsomal phospholipids of the human motor cortex during normal ageing. All 
phospholipids that changed in composition with age were of low-to-moderate 
abundance within both the mitochondrial and microsomal fractions. No changes with 
age were seen in any PS phospholipid in either the mitochondrial or microsomal 
membranes in the motor cortex. Likewise, no age-related changes were observed for 
any mitochondrial PE phospholipids. Compared to previously studied regions, the 
motor cortex showed fewer changes in phospholipids containing PUFA, but some 
decreases with age in phospholipids containing AA and adrenic acid were seen in 
microsomal PC and PE. Considering these and previous findings, the motor cortex may 
be a better region to use as a control tissue than the cerebellum both when studying 
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changes in phospholipids during normal ageing and during the pathogenesis of age-
related diseases such as AD. 
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Chapter 9 Discussion and Conclusion 
9.1 Introduction 
The primary aim of this thesis was to determine if any age-related changes occur in 
phospholipids across five regions of the human brain. This chapter analyses the changes 
occurring across those brain regions in both the mitochondrial and microsomal 
membranes, and compares these results to that reported previously in the literature for 
both normal ageing and during the pathogenesis of the different dementias, specifically 
within AD. The findings from this thesis will then be examined to see where they fit 
into the two theories of ageing outlined in Chapter 2 (section 2.4); chiefly, either the 
mitochondrial free radical theory of ageing or the “inflammageing” theory of ageing. 
Finally, future recommendations for this research will be suggested 
9.2 Regional differences in phospholipid composition during normal 
ageing 
9.2.1 Method 
To facilitate discussion of the results from the five different regions of the human brain 
examined within this thesis, the slope of the regression line for all of the statistically 
significant changes with age in the PC, PE and PS phospholipids of the prefrontal 
cortex, hippocampus, entorhinal cortex, cerebellum and motor cortex were collated and 
converted into heat maps for both the mitochondrial (Figure 9-1) and microsomal 
fractions (Figure 9-2). These heat maps were created in R (v. 3.1.1) using the “gplots” 
package. An example of the script used in R to create these heat maps is included in 
Appendix 1. Hierarchical clustering was used to look for any similarities in age-related 
phospholipid changes across the five regions examined within the two membrane 
fractions. The normalised slope of phospholipids transformed for linear regression was 
calculated from the back-transformed amounts present at 20 and 100 years of age to 
allow for comparison with non-transformed regressions. Phospholipids that underwent 
the largest age-related changes are present at the top of the heatmap, while those that 
experienced biggest decreases with age are at the bottom. 
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9.2.2 Results and discussion 
9.2.2.1 Age-related changes in mitochondrial phospholipids 
Hierarchical clustering analysis of the mitochondrial membranes of the five brain 
regions examined in this thesis found three distinct groups displaying similar changes 
with age: the cerebellum alone, the hippocampus and prefrontal cortex, and the motor 
and entorhinal cortices (Figure 9-1). The phospholipid with the largest age-related 
increase was PS 18:0_22:6 in the hippocampus, prefrontal cortex and cerebellum, 
followed by PE 18:0_22:6 in the cerebellum only. The largest decreases with age were 
seen in PS 18:0_18:1 within the cerebellum, PE 18:0_20:4 in the cerebellum and 
prefrontal cortex, and PS 18:0_22:4 in the cerebellum and hippocampus. Only a single 
phospholipid molecular species showed statistically significant age-related changes 
across all five regions of the brain: PC 16:0_18:2, which increases with age. 
Surprisingly, there were two mitochondrial phospholipids that showed an opposite trend 
with age between two different regions. In the entorhinal cortex PE 16:0_18:1 and PE 
17:0_22:6/O-18:0_22:6 increased with age, whereas both phospholipids decreased with 
age in the prefrontal cortex. 
The mitochondrial phospholipids of the cerebellum appeared to share many similar 
phospholipids undergoing age-related changes like those in the prefrontal cortex and 
hippocampus. All three regions experienced increases with age in PS 18:0_22:6, PE 
18:1_22:6, and PC 16:0_18:2, and age-related decreases in PE 18:0_22:4. The 
cerebellum and prefrontal cortex share common increases with age in PC 16:0_22:6 and 
PE O-18:1_22:6 and common decreases in PE 18:0_18:1 and PE 18:0_20:4. However, 
in the cerebellum and hippocampus only decreases in PS 18:0_20:4 were found in 
common. The main difference separating the cerebellum from the prefrontal cortex and 
hippocampus is the magnitude of the age-related changes occurring. The cerebellum had 
many large changes with age clustered at the top and bottom of the heat map, indicating 
that these are comparatively large changes in phospholipids with age. However, both 
the hippocampus and prefrontal cortex had more phospholipids present in the middle of 
the heat map, which implied smaller but significant changes with age within these 
regions. The hippocampus in particular had many such small but statistically significant 
age-related changes, while the prefrontal cortex occupied the middle ground between 
the hippocampus and cerebellum. 
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Figure 9-1: Summary of significant changes seen during normal ageing in the 
phospholipid composition (% of phospholipid class) in the mitochondrial fraction of the 
human prefrontal cortex (PFC), hippocampus (H), entorhinal cortex (EC), cerebellum 
(C), and motor cortex (MC). Increases in phospholipids with age are shown in green 
and decreases in red. Hierarchical clustering of the five brain regions is shown by the 
dendrogram at the top. Heat map was generated in R (v 3.1.1) using the gplots package.  
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The entorhinal and motor cortices are grouped together due to a lack of age-related 
changes in phospholipids within the mitochondrial membranes. Only three age-related 
changes in mitochondrial phospholipids were seen in the motor cortex: increases in PC 
16:0_18:2 and decreases in PE 16:0_20:4 and PS 18:0_20:1. In contrast, the entorhinal 
cortex only exhibited increases with age within the mitochondrial membranes: in two 
PC phospholipids and six PEs. Common between the mitochondrial membranes of the 
two regions is a lack of age-related changes within the PS class. As discussed in 
Chapter 8 (section 8.1), the motor cortex, in particular, is known to exhibit few changes 
in grey matter volume and/or cortical thickness with age until advanced age, and so it is 
unsurprising that few age-related changes were seen to phospholipids in either 
membrane fraction within in this region. 
9.2.2.2 Age-related changes in microsomal phospholipids 
Analysis of all the statistically significant age-related changes seen in the microsomal 
membranes of the five brain regions by hierarchical clustering found both similarities 
and differences to that observed in the mitochondrial membranes. In the microsomes the 
five regions were classified into two groups: the first group consisting of the cerebellum 
only, and the second group containing the hippocampus, frontal, entorhinal and motor 
cortices (Figure 9-2). Within the second group, several sub-groups were also identified, 
with the entorhinal cortex and motor cortex being grouped together.  
There were many similarities seen between the microsomal and mitochondrial 
membranes. The largest increase with age was in microsomal PS 18:0_22:6 in the 
cerebellum and prefrontal cortex, while the largest age-related decreases were seen in 
cerebellar PS 18:0_18:1 and PE 18:0_20:4. Again, there were several phospholipids 
showing changes with age in common between the cerebellum and prefrontal cortex. 
This included increases in PS 18:0_22:6, PE 18:1_22:6 and PC 16:0_18:2, and 
decreases in PE 18:0_18:1. Similar to the mitochondrial fraction, the main difference 
between the cerebellum and the other four brain regions appears to be due to the vast 
changes with age seen in several phospholipids of the cerebellum. Compared to the 
other four regions, many large age-related changes were observed in microsomal 
phospholipids of the cerebellum, as shown by the clustering of the data in the extreme 
ends of the heat map. A final similarity between both membrane fractions was the  
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Figure 9-2: Summary of significant changes seen during normal ageing in the 
phospholipid composition (% of phospholipid class) in the microsomal fraction  of the 
human prefrontal cortex (PFC), hippocampus (H), entorhinal cortex (EC), cerebellum 
(C), and motor cortex (MC). Increases in phospholipids with age are shown in green 
while decreases are in red. Hierarchical clustering of the five brain regions is shown by 
the dendrogram at the top. Heat map was generated in R (v 3.1.1) using the gplots 
package. 
  
CHAPTER 9 
 
172 | P a g e  
 
grouping of the entorhinal and motor cortices together on the basis of having the fewest 
changes with age to their phospholipids. However, there were a higher number 
phospholipids changing with age identified within the microsomal membranes of the 
motor cortex compared to the mitochondria. Unlike the mitochondrial membranes, the 
prefrontal cortex and hippocampus were not grouped together via hierarchical clustering 
within the microsomal membranes. Only a single phospholipid had age-related changes 
common to these two regions within the microsomal membranes: increases in PE 
18:1_22:6. Indeed, more age-related changes were found in phospholipids common 
between the cerebellum and hippocampus than prefrontal cortex and hippocampus, 
including increases in PE 18:1_22:6 and PE 15:0_22:4/O-16:0_22:4, and decreases in 
PE 18:0_22:4 and PC 18:0_18:1. Additionally, the hippocampus displayed fewer 
overall changes with age in microsomal phospholipids compared to those seen in the 
mitochondrial fraction. Finally, unlike the mitochondrial fraction there was no single 
microsomal phospholipid that changed with age in all five regions with age. PC 
16:0_18:2, which increased with age in the mitochondrial fraction of all five brain 
regions, only increased with age in the microsomal membranes of the cerebellum, motor 
and prefrontal cortices. The microsomal phospholipid with the highest number of 
changes across the five regions was PE 18:1_22:6, which increased with age in the 
cerebellum, hippocampus, and in the entorhinal and prefrontal cortices.  
9.3 Comparison to current literature 
In Chapter 2 (section 2.2) the current knowledge on changes in phospholipid 
composition in the human brain during normal ageing was reviewed. There are 
currently no studies available that examine changes in molecular phospholipids with 
age, but others have reported analysis of total phospholipids, phospholipid classes and 
phospholipid-fatty acids. Below is a brief analysis of how the results from this thesis 
compare to that reported in the literature for total phospholipids, phospholipids classes, 
and phospholipid-fatty acids. 
9.3.1 Changes to phospholipids during normal ageing 
9.3.1.1 Total phospholipids 
No age-related changes were found in total quantified phospholipids within any of the 
five regions examined in the present study for either the mitochondrial or microsomal 
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fractions. This finding agrees with that found previously in the cerebellum [88,90], but 
disagrees with that of the frontal cortex [89–91,93] and hippocampus [90,93] (Chapter 
2, Table 2-1). These discrepancies could be due to the differences in methods between 
the current and previous studies. All previous studies used the phosphorous assay to 
determine total phospholipid content, which measures all lipids with phosphorous 
present within the brain including phosphatidylglycerol, phosphatidylinositol, 
phosphatidic acid, cardiolipin and sphingomyelin. While phosphatidylglycerol and 
phosphatidic acid are only minor membrane constituents, phosphatidylinositol and 
sphingomyelin comprise a comparatively larger proportion of the cellular membranes 
within the brain [35] and significant age-related changes to either phospholipid class 
could feasibly influence changes in total phospholipids with age. Similarly, age-related 
changes to cardiolipin levels within the brain could affect the level of total phospholipid 
measured by the phosphorous assay. While the precise amount of cardiolipin present 
within mitochondria of the human brain is currently unknown, studies using rodents 
have estimated it at 9-10% of total mitochondrial phospholipid [220,221].  
9.3.1.2 Phospholipid classes 
Generally, the findings of the present thesis agree with the previous literature in respect 
to changes with age in total PC, PE and PS within the different regions of the human 
brain (Chapter 2, Table 2-2). Overall, no changes were seen with age to total PC, PE or 
PS within the frontal cortex, cerebellum and hippocampus, which agrees with the 
weight of evidence available for these three brain regions [90,91,93]. Only the 
entorhinal cortex changed with age in the amount of phospholipid classes present, 
including increases in mitochondrial PC and decreases in mitochondrial PE (Chapter 6), 
but no previous studies of age-related changes in phospholipids of this region are 
available for comparison. 
9.3.1.3 Total phospholipid fatty acids 
Within the five regions examined in this study analysis was only performed for changes 
with age to the predominant PUFA, and so only the current literature on these fatty 
acids have been included for analysis (Chapter 2, Table 2-3). Three of the five regions 
examined in this thesis have been previously studied for changes in total phospholipid 
fatty acids during normal ageing: the frontal and premotor cortices, as well as the 
hippocampus [92–96]. The present study agrees with previous findings of changes to 
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AA, adrenic acid and DHA with age within the human brain; however, some differences 
between the current and previous studies occurred. In the hippocampus, decreases in 
mitochondrial AA were seen with age while no changes in AA levels had been reported 
in this region previously [93]. Within the frontal cortex the present work found 
decreases in mitochondrial and microsomal AA with age, a finding which agrees that of 
McNamara et.al. [95]. However, this disagrees with three other studies that have 
reported no change in AA levels within the frontal cortex with age [92–94]. Likewise, 
increases with age in mitochondrial DHA were reported in the prefrontal cortex in the 
present study, which conflicts with previous studies that found no change in DHA with 
age in the frontal cortex [92–94]. The discrepancies between the current and previous 
findings within the frontal cortex could be explained by differences in methods used to 
identify and quantify phospholipids between the current and present studies. However, 
these dissimilarities might also be explained by differences between the anatomical and 
functional area of the frontal cortex examined by each study. The frontal cortex consists 
of a number of cyto- and myeloarchitectural regions divided on function, histology and 
white matter connections [222], all of which may have differing phospholipid 
compositions. The present study examined two regions of the frontal cortex: the 
dorsolateral prefrontal cortex (BA 9/46), and the primary motor cortex (BA 4). Other 
studies examined the frontal eye fields (BA 8) [92], the premotor cortex (BA 6) [96], 
the orbitofrontal cortex (BA 10) [95] or an undisclosed section of the frontal cortex 
[93,94]. For the purposes of comparison, the previous study of the premotor cortex [96] 
was grouped in with the results of this thesis for the primary motor cortex as they share 
similar histological features (i.e. lack of a granular layer). Likewise, the hippocampus 
proper can be divided into various subfields with different histology and connections to 
other regions of the brain, and feasibly each subfield could also have differences in 
phospholipid composition. This possibility was not explored in this thesis, however, due 
to the limited amount of tissue available for use.  
9.3.1.4 Phospholipid fatty acids by class 
Only a single study has examined the changes occurring in PC and PE fatty acids by 
class during normal ageing within the human brain, finding no changes with age to any 
PC or PE fatty acids within the frontal cortex or hippocampus [93]. The present results 
generally agree with those findings, with a few exceptions. Within the hippocampus no 
changes with age were seen in any of the three PUFA examined within the PC and PE 
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classes within both the mitochondria and microsomes, which agrees with the previous 
findings of Söderberg et al. [93]. However, there were several changes recorded within 
the PS class in the hippocampus, including decreases in mitochondrial PS-AA, 
decreases in mitochondrial and microsomal PS-adrenic acid, and increases in 
mitochondrial PS-DHA. Likewise, the present thesis also generally agrees with that 
reported previously for PC- and PE-PUFA in the frontal cortex, with the exception of 
decreases with age mitochondrial PC-adrenic acid, as well as in mitochondrial and 
microsomal PE-AA. Several changes with age were also seen for the first time in the 
frontal cortex in PS-fatty acids, including decreases in microsomal PS-AA and increases 
in mitochondrial and microsomal PS-DHA. 
9.3.2 Changes to phospholipids in dementia compared to healthy ageing 
As reviewed in Chapter 2 (section 2.3), many changes to phospholipids have been 
reported in the literature during the pathogenesis of the different dementias, with AD 
having the most evidence for an involvement of phospholipids. The changes observed to 
phospholipids in AD in previous studies could be classified into three broad categories: 
changes to the amount of total phospholipid present, changes in the amount of particular 
phospholipid classes, and changes to total or class-specific phospholipid-fatty acids. 
The first characteristic separating the changes to phospholipids during normal ageing 
versus that seen in AD is the lack of changes in total quantified phospholipids in normal 
ageing. A number of changes to total phospholipids have been reported in several brain 
regions in AD, including decreases in frontal grey [86,109] and white matter [109,111], 
as well as in the hippocampus [86,109,110]. No changes to total phospholipid amount 
were observed in either the mitochondrial or microsomal membranes for any brain 
region studied in this thesis. The second factor separating the changes seen during 
normal ageing and those found in AD is the lack of changes to levels of phospholipid 
classes. The present work showed that the only region to exhibit any age-related 
changes to phospholipid classes was the entorhinal cortex, in which increases in 
mitochondrial PC and decreases in mitochondrial PE were observed (Chapter 6, Figure 
6-2). Finally, and perhaps most importantly, a critical defining change was seen for the 
fatty acids present in phospholipids during normal ageing versus those reported 
previously for AD; namely that increases in DHA were observed during normal ageing. 
While many studies provided conflicting evidence on changes to DHA in AD (Chapter 
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2, section 2.3.1), most reported either a decrease [87,93,123] or no change 
[86,87,96,108,121] in DHA levels in either total phospholipid or within the 
phospholipid classes across various brain regions with the disease. However, in the 
present study increases were noted in many molecular phospholipids containing DHA in 
both membranes fraction and in nearly all of the regions studied. As stated in Chapter 2 
(section 2.1.2), PUFA such as DHA have a number of important roles in cellular 
membranes. An absence of DHA from cellular membranes, as seen in the peroxisomal 
disorder Zellweger syndrome, results in acute neurological impairment and death within 
the first year of life (Chapter 2, section 2.1.4). We know that DHA is preferentially 
incorporated into PS phospholipids during biosynthesis in the brain and that an 
increased level of PS-DHA leads to decreased apoptosis within neuro-2A cells (Chapter 
4, section 4.3). Therefore, it is feasible that increased levels of DHA with the cellular 
membranes of the human brain could be both promoting longevity and protecting 
against age-related neurodegenerative disease. So far clinical trials of DHA 
supplementation in the healthy elderly, elderly with mild cognitive impairment and 
elderly with neurodegenerative disease such as AD have shown mixed outcomes, with 
those with mild cognitive impairment showing the most consistent improvement across 
studies (reviewed by [73]). Understanding how this accretion of DHA within neural 
cellular membranes occurs, and how this may be influenced in order to promote healthy 
ageing and prevent the development of neurodegenerative disease such as AD is likely 
to be an area of interest in the future. 
9.4 Theories of ageing 
In Chapter 2 (section 2.4), the current theories of ageing pertaining to phospholipids 
were reviewed, including the mitochondrial and free radical oxidative theory of ageing 
and the “inflammageing” theory of ageing. The results of this thesis in relation to the 
tenets of these two theories will be outlined below 
9.4.1 Mitochondrial free radical oxidative theory of ageing 
The mitochondrial free radical oxidative theory of ageing was described in detail in 
Chapter 2 (section 2.4.2). Briefly, this theory proposes that ageing is the net result of 
damage to macromolecules such as protein, DNA and lipids over the lifetime of an 
organism by ROS produced by mitochondrial dysfunction. Within phospholipids, it is 
the fatty acids that are most susceptible to damage by ROS, chiefly PUFA that contain 
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more than one double bond (Chapter 2, Figure 2-7). Theoretically, the greater the 
number of double bonds the more susceptible the fatty acid is to oxidative damage. 
Accordingly, DHA, a PUFA with six double bonds, would be most susceptible to 
oxidative damage by ROS, alongside other PUFA such as docosapentaenoic acid (n-3 
and n-6), and the n-6 fatty acids AA and adrenic acid. Because ROS are primarily 
generated in mitochondria, we would expect that there would be a greater loss of 
PUFA-containing phospholipids within this subcellular fraction. 
Within this thesis, numerous changes occurred to PUFA-containing phospholipid 
molecular species in all regions of the brain. The findings generally followed the same 
trend across the different regions: decreases with age were observed in long chain n-6 
PUFA such as AA and/or adrenic acid, whereas age-related increases with age were 
seen in phospholipids containing DHA. DHA is the only n-3 fatty acid found in 
measurable amounts in phospholipids of the human brain, with only traces of EPA 
(20:5n-3) known to be present. Indeed, no EPA was observed in this thesis in any region 
of the brain examined. No particular preferences for age-related changes were observed 
in the mitochondrial membranes versus microsomal. While the decreases in AA and 
adrenic acid found in this thesis were expected under the mitochondrial free radical 
oxidative theory of ageing, the increase in phospholipids containing DHA in many 
regions of the brain directly contradicts this theory. Therefore, the results of the thesis 
do not align with the mitochondrial free radical oxidative theory of ageing as being the 
driving force behind normal ageing in the human brain. However, these findings are far 
from conclusive, and require the further analysis of other molecules involved in this 
pathway. 
9.4.2 “Inflammageing” 
The “inflammageing theory of ageing was reviewed in Chapter 2 (section 2.4.3) and is 
the idea that ageing is driven by chronic, low-grade inflammation over the lifetime of an 
organism. Specifically, increased levels of inflammatory markers such as interleukins 
and tumour necrosis factors have been observed with advanced age [155–157]. 
Theoretically, phospholipids could play a role in the inflammageing theory, as AA 
preferentially cleaved from phospholipids is a precursor in several pro-inflammatory 
enzymatic pathways. Due to this, it is predicted by this theory that there will be a 
decline in phospholipids containing AA during ageing. Age-related decreases in 
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phospholipids containing other long-chain n-6 fatty acids such as adrenic and 
docosapentaenoic acid are also expected under this theory, as both can undergo β-
oxidation within the peroxisomes to form AA (Chapter 2, Figure 2-4). Minimal changes 
with age in levels of phospholipids with DHA are expected under this theory due to the 
comparably low affinity of both cytosolic phospholipid A2 and COX-1/2 for DHA 
(Chapter 2, section 2.4.3). Additionally, the changes with age due to chronic, low-grade 
inflammation are not expected to be confined to a single membrane fraction. 
Within the five regions of the human brain examined in this thesis decreases occurred 
with age in numerous phospholipids containing long-chain n-6 fatty acids, particularly 
AA and adrenic acid. n-6 docosapentaenoic acid was not able to be separated from its n-
3 isomer by the mass spectrometry method used, and so any isomer-specific age-related 
changes to this fatty acid remain undiscovered. Increases with age in molecular 
phospholipids containing DHA were observed in both the mitochondrial and 
microsomal fractions of most of the regions of the brain examined in this thesis. The 
findings of the present work correspond to that predicted by the inflammageing theory, 
indicating that chronic, low-grade inflammation may by be a considerable driving force 
behind normal ageing within the human brain. However, more work is needed to 
confirm this finding, and any recommendations for future research to corroborate this 
involvement of phospholipids in the inflammageing theory of ageing will be discussed 
below. 
9.5 Summary and future recommendations 
The primary aim of this thesis was to quantify for the first time the changes occurring to 
molecular phospholipids within the three major classes during normal ageing across five 
regions of the human brain. There were three main findings that could be observed 
across the five regions. Firstly, there were no changes to total quantified phospholipids 
with ageing uncovered within this thesis. Secondly, few changes with age were 
observed in the total amount of PC, PE or PS phospholipids within the mitochondrial or 
microsomal membranes in most brain regions. The only region to experience such age-
related changes was the entorhinal cortex, in which decreases in total mitochondrial PC 
and increases in total mitochondrial PE with age were observed (Chapter 6, section 
6.2.2). Finally, many age-related changes were reported in a diverse range phospholipid 
molecular species within both the mitochondrial and microsomal membranes, with no 
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preference for changes in either membrane fraction over the other. Many phospholipids 
with n-6 fatty acids decreased with age in most of the examined brain regions while 
increases were seen in many phospholipids containing the n-3 fatty acid DHA. This 
age-related increase in DHA within the brain was a key feature that distinguished the 
changes to phospholipids during normal ageing from those reported in the literature for 
dementia such as AD (section 9.3.2). Alongside the lack of change to one specific 
membrane system over another (i.e. mitochondrial versus microsomal), the results of 
this thesis were determined to support the inflammageing theory of ageing rather than 
the mitochondrial free radical oxidative theory of ageing.  
Since this is the first report of changes occurring to molecular phospholipids with age in 
the human brain, the findings of this thesis should be confirmed by future studies 
utilising a different, larger, cohort of subjects. The finding that DHA gradually increases 
within the phospholipids of the human brain with age in particular warrants further 
analysis to confirm and to establish the mechanism driving such changes. It will be 
difficult, if not impossible to test if diet drives this increase in DHA with age with a 
human post-mortem cohort. However, examining the changes with age in the activity of 
enzymes involved in the formation of DHA from short chain precursors in post-mortem 
tissue is a possibility, as well as the exploration of age-related changes in the 
deacylation and reacylation pathways that remodel phospholipids to contain 
predominately PUFA in the sn-2 position. All three phospholipid classes can be 
produced by remodelling pathways, some of which are known to have specificity for 
phospholipids containing DHA. PSS2 is such an enzyme, which synthesises PS from PE 
and is known to have a preference for phospholipids with DHA in the sn-2 position 
[46]. PSD, which synthesises PE preferentially from PS phospholipids with PUFA in 
the sn-2 position within the inner mitochondrial membrane [48], is another phospholipid 
synthesis pathway that should be targeted for future research. There is little information 
overall available on the activity of enzymes involved in the synthesis of molecular 
phospholipids within the human brain, and so investigating this and any age-related 
changes would fill a considerable gap in the current literature.  
Due to the mass spectrometry methods used in this study, the changes with age within 
the brain to alkyl- and alkenyl-ether (plasmalogens) were not able to be separated from 
those of their odd-chain diacyl counterparts and so any age-related changes in these 
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phospholipids within the human brain remain to be discovered. Shotgun methods are 
available to separate such phospholipids from each other, either by derivatisation or by 
exploiting the lability of the ether-bond present. One example of such a method is the 
hydrolysis of the vinyl ether bond present in plasmalogens by acid vapour, a technique 
that separates plasmalogens from both isobaric alkyl-ether and odd-chain diacyl 
phospholipids [184]. Another involves selective derivitisation of plasmalogens within a 
lipid mixture, and the resulting mass-shift being used to identify plasmalogens 
preferentially from alkyl-ether and odd-chain diacyl phospholipids [223]. Alternatively, 
age-related changes to ether-phospholipids could be explored using liquid 
chromatography mass spectrometry. However, such techniques would require repeating 
the entire cohort and was unfeasible for the present thesis due to time and financial 
constraints. All of the samples extracted for this study have been stored, and so such a 
study could be conducted in the future. 
The data collected within this thesis supported the predictions of the inflammageing 
theory of ageing over that of the mitochondrial free radical oxidative theory of ageing. 
However, to definitively determine what is driving age-related changes within the 
human brain more study need to be performed. Enzymatic (inflammation) and non-
enzymatic (oxidative) pathways produce different molecules which can be measured in 
post-mortem tissue and quantified. Previous studies have found increases in several 
lipid products of oxidative stress with age, including MDA in the brain tissue of aged 
rats [139–143] and humans [144], 4-HNE in the brains of aged mice [145], senescence-
accelerated mice [146], rats [147], and dogs [148], and F2-isoprostanes in human 
cerebrospinal fluid [149,150]. However, these studies are far from providing the 
complete assessment of age-related changes to the levels of oxidative products with the 
human brain, and much work remains to confirm these findings. A thorough literature 
search for any reported age-related changes in expression or activity levels of enzymes 
involved in the production of inflammatory eicosanoids from AA within any human 
tissue failed to find any such data. Therefore, it remains to be confirmed if the changes 
seen during normal ageing within this thesis can be directly attributed to low-grade 
chronic inflammation. 
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